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Abstract 
 
Ginkgo biloba has been advocated as a neuroprotective agent for several years in glaucoma. 
In this study, immunohistochemistry was used to identify known potential molecular targets 
of Ginkgo biloba related to retinal ganglion cell (RGC) apoptosis in experimental glaucoma, 
including amyloid precursor protein (APP), Aß, cytochrome c, caspase-3 and tumor necrosis 
factor receptor-1 (TNF-R1). Furthermore, using apoptotic inducers related to mechanisms 
implicated in glaucoma, namely Dimethyl sulphoxide (DMSO), ultraviolet C (UVC) and 
Sodium Azide (NaN3),  the effects of the terpenoid fraction of Ginkgo biloba (Ginkgolide A, 
Ginkgolide B and Bilobalide)  were investigated separately in cultured retinal ganglion cells 
(RGC-5). Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay and morphological analysis of DMSO treated 
RGC-5 was performed using Hoechst 33342 stain. 
Immunohistochemistry showed a strong inverse correlation between Aß and APP in ocular 
hypertension (OHT) animals, with APP and Aß accumulation peaking at 1 and 12 weeks after 
intraocular pressure (IOP) elevation respectively. Cytochrome c and TNF-R1 expression 
peaked at 3 weeks, and active caspase 3 activity at 12 weeks after IOP elevation. 1% DMSO, 
UV40, 1mM NaN3 and 50µM Aβ25-35 dose dependently reduced RGC-5 survival at 24 
hours by 27%, 20%, 35% and 27% respectively. These effects were inhibited by Ginkgolide 
A, Ginkgolide B and Bilobalide in different assays at different levels. In these experiments, 
all three compounds showed a dose-related response although some intrinsic toxicity was 
observed with Ginkgolide A. 
Ginkgolide B had the most profound neuroprotective effects in the majority of assays at a 
concentration range of 0.5-5µg/ml, whereas Ginkgolide A and Bilobalide had variable 
activity.  
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Although the effect of simultaneous administration of all three fractions was not assessed, 
work in this thesis suggest that Ginkgolide B can be neuroprotective to RGCs in preventing 
apoptosis and cell death, therefore may be of use as a neuroprotective strategy in glaucoma 
management.  
 
Key Word: glaucoma, neuroprotection, retinal ganglion cell apoptosis, Ginkgo biloba 
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1. Introduction 
 
1.1 Glaucoma 
1.1.1 Overview 
 
Glaucoma is a distinctive group of progressive optic neuropathies characterized by gradual 
degeneration of neuronal tissue due to RGC loss, with accompanying loss of visual field over 
time (Quigley et al., 1995;Gupta and Weinreb, 1997). It is a leading cause of irreversible 
blindness estimated to affect 79.6 million people worldwide by 2020 (Quigley and Broman, 
2006). Glaucoma can be classified into congenital (developmental) or acquired, and based on 
the mechanism of aqueous outflow obstruction, it is further subdivided into open-angle 
glaucoma (OAG) and closed-angle glaucoma types. Each classification can be primary, when 
it is not associated with another cause and secondary, when there is an ocular or non-ocular 
disorder affecting aqueous dynamics.  
 
1.1.2 Glaucoma risk factors 
 
Risk factors have been identified both for developing OAG, and for its progression. Although 
intraocular pressure (IOP) is the most important risk factor in the pathogenesis of glaucoma, 
optic nerve cupping and visual field loss can progress despite successful reduction in IOP via 
medical and surgical approaches (Leske et al., 1999;Oliver et al., 2002;Rossetti et al., 2010). 
In the Early Manifest Glaucoma Trial (EMGT) around 27% of treated patients with 30% 
reduction in IOP showed progression even after 6 years of follow up (Leske et al., 
2003;Leske et al., 2007). Moreover, 12% of treated patients recruited in the Collaborative 
Normal Tension Glaucoma Study (CNTGS) revealed progression in the course of the disease 
after 7 years of follow up (Group, 1998). Table 1.1 shows risk factors for developing 
  
 
 
 
17 
glaucoma and table 1.2 shows risk factors for glaucoma progression. 
 
Table 1.1 Risk Factors for developing Glaucoma 
Parameter Risk factor                         References 
Age > 40 years  (Quigley and Vitale, 1997;Mukesh et al., 2002;de Voogd et 
al., 2005;Boland and Quigley, 2007;Leske et al., 2008)  
Ancestry African Caribbean (Tielsch et al., 1991;Wormald et al., 1994;Leske et al., 2008)   
Family 
History 
1st degree relatives (Tielsch et al., 1994;Boland and Quigley, 2007)   
IOP >21 mm Hg    (Kass et al.;Bengtsson et al., 2007;Leske et al., 2007)     
C/D Ratio >  0.7 (Le et al., 2003)   
Myopia > 2 D (Mitchell et al., 1999;Ramakrishnan et al., 2003)   
CCT < 555 µm (Leske et al., 2008) 
Lower Ocular  
SPP, DPP &  
MPP 
SPP=SBP-IOP 
DPP=DBP-IOP 
MPP= 2/3MAP-IOP 
(Leske et al., 2008) 
 
 
IOP= intra ocular pressure, C/D= cup to disc, D= diopter, CCT= central corneal thickness, SPP= systolic 
perfusion pressure, DPP= Diastolic perfusion pressure, MPP= mean perfusion pressure, MAP = mean arterial 
pressure. 
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Table 1.2 Risk factors for Glaucoma Progression 
Parameter Risk factor                         References 
Age > 68 years (Gordon et al., 2002;Leske et al., 2007)   
IOP > 21 mmHg  (Gordon et al., 2002;Heijl et al., 2002;Bengtsson et al., 
2007;Leske et al., 2007) 
Bilateral 
involvement 
positive (Leske et al., 2003;Leske et al., 2007)  
CCT < 555 µm   (Brandt, 2004;Leske et al., 2007;Miglior et al., 2007;Brandt 
et al., 2008)   
Greater V/F PSD 
per 0.2 dB 
 
positive (Gordon et al., 2002;Miglior et al., 2007) 
Disc haemorrhage positive   (Leske et al., 2003;Leske et al., 2007;Bengtsson et al., 
2008)  
Pseudoexfoliation positive   (Leske et al., 2003;Grodum et al., 2005;Leske et al., 2007)  
Vertical C/D ratio > 0.7 (Gordon et al., 2002;Miglior et al., 2007) 
Vertical C/D ratio 
asymmetry 
positive (Miglior et al., 2007) 
SPP ≤125 mmHg (Leske et al., 2007) 
SBP ≤160 mmHg (Leske et al., 2007) 
Diabetes mellitus positive (Lichter et al., 2001)  
Cardiovascular 
diseases 
positive (Leske et al., 2007;Miglior et al., 2007;Brandt et al., 2008)   
 
V/F= visual field, PSD=Pattern standard deviation, SPP=systolic perfusion pressure, SBP=systolic blood 
pressure.  
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1.1.3 Cell Death Mechanisms 
 
Cellular breakdown can be categorized into three widely identified forms: apoptosis, necrosis 
and autophagic cell death (Jellinger, 2001;Elmore, 2007;Kroemer et al., 2009;Levine and 
Kroemer, 2009). 
1.1.3.1 Apoptosis 
 
Apoptosis, a gene-directed programmed form of cell death, is an energy-dependent process 
essential in embryogenesis and tissue homeostasis (Wenzel et al., 2005). Inappropriate 
apoptosis is heavily implicated in the pathogenesis of many neurodegenerative diseases 
(Thompson, 1995;Perry et al., 1998) including glaucoma (Quigley et al., 1995;Cordeiro et al., 
2004). A specific series of morphological features including formation of apoptotic bodies, 
chromatin condensation and DNA fragmentation within an intact cell membrane are 
characteristically seen (Kerr et al., 1972;Kerr, 2002). Apoptosis is brought about by the 
intrinsic (mitochondrial) pathway mediated via cytochrome c release (Ekert and Vaux, 2005) 
or the extrinsic (the death receptor) pathway involving transmembrane receptors which are 
members of tumor necrosis factor (TNF) receptor superfamily (Locksley et al., 2001). The 
intrinsic apoptotic pathway can be either caspase-dependent or caspase-independent. In the 
dependant pathway the proteolytic activity of caspases, aspartate-specific cysteine proteases, 
appears to be central with initiators (caspase-8 and 9) and the executors (caspase-3, 6 and 7). 
A caspase-independent pathway can be activated by an increased intracellular calcium level 
and is mediated via the activity of other effectors such as calpain-mediated release of 
apoptosis inducing factor (AIF) and calpain-mediated release of caspase-12 (different from 
traditional caspases). AIF and caspase12 both translocate to the nucleus to participate in 
DNA damage (Tezel and Yang, 2004;Sanges et al., 2006;Sanges and Marigo, 2006). 
However, it has becoming increasingly apparent that the caspase-dependent and the caspase-
  
 
 
 
20 
independent pathways are not separate entities but that they are linked together at certain 
points (Igney and Krammer, 2002). Nonetheless, it is believed that each pathway has 
different mechanisms. So far, there are a variety of proposed triggers for apoptosis including 
abnormal aggregation of subcellular proteins, oxidative stress, inflammation and immune 
system modulation, and withdrawal of neurotrophic support, which will be discussed in 
further detail later. 
1.1.3.2 Necrosis 
 
In comparison with apoptosis, necrosis, which is considered to be a passive pathological 
process of cellular breakdown, involves swelling of the cytoplasmic membrane with 
formation of cytoplasmic vacuoles, loss of plasma membrane integrity and subsequently loss 
of intracellular contents in the absence of DNA fragmentation (Kerr et al., 1972;Nicotera et 
al., 1999a;Nicotera et al., 1999b). Although the causative factors of necrotic cell death are 
still unspecified, several interconnecting elements have been implicated including energy 
depletion and direct injury to the cell membrane (Kroemer et al., 2009). An activation of 
death domain receptors such as tumor necrosis factor receptor 1 (TNFR1) and Toll-like 
receptors such as TLR3 have been observed to provoke necrotic cell death (ibid).  
1.1.3.3 Autophagic cell death 
 
 The term "autophagy" from Greek means "self-eating", and autophagic cell death, another 
form of cellular breakdown, is characterized by sequestration and vacuolization of cytoplasm 
and organelles and degradation by the cell’s lysosomes. It is an energy-dependent process in 
which chromatin condensation, DNA fragmentation and phagocytosis are not seen (Kroemer 
and Levine, 2008;Levine and Kroemer, 2008;Kroemer et al., 2009;Levine and Kroemer, 
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2009). Activation of autophagy in RGCs has been demonstrated after optic nerve transection, 
and suggested to have a cell-protective role in neurodegenerative diseases (Kim et al., 2008). 
1.1.4 Mechanisms of RGC death in glaucoma 
 
 
In chronic glaucoma retinal ganglion cell (RGC) apoptosis appears to be an early event 
(Quigley et al., 1995;Kerrigan et al., 1997;Cordeiro et al., 2004). It is estimated that at least 
25% to 35% RGCs in human eye with glaucoma (Kerrigan-Baumrind et al., 2000) and up to 
50% RGCs in the animal model of experimental glaucoma (Harwerth et al., 2002) must have 
been lost before a visual filed defect can be detectable.  
 Several damaging mechanisms have been implicated in the pathogenesis of apoptotic RGC 
death in glaucoma; although a single causative mechanism has yet to be identified. Even 
though IOP may be viewed as a direct inducer of RGC stress and apoptosis (Guo et al., 
2005a;Kwon et al., 2009), damage to RGCs can occur even in the presence of a low level of 
IOP (Sommer, 1989;Drance, 2004). In conditions of elevated IOP, mechanical stress on the 
lamina cribrosa can lead to initial axonal degeneration, as suggested by Howell et al (2007) 
using the DBA/2J mouse model of glaucoma. This study also suggested that it is possible to 
protect RGCs against such damage using the Wallerian degeneration slow allele, which 
allowed functional protection from glaucoma in the DB2-J2.Wld
s
 mouse model (Howell et 
al., 2007). Glaucoma appears to be of a multifactorial nature with complex genetic and 
environmental factors (Fingert et al., 1999;Ray et al., 2003;Libby et al., 2005;Mabuchi et al., 
2007). In addition to IOP, several other stress inducer factors have been identified such as 
tissue hypoxia (Kaur et al., 2008;Tezel et al., 2010), and glial cell activation (Lebrun-Julien et 
al., 2009).     
The various proposed mechanisms of RGCs death in glaucoma have been investigated 
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through the use of a variety of in vitro and in vivo studies include: oxidative stress (Neufeld et 
al., 1999;Ko et al., 2005;Tezel, 2006), protein misfolding (McKinnon et al., 2002a;Yoneda et 
al., 2005;Guo et al., 2007a), inflammation (Tezel et al., 2001;Tezel et al., 2007), 
mitochondrial dysfunction (Mittag et al., 2000;Tatton et al., 2001;Tezel and Yang, 2004), and 
excitotoxicity (Dreyer et al., 1996;Osborne et al., 1999;Guo et al., 2006;Salt and Cordeiro, 
2006). These mechanisms will be discussed further below: 
1.1.4.1 Oxidative stress 
 
 
Oxidative stress is a pathological condition in which the rate of reactive oxygen species 
(ROS) production exceeds the body’s anti-oxidative capacity. ROS are partially reduced, 
highly reactive metabolites of molecular oxygen, containing an unpaired electron. ROS is 
generated primarily via the electron transport chain at relatively low levels during aerobic 
metabolism and plays an integral part in signal transduction. Ischemia potentially by vascular 
dysregulation and reperfusion injury to cells are critical inducers for oxidative stress 
(Flammer et al., 1999), leading to further ROS generation with ATP depletion and 
mitochondrial failure, triggering the caspase-dependent and caspase-independent 
mitochondrial cell death pathways (Murphy, 1999).  
The increased levels of ROS enhance lipid peroxidation, protein peroxidation (Siu and To, 
2002) and single strand breaks in nucleic acids (Finkel, 1998;Finkel and Holbrook, 2000). 
ROS have also been found to induce Muller cell activation and dysfunction, generating 
further oxidative material (Yuan and Neufeld, 2001;Neufeld and Liu, 2003;Tezel et al., 
2003). 
      ROS and NO pathways 
 
ROS generation has been implicated in the pathogenesis of glaucoma (Bonne et al., 
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1998;Levin, 1999), inducing remolding and excavation of the lamina cribrosa, damaging the 
trabecular meshwork and facilitating glutamate–dependant RGC death (Fern et al., 
1993;Chidlow et al., 2007;Cheung et al., 2008a). In glaucomatous stress, excessive 
production of ROS enhances the production of nitric oxide (NO) (Neufeld, 1999;Neufeld and 
Liu, 2003), which can have direct cytotoxic effects on the RGCs in a caspase-dependent and 
caspase-independent manner.  
 
The extent of the oxidative damage appears to depend on the type and reactivity of ROS, the 
rate of their production and the cellular antioxidant defense mechanism. The retinal 
protection against the damaging effects of ROS is composed mainly of glutathione 
peroxidase, glutathione reductase, glutathione S-transferase, ascorbic acid, catalase, and 
superoxide dismutase (Ferreira et al., 2004). An increased level of autoantibodies against 
glutathione S-transferase (Yang et al., 2001), and a compromised antioxidant capacity 
(Gherghel et al., 2005) have been documented in glaucoma patients. Corresponding data in 
the rat model of raised IOP displayed increased levels of antioxidant enzymes (Moreno et al., 
2004). Excessive production of ROS enhanced the production of NO in the rat model of 
glaucoma (Siu et al., 2002) and in astrocytes and glial cell at the optic nerve head of 
glaucoma patients, enhancing activation of the N type Ca
2+
 channels in RGCs (Hirooka et al., 
2000). NO can further interact with a superoxide anion (O2
-
) to form the highly potent 
oxidant peroxynitrite (ONOO-) (Luthra et al., 2005), as shown in figure 1.1  
 
Methods of reducing ROS production have been shown to enhance RGC survival following 
axotomy (Geiger et al., 2002), whilst intravitreal injection of a nitric oxide donor has been 
shown to induce RGC death (Oku et al., 1997). Therefore, blocking the production of NO 
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could arrest the development of glaucomatous optic neuropathy (Liu and Neufeld, 2000;Yuan 
and Neufeld, 2001). Complications, however, arise from the potential antiapoptotic action of 
ROS through the phosphorylation of nuclear factor (NF)- қB, via reduction of its inhibitory 
protein IКBα, and subsequent inhibition of caspases (Mattson et al., 2000). ROS has also been 
shown to up-regulate the expression of the antiapoptotic member of Ras proteins, which are 
phosphoinositide-3-kinases (PI3K) that enhance cell survival by inactivating bad proteins and 
Caspase-9 (Rebollo and Martinez, 1999;Mattson et al., 2000). 
 
 
Figure 1.1 Oxidative stress in RGCs 
In oxidative stress excessive production of ROS enhances the production of NO by the iNOS enzyme. NO will 
interact with a superoxide anion (O2-) to form the highly potent oxidant peroxynitrite (ONOO). ROS will also 
activate the phosphorylation of NF-қB and Ras proteins. The increased levels of ROS enhance cell membrane 
lipid peroxidation and the nuclear DNA fragmentation.  
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1.1.4.2 Protein Misfolding  
 
 
Amyloid deposits, consisting of aggregates of Aβ, are a characteristic feature of several 
neurodegenerative diseases such as Alzheimer’s (Pepys, 2006), Parkinson’s disease (Bayer et 
al., 2002) and mild cognitive impairment (Attems and Jellinger, 2006;Verwey et al., 
2008;Villemagne et al., 2008). They have also been recently implicated in the pathogenesis 
of retinal damage (Shimazawa et al., 2008), Age Related Macular Degeneration (AMD 
(Johnson et al., 2002), and glaucoma (McKinnon et al., 2002a;Yoneda et al., 2005;Goldblum 
et al., 2007;Guo et al., 2007a). 
      Amyloid-β pathway 
 
 
Amyloid precursor protein (APP) is a trans-membrane protein expressed by many cells, 
including CNS neurons and RGCs (Morin et al., 1993). APP cleavage involves three 
proteases: α-secretase generates the soluble non-pathogenic αAPP that serves trophic 
functions inside cells (Li et al., 1997), whereas β and γ secretase produce Aβ.  
The β-secretase enzyme is believed to be the primarily responsible initiator of the 
amyloidogenic processing of APP (Pastorino and Lu, 2006), with cleavage of APP by β-
secretase generating the βAPP and C99 fragments. Further proteolysis of βAPP by γ 
secretase enzyme yields the insoluble Aβ and P6 fragment (Augustin et al., 2009) as 
summarized in figure 1.2. Cleavage of the C-terminal cytoplasmic tail of APP to yield Delta 
C-APP, further potentiating Aβ production has been shown in neuronal cells and in apoptotic 
RGCs in a rat model of ocular hypertension (Gervais et al., 1999;McKinnon et al., 2002a). 
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Figure 1.2 The pathways for AB formation 
The production of Aβ, an amino-acid peptide, derived from the proteolytic processing of a larger plasma 
membrane bound protein known as amyloid precursor protein APP. APP is cleaved by β-secretase enzyme to 
produce βAPP and a C99 fragment. Further cleavage of C99 by γ-secretase will produce Aβ and P6.  
 
 
 
 
 
       Heat shock proteins (HSPs) 
 
Also of interest with regards to protein misfolding is Heat shock proteins (HSPs), a group of 
specialized molecular chaperons that mediate various physiological functions inside cells. 
HSPs are up-regulated in stressful conditions to restore normal structural integrity (Soti et al., 
2005). Several families of HSP have been implicated in glaucoma and other 
neurodegenerative diseases (Tezel et al., 1998;Tezel et al., 2000;Pepys, 2006) with increased 
levels of circulating autoantibodies to alpha-crystallins and HSP27 (Tezel et al., 1998), and 
increased immunostaining of HSP-60, HSP-27 in RGCs and the retinal blood vessels in 
glaucoma patients (Tezel et al., 2000). Systemic administration of Geranylgeranylacetone, an 
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anti-ulcer agent, in the rat glaucoma model has been shown to increase the expression of 
HSP-72 with a marked reduction in RGC loss (Ishii et al., 2003), possibly through interaction 
with different protein kinases such as Akt kinase, and the inhibiting NF-қB (Thomas et al., 
1998;Neckers, 2007).  
 
1.1.4.3 Inflammation 
 
Growing evidence in clinical and experimental studies strongly suggests the involvement 
of the immune system in glaucoma (Tezel, 2009). The sustained neuronal damage in 
glaucoma and other ischemic neurodegenerative conditions can trigger immune responses, 
leading to an excessive production of T-cells. The activated T cell subsequently attacks the 
antigen presented to its receptor by the major histocompatibility complex 9 (MHC 9). Up-
regulation of the MHC class II molecules on rat glial cells and stimulation of T cell activation 
in cultured retinal and optic nerve tissue have been demonstrated (Tezel et al., 2007). In a rat 
model devoid of T cells due to thymectomy there was increased RGC death after optic nerve 
crush (Yoles et al., 2001). Furthermore, several research studies showed that, augmentation 
of immune system by passive transfer of T cells directed against myelin basic proteins or 
active immunization with the myelin derived peptide, reduces RGC loss after optic nerve 
injury (Schwartz, 2001). A similar finding has been reported in rats injected with activated 
anti-myelin basic protein T cells after partial optic nerve crush (Moalem et al., 1999;Moalem 
et al., 2000) . The release of TNF-α, a potent proinflammatory cytokine, and its subsequent 
binding to the death receptor, TNF-α Recpor-1 (TNR-R1), triggers a caspase-dependent and a 
caspase-independent component of mitochondrial death promoting pathways. The TNF-α –R 
complex is able to recruit adaptor proteins that activate caspase 8, which in turn activates 
caspase 3 (Pastorino et al., 1996;Tezel et al., 2004). 
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      TNF-α  
 
TNF-α, also known as cachectin, is a cytokine that plays an important role in the regulation 
of immune cells, inflammation, as well as the induction of the caspase-dependent and caspase 
independent mitochondrial apoptotic pathways. TNF-α binding with TNF Receptor 1 (TNF-
R1) triggers a series of intracellular events initiated by recruitment of key adaptor proteins 
leading to activation of NF-қB, a redox sensitive transcription factor that is heavily 
implicated in apoptosis (Lu et al., 2010;Meinel et al., 2010). TNF-α-R1 complex upregulates 
IқB Kinases that activates the phosphorylation of the inhibitory protein IқB releasing 
activated NF-қB. The activated NF-қB can then translocate to the nucleus to exert its 
apoptotic effects (Karin and Delhase, 2000). Excessive expression of TNF-α has been 
documented on RGCs in vitro and in vivo (Fuchs et al., 2005;Kitaoka et al., 2006). Similar 
results were shown in cultured glial cells exposed to ischemic conditions and high IOP as 
well as in human glaucomatous eyes (Tezel and Wax, 2000;Tezel et al., 2001). Conversely, 
TNF-α is also proposed to have a neuroprotective action mediated through upregulating NF-
қB. TNF-α Receptor apoptotic pathway is shown in Figure 1.3 
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Figure 1.3 TNF-α death receptor pathways 
TNF-α binding with the death receptor TNFR1 has been implicated in the induction of caspase-dependent and 
caspase independent mitochondrial apoptotic pathways. It also up-regulates IқB Kinases that activates the 
phosphorylation of IқB to release active NF-қB. The activated NF-қB will then translocate to the nucleus to 
exert its apoptotic effects. Furthermore, activated NF-қB could exerts its proposed neuroprotective effects.  
 
 
      TNF Receptor 1 and TNF Receptor 2 
 
TNF-α activities are mediated via interaction with two distinct receptors, the death domain-
containing TNF-receptor 1 (TNF-R1) and the non-death domain-containing TNF-receptor 2 
(TNF-R2) (Wajant and Scheurich, 2001). TNFR1 has been confirmed to mediate majority of 
TNF-α biological activity (Chen and Goeddel, 2002) and has been suggested to be involved 
in the neurodegenerative process of glaucoma (Tezel et al., 2001), neuronal cell loss and 
retinal ischemia (Fontaine et al., 2002), whereas TNF-R2 showed neuroprotective activity 
and reduced retinal ischemia (ibid). 
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1.1.4.4 Mitochondrial Dysfunction  
 
Mitochondrial dysfunction is believed to play a major role in cell death due to changes in 
oxidative phosphorylation, ATP synthesis and ROS production. Mitochondria are the main 
energy source inside cells and the primary site of ROS production, making it a major target 
for reducing oxidative stress. A decrease in mitochondrial membrane potential and an 
increase in the membrane permeability have been implicated as a causative factor for RGC 
apoptosis in glaucoma (Mittag et al., 2000;Tatton et al., 2001;Tezel and Yang, 2004). 
Glaucoma-related stimuli such as hypoxia, TNF-α and oxidative stress can trigger the 
mitochondrial-mediated RGC death pathway. In glaucomatous stress, mitochondria buffer 
excess cytosolic Ca+2 leading to intra-mitochondrial accumulation of Ca2+, mitochondrial 
membrane depolarization and the production of ROS (Kristian and Siesjo, 1998). This has 
been shown to trigger the opening of the mitochondrial permeability transition pore (PTP) 
with subsequent release of apoptosis-inducing proteins, such as cytochrome c (Nickells, 
1999), and CPP32 (caspase 3 activators) (Marchetti et al., 1996;Hirsch et al., 1997).  
Released cytochrome c from the mitochondria, complexes with apoptotic protease-activating 
factor-1 (Apaf-1) and procaspase 9 to form the apoptosome, which in turn activates caspase 
3, leading to chromatin condensation and DNA fragmentation. Furthermore, cytochrome c 
release has been implicated in inducing mitochondrial dysfunction and ROS production 
(Ricci et al., 2003), creating a positive feedback loop. 
The release of cytochrome c is regulated by the competitive actions, at the surface of the 
mitochondria of a family of cell death regulators, the Bcl-2 protein family (Ow et al., 2008). 
This family of proteins includes both pro as well as anti-apoptotic molecules and the ratio 
between these molecules is crucial in a cell’s final decision to live or die (Gross et al., 
1999a). The members of BCL-2 family of proteins have been found to have up to four BCL-2 
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homology (BH) domains  that correspond to α-helical segments and nominated as BH1, BH2, 
BH3 and BH4 (Gross et al., 1999a). In figure 1.4 it can be seen that the BCL-2 family of 
proteins can be divided into the pro-survival Bcl-2 subfamily which includes Bcl-2, Bcl-XL, 
Bcl-w, Mcl-1 and A1, the pro-apoptotic Bax subfamily including Bax, Bak and Bok, and the 
pro-apoptotic BH3 subfamily that includes Bad, Bid, Bik, Blk, Hrk, BNIP3 and Bim (Gross 
et al., 1999a). 
 The Bcl-2 protein can prevent apoptosis induced by various stimuli and has a vital role in 
maintaining mitochondrial integrity, whereas conversely, Bax has been implicated in 
mitochondrial-mediated apoptosis in various neuronal cells by promoting the release of 
cytochrome c from the mitochondria  (Merry and Korsmeyer, 1997;Gross et al., 1999a). It is 
believed that a high Bax/Bcl-2 ratio affects mitochondrial outer membrane permeability via 
multiple mechanisms (Scorrano and Korsmeyer, 2003) and stimulates mitochondrial-induced 
death pathways (Deckwerth et al., 1996;Wei et al., 2001) as summarized in figure 1.4  
Mitochondria are also involved in the exacerbation of extrinsic or death receptor mediated 
apoptosis. Bid, a proapoptotic protein member of the Bcl-2 family is cleaved by death 
receptors and caspase-8 to yield a truncated Bid (Li et al., 1998), which is able to translocate 
to the mitochondria and mediate cytochrome c release. 
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Figure 1.4 Summary of anti and pro-apoptotic BCL-2 family members 
Taken from (Gross et al., 1999a) 
 
 
Figure 1.5 Mitochondrial death pathways 
The caspase-dependent mitochondrial death pathway is initiated by cytochrome c release inducing activation of 
caspase-9, and caspase-3, which is the primary activator of DNA fragmentation, whereas the caspase-
independent pathway, activated by calpain, will induce release of AIF, which will translocate to the nucleus to 
enhance DNA damage. Apoptotic stimuli, such as stress or activation of death receptors, converts Bid to tBid, 
which affects mitochondrial membrane permeability and leads to release of death inducing proteins such as 
cytochrome c. A high Bax/Bcl-2 ratio can also affect mitochondrial outer membrane permeability and stimulate 
the intrinsic mitochondrial pathway and cytochrome c independently of tBid. Trophic factor receptors and the 
antiapoptotic members of Bcl-2 family have inhibitory effects on cytochrome c release preventing activation of 
mitochondrial death pathways.  
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1.1.4.5 Excitotoxicity 
 
Excitotoxicity is the pathological process by which RGCs (Osborne et al., 1999;Casson, 
2006) and other neuronal cells die as a result of excessive extracellular glutamate (Olney, 
1969;Choi, 1992;Doble, 1999). As outlined in figure 1.5 glutamate released from the 
apoptotic cell can trigger necrotic death of surrounding cells that have been spared from the 
original insult initiating a cascade of autodestruction, further cellular injury and death 
(Osborne et al., 1999;Casson, 2006;Cheung et al., 2008a). Several studies have confirmed the 
neurotoxic effect of glutamate in the retina (Hyndman, 1984;Gross et al., 1999b;Kawasaki et 
al., 2000;Luo et al., 2001), whilst others have suggested that glutamate-mediated RGC injury 
and death contributes to glaucoma (Dreyer et al., 1996;Brooks et al., 1997;McIlnay et al., 
2004;Moreno et al., 2005;Guo et al., 2006;Salt and Cordeiro, 2006). 
 
      Mechanism of Excitotoxicity 
 
  
Glutamate binding of NMDA receptors depolarizes the RGCs, permitting the influx of Ca
2+
. 
Excess Ca
2+
 further increases Ca
2+
 entry through voltage-gated Ca
2+ 
channels, enhancing Ca
2+ 
release from the
 
endoplasmic reticulum, stimulating Ca
2+
/Na
+
 exchange and further 
increasing the Ca
2+
 dependent release of vesicular glutamate from the nerve terminal. This 
glutamate will induce further Ca
2+
 influxes through NMDA, AMPA and Kainate receptors 
(Casson, 2006). The high intracellular Ca
2+ 
triggers a cascade of events including disruption 
of mitochondrial function, leading to increased reactive oxygen species (ROS) production 
and the release of cytochrome c and apoptosis inducing factor (AIF) in mitochondria 
((Marigo, 2007). Subsequently AIF translocates from the cytoplasm to the nucleus where it 
initiates nuclear chromatin condensation and DNA fragmentation (Figure 1.5 a), thereby 
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triggering the caspase-independent apoptotic pathway (Zhang et al., 2002). Release of 
mitochondrial cytochrome c (Figure 1.5 b) triggers a range of events including the activation 
of caspase-9, and the subsequent activation of caspase-3. In addition, raised intracellular 
calcium as illustrated in figure 1.5, also stimulates calcium dependent proteases such as 
calpain (Zhang and Bhavnani, 2006), proteolytic enzymes such as lipases, proteases, and 
nucleases (Casson, 2006), and the inducible form of nitric oxide synthase enzyme (iNOS) 
generating nitric oxide and reactive oxygen species (ROS).  
 
 
Figure 1.6 Excitotoxicity in RGCs 
In excitotoxicity, the high intracellular Ca+2 levels lead to release of the mitochondrial apoptotic inducing factor 
(AIF) (a), which translocates to the nucleus and initiates nuclear chromatin condensation and DNA 
fragmentation thereby triggering the caspase-independent apoptotic pathway. Release of mitochondrial 
cytochrome c (b) induces activation of caspase-9, and caspase-3. Caspase-3 is the primary activator of DNA 
fragmentation, as well as stimulation of the calcium dependant protease. High Ca
+2
 levels (c) will also induce 
the production of the inducible form of Nitric Oxide Synthase enzyme (iNOS) generating free radicals such as 
nitric oxide.  
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1.1.4.6 Neurotrophin Deprivation 
 
Neurotrophic factors are small molecular weight peptides that are widely expressed in the 
RGCs (Jelsma et al., 1993) and have an indispensible role in growth, differentiation and 
survival. They include: nerve growth factor (NGF) which bind with one of the tropomyosin-
related kinase receptors known as  neurotrophic tyrosine kinase receptor type 1 (Trk A) 
(Kaplan et al., 1991), brain-derived neurotrophic factor (BDNF), Neurotrophine 4 and 5 
(NT4 and NT5) which exert their action via neurotrophic tyrosine kinase, receptor, type 2 
(Trk B) (Barde et al., 1982;Berkemeier et al., 1991) and NT3 which binds  neurotrophic 
tyrosine kinase receptor type 3 (TrkC) (Hohn et al., 1990;Rosenthal et al., 1990). Several 
research studies demonstrated that the flow of the neurotrophic factors from the superior 
colliculus in the CNS to the RGCs is markedly reduced in the animal model of glaucoma, 
where both the retrograde and the anti-retrograde axonal transport are compromised 
(Anderson and Hendrickson, 1974;Hayreh et al., 1979;Rudzinski et al., 2004). This leads to a 
reduction in neuronal trophic support, which in turn compromises neuronal survival and 
triggers a series of molecular events, stimulating the apoptotic cascade, as seen in RGCs 
following transection of the optic nerve (Berkelaar et al., 1994).   
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1.1.5 Neuroprotection in glaucoma 
 
 
Neuroprotection can be defined as a therapeutic approach aiming at directly preventing, 
hindering and, in some cases, reversing neuronal cell damage (Society, 2008) 
Neuroprotection in glaucoma is becoming a key research area as traditional strategies of 
lowering IOP have been shown to be unable to prevent progressive vision loss in all 
glaucoma patients, where  some patients can continue deteriorating in spite of an apparently 
controlled IOP (Group, 1998). 
Research studies have shown that RGC damage is not confined to the primary insulted 
neurons, but that secondary injury follows which affects the neighboring neurons as well 
(Chidlow et al., 2007). It is therefore believed that in glaucoma, treatment modalities that 
directly target both primary and secondary degeneration of the RGCs are required. This 
makes the prospect of discovering alternative therapeutic approaches independent of IOP 
reduction highly sought after, as IOP lowering therapy is indirect and not completely 
effective at preventing RGC loss.  
RGCs and the optic nerve are integral parts of the central nervous system (CNS) and a link 
has been demonstrated between mechanisms of cell death in glaucoma and Alzheimer's 
disease (AD) (Weber et al., 2000;Guo et al., 2006;Gupta et al., 2006;Guo et al., 2007b). 
Therefore, glaucoma may be viewed as a neurodegenerative disease of the CNS, and 
neuroprotective agents that have been approved for the treatment of neurodegenerative 
diseases such as AD (Reisberg et al., 2003) and Amyotrophic lateral sclerosis (ALS) 
(Bensimon et al., 1994;Lacomblez et al., 1996), are being assessed for the treatment of 
glaucoma (Cheung et al., 2008a).  
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1.1.6 Targets for neuroprotection in glaucoma  
 
The various proposed mechanisms of RGC cell death which have been detailed previously 
section (1.1.4); have been investigated through the use of both in vitro and in vivo models, as 
shown in Table 1.3. The advantages, disadvantages and how closely these different models 
correlate to primary open angle glaucoma (POAG) in humans have recently been the focus of 
some comprehensive reviews (Johnson and Tomarev, 2010).  It is important to recognize that 
there is still no perfect model of glaucoma, and translating results from preclinical to clinical 
studies is often problematic. 
 
The possible role of ROS in glaucoma has led to the investigation of multiple anti-oxidants as 
potential neuroprotective agents on RGCs both in vivo and in vitro as summarized in Table 
1.3 including Aminoguanidine, Brazilian Green Propolis, Carotenoids such as Lutein and 
Zeaxanthin, beta-carotene and Docosahexaenoic acid. Other drugs in this group are: Trolox, 
15d-PGJ2 and troglitazone.  
 
 Ginkgo biloba is perhaps the most promising antioxidant compound and will be discussed in 
detail in the second section of this chapter. Another compound with high neuroprotective 
potential within this group is Melatonin, a potent, naturally occurring antioxidant with free 
radical scavenging activity, which displays a critical role in aqueous humour circulation 
(Wiechmann and Wirsig-Wiechmann, 1994;Dubocovich et al., 1997;Sugden et al., 
1997;Wiechmann et al., 1999). Its neuroprotective actions are believed to be mediated via 
multiple mechanisms including reducing single and double strand breaks in DNA (Sun et al., 
2002), increasing Akt phosphorylation (Kilic et al., 2005a;Lee et al., 2006;Tajes Orduna et 
al., 2009), reducing NO-induced apoptosis (Siu et al., 2004) and inhibiting the mitochondrial 
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transition pores and cytochrome c release (Andrabi et al., 2004;Jou et al., 2004;Kilic et al., 
2004). Melatonin demonstrated a neuroprotective effect on RGCs in vivo (Siu et al., 
2004;Tang et al., 2006), it also protected rabbit retinal neurons in vitro (Cazevieille and 
Osborne, 1997). 
Modulation of NMDA receptor has constituted a major area of research in glaucoma 
neuroprotection (Guo et al., 2006;Dong et al., 2008). In vivo and in vitro studies have 
suggested that blocking both the NMDA and the non-NMDA receptors simultaneously offers 
optimal protection against ischemic neurodegeneration (Mosinger et al., 1991;Leinders-
Zufall et al., 1994). There are several anti-excitotoxic drugs that have been investigated in 
vivo and in vitro, that exert their neuroprotective actions by overcoming the glutamate-
induced excitotoxicity on the NMDA receptors such as the Ifennprodil, Eliprodil, Flupirtine 
and dextromethomethorphan as in Table 1.3 but the most prominent amongst them are 
MK801 and memantine. MK801, also known as (+)-5-methyl-10, 11-dihydro-5H-dibenzo [a, 
d]cyclohepten-5, 10-imine maleate, is a non-competitive antagonist of the NMDA receptor 
and has demonstrated neuroprotective potential in the CNS for many years (Foster et al., 
1988;el-Asrar et al., 1992;Tamura et al., 1993). 
 
MK-801 has also been found to protect RGCs both in vitro (Tsuda, 2004) and in vivo in the 
optic nerve injury model (Russelakis-Carneiro et al., 1996), the laser-induced retinal injury 
rat model (Solberg et al., 1997), and in the OHT models (Chaudhary et al., 1998;Guo et al., 
2006). Work on the experimental model of high IOP-induced retinal ischemia verified the 
neuroprotective effect of MK801 to be mediated through decreasing Bad expression (Russo 
et al., 2008). The effect of MK-801 in vivo on RGC apoptosis in a staurosporine-induced 
retinal toxicity model
 
showed a reduction in the number of
 
apoptotic RGCs in comparison to 
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the controls (Guo et al., 2006). Unfortunately, MK801 is not used clinically because of its 
neurotoxic effect (Olney et al., 1989;Fix et al., 1993), which is believed to be due to high 
affinity to the NMDA receptors and its long stay time in the channel (Lipton, 1993). 
 
Another interesting drug is Memantine, also known as 1-amino-3, 5-dimethyl-adamantane, is 
a three-ringed structural derivative of the anti-influenza drug, amantadine (Cheung et al., 
2008a). The additional amine (–NH2) and two methyl (–CH3) side groups are thought to be 
responsible for the increased residency with, and affinity for, NMDA receptors in relation to 
amantadine (Lipton, 2006). Memantine, however, exhibits strong voltage dependency with 
rapid blocking/unblocking kinetics, displaying weak potency during the normal synaptic 
transmission (Johnson and Kotermanski, 2006). 
 The Food and Drug Administration (FDA) approved Memantine, for treating moderate to 
severe Alzheimer’s disease (Reisberg et al., 2003). It is the only neuroprotective agent that 
has completed a phase III clinical trial in patients with OAG. Memantine’s efficacy as a 
neuroprotectant for glaucoma, however, was shown to be ineffective, with the variable 
mechanisms of retinal ganglion apoptosis being offered as an explanation (Osborne, 2008), 
although an inadequate design of study and an inappropriate end point could be the reasons 
for this result. 
 
Potential neuroprotective agents aimed at targeting AMPA/Kainite receptors has been widely 
studied, DNQX, 6,7-Dinitroquinoxaline-2,3-dione, is an AMPA receptor antagonist that has 
shown greater enhancement of RGC survival than MK-801 (Schuettauf et al., 2000), whilst 
Riluozole has been shown to decrease pressure induced apoptosis and enhance ERG wave 
recovery, highlighting the benefits of targeting multiple receptors in excitotoxic cell death. 
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Another potential neuroprotective pathway is through the mediation of acetylcholine (ACh) 
receptors, as has been seen in studies on the ACh esterase inhibitor, Galatamine, a drug 
clinically used in the treatment of AD. Galatamine potentially activates muscarine AChR, 
leading to RGC protection independent of IOP level (Almasieh et al., 2010). 
 
Drugs designated to target β-Amyloid (Aβ) include β-secretase inhibitors (ΒSI) such as N-
benzyloxycarbonyl-Val-Leu-leucinal (Z-VLL-CHO) which has been found to reduce RGC 
apoptosis in vitro and in vivo (Yamamoto et al., 2004;Guo et al., 2007a), as well as Congo 
red and Anti-Aβ antibodies (Lorenzo and Yankner, 1994;Guo et al., 2007a). Triple therapy, 
targeting different stages of the Aβ pathway using ΒSI, Anti-Aβ antibodies and Congo red, 
has a superior neuroprotective effect on RGC apoptosis in a rat ocular hypertension, both in 
vitro and in vivo in relation to singular treatments (Guo et al., 2007a). 
 
Several compounds, outlined in Table 1.3, have been proposed to enhance the available 
energy within the cell and prevent mitochondrial depolarization. Coenzyme Q10 (CoQ10), also 
known as Ubiquinone, plays an indispensable role in energy metabolism. It serves as a co-
factor within the respiratory chain, carrying electrons and facilitating ATP production. It has 
been found to be highly effective as a neuroprotectant in animal models of neurodegenerative 
diseases such as Parkinson's disease, Huntington's disease and Friedreich's ataxia (Beal, 
2003). Its neuroprotective effect on RGCs both in vivo and in vitro, is believed to be 
multifactorial (Nucci et al., 2007b;Nakajima et al., 2008), exerted not only through mediation 
of electron transport from complex I and II to complex III within the electron transport chain 
but also through its antioxidant properties, regulation of gene expression, and inhibition of 
the PTP (Papucci et al., 2003;Cheung et al., 2008a). 
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Anti-inflammatory drugs, which target the TNF-α signalling pathway and displayed 
neuroprotective activity has become an area of increasingly active investigation including as 
can be seen in Table.1, Agmatine, Curcumin, Pitavastatin, and GLC756. 
 
The most promising anti-inflammatory drug is Copolymer-1 (Cop-1), also known as 
glatiramer acetate, which was approved by the FDA to treat Multiple Sclerosis (MS). Cop-1 
is a low affinity synthetic non-encephalitogenic analogue to myelin basic protein, triggering a 
neuroprotective autoimmune response, by binding to MHC proteins and cross reacting with 
various T cell and CNS myelin. Cop-1 displayed neuroprotective activity on RGCs in vivo in 
the rat model of optic nerve crush (Kipnis et al., 2000), in animal models of high IOP 
(Bakalash et al., 2003;Ben Simon et al., 2006), and against glutamate-induced excitotoxicity 
(Schori et al., 2001). This neuroprotective effect is believed to be mediated by increasing the 
number of T-Lymphocytes in a rat model of glaucoma (Li et al., 2008). 
 
Various growth factors have successfully been investigated as a neuroprotectant, as seen in 
Table 1.3 Ocular application of the NGF has demonstrated neuroprotective effects both 
experimentally in the Morrison’s glaucoma model (Lambiase et al., 2009;Colafrancesco et 
al., 2010) and clinically in patients with progressive visual field defects despite controlled 
IOP (Lambiase et al., 2009).  However, sustainability remains a limitation. Following 
prolonged treatment with neurotrophins, RGCs exhibited a decrease in neurotrophin receptor 
expression reducing the effectiveness of the treatment. To overcome this a combination of 
neurotrophin and TrkB gene transfer has been performed to up regulate the receptors and 
protect RGCs in vivo in the axotomy model (Cheng et al., 2002). 
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The field of gene therapy in neuroprotection has been recently investigated and it is growing 
rapidly (Wax and Patil, 1994;Liu et al., 2009). In glaucoma it is becoming a highly accessible 
approach (Harvey et al., 2006), because trabecular meshwork, ciliary epithelium, ciliary 
muscle, Muller cells and RGCs are all appropriate target structures for gene therapy, with 
various delivery systems having been tested including: adenoviruses (Ads), 
adenoassociated viruses (AAVs), herpes simplex viruses (HSVs), lentiviruses (LVs; feline 
immunodeficiency virus (FIV) human immunodeficiency virus (Kroemer et al.), liposomes 
(LPs), and naked DNA(Borras et al., 2002). 
 
A promising agent for glaucoma therapy is BIRC-4, also known as XIAP (IAP: inhibitors of 
apoptosis protein). Intravitreal injection of adeno-associated viral vector using chicken-β-
actin (AAV-CBA) coding for human BIRC4 in the rat model of chronic glaucoma resulted in 
marked reduction in RGC apoptosis which lasted for 12 weeks. This neuroprotective effect is 
believed to be mediated either via direct inhibition of caspase-3 and caspase-8, or indirectly 
by maintaining the neurotrophin production from Muller cells and influencing aqueous 
humour circulation or a combination of both (McKinnon et al., 2002b).   
 
The last group in Table 1.6 includes compounds with multiple mechanisms of action: 
Estrogens, Brimonidine and Cannabinoids. Estrogens, cholesterol derived steroid hormones, 
maintain the normal function of various organs, with estrogen receptors ERα and ERβ widely 
expressed in human and animal retinal tissues (Kobayashi et al., 1998;Ogueta et al., 1999). 
Estrogen has demonstrated neuroprotective effects on animal models of Alzheimer's 
(Simpkins et al., 2005) and other neurological diseases (Hoffman et al., 2006) The 
neuroprotective action of estrogen is believed to be mediated via multiple mechanisms; the 
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binding with estrogen receptors ERα and ERβ (Singer et al., 1996;Dubal et al., 
2001;D'Astous et al., 2004), activation of antiapoptotic genes such as Bcl-2 and Bcl-xl 
(Garcia-Segura et al., 1998), inhibition of mitochondrial oxidative stress (Razmara et al., 
2007), inhibition of β-amyloid induced neuronal death, as well as stimulation of Akt/PI-3k 
pathway (Honda et al., 2000;Zhang et al., 2001). 17β-estradiol of rat cortical neurons exposed 
to glutamate demonstrated increased neuronal integrity and function mediated possibly via a 
reduction in the levels of caspase-3 and calpain (Sribnick et al., 2004).  
An Estradiol analogue has also demonstrated protective effects on the retinal pigment 
epithelium (RPE) (Dykens et al., 2004;Yu et al., 2005), and on the RGCs in vitro (Kumar et 
al., 2005) and in vivo (Nakazawa et al., 2006;Zhou et al., 2007).  
 
Brimonidine tartrate 0.2% is known also as UK-14, 304, is a third generation α2 adrenergic 
agonist that draws the interest of many researchers in the field of neuroprotection. The 
neuroprotective effect of Brimonidine on RGCs has been demonstrated in vivo (Wheeler et 
al., 1999;Donello et al., 2001;WoldeMussie et al., 2001) and in vitro (Knels et al., 2008). The 
mode of action for Brimonidine however remains unclear with various proposed 
mechanisms. The positive effect of Brimonidine on RGC survival, that includes a reduction 
in their soma size in a rat model of ocular hypertension, is believed to be mediated through 
the attenuation of glutamate toxicity and the up regulation of brain-derived neurotrophic 
factors (Hernandez et al., 2008). However, in a rat model of pressure-induced retinal 
ischemia, Brimonidine’s neuroprotective effect was suggested to be mediated via induction 
of anti-apoptotic genes Bcl-2 and Bcl-x, as well as extracellular-signal-regulated kinases and 
phosphatidylinositol-3′ kinase/protein kinase Akt pathways (Lai et al., 2002). Whilst, 
Brimonidine’s effect on RGCs in isolated rat retinas, as well as in vivo in rat and rabbit 
glaucoma models was shown to be mediated through the reduction of α2-adrenoceptor 
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mediated reduction of intracellular cAMP (Dong et al., 2008). 
A clinical trial assessing the non-IOP-related effects of Brimonidine, demonstrated a 
reduction in visual field deterioration in comparison to 360° laser trabeculoplasty (Gandolfi 
et al., 2004), whilst the promising result of Brimonidine treatment in the Low-Pressure 
Glaucoma Treatment Study are now published (Krupin et al., 2011). 
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Table 1.3 Summary of potential neuroprotective agents and their pro-apoptotic targets 
Pro-Apoptotic 
Mechanism  
Target      Compound   Model     References 
Oxidative stress NOS Ginkgo biloba in vitro Alloxan, Glutamate 
Dexamethsone. 
in vivo   OHT 
 (Thiagarajan et al., 2002)      
 
(Hirooka et al., 2004) 
  Aminoguanidine            in vitro explant                                                                                       
in vivo OHT                                                    
(Katsuki et al., 2004)
 (Neufeld et al., 1999;Neufeld, 2004)    
 ROS Brazilian green 
Propolis 
in vitro H2O2, SSP, Oxygen-Glucose 
deprivation/Reoxygenation 
in vivo   NMDA 
(Inokuchi et al., 2006;Nakajima et al., 2009a) 
 
(Inokuchi et al., 2006)    
  Carotenoids  in vitro H2O2, SS     
in vivo  OHT, Ischemia 
(Nakajima et al., 2009b) 
(Neacsu et al., 2003;Li et al., 2009) 
  Melatonin  in vitro     Ischemia, Kainate   
in vivo Ischemia, Kainate                    
(Cazevieille and Osborne, 1997) 
(Siu et al., 2004;Tang et al., 2006) 
  Tocopherol   in vitro H2O2 
in vivo ischemia 
(Nakajima et al., 2008) 
(Aydemir et al., 2004) 
  PPAR-g agonists             in vitro glutamate (Aoun et al., 2003)  
Protein Misfolding Aß Congo Red in vitro 
in vivo OHT,  Aß 
(Yamamoto et al., 2004) 
 (Lorenzo and Yankner, 1994;Guo et al., 2007a) 
  Anti-ß-amyloid in vitro 
in vivo OHT,  Aß 
(Yamamoto et al., 2004) 
 (Lorenzo and Yankner, 1994;Guo et al., 2007a) 
 ß-secretase  
 
Z-VLL-CHO                       in vitro 
in vivo OHT,  Aß 
(Lorenzo and Yankner, 1994) 
(Guo et al., 2007a) 
 HSP GGA in vivo OHT (Ishii et al., 2003) 
Mitochondrial 
Dysfunction 
ROS FK506 
 
in vivo Optic Nerve Crush 
in vitro Ischemia 
(Huang et al., 2005) 
(Chidlow et al., 2002) 
  Lipoic Acid In vivo (Aged, Ischemia) (Hagen et al., 1999;Chidlow et al., 2002;Liu et al., 
2002)                                                   
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Pro-Apoptotic 
Mechanism 
Target      Compound   Model     References 
 ROS, NF-kB 
 
 
Creatine 
 
in vitro Glutamate 
in vivo Animal Model, MPTP 
(Klivenyi et al., 1999;Juravleva et al., 2005) 
(Matthews et al., 1998;Klivenyi et al., 
1999;Matthews et al., 1999) 
  
Unknown 
 
 
EGCG 
 
In vitro Ischemia, Light insult, H2O2 
 
in vivo Ischemia. 
 
(Yang et al., 2007;Zhang et al., 2007;Zhang et al., 
2008) 
(Negishi et al., 2004;Zhang et al., 2007;Zhang et 
al., 2008) 
 PI3-Akt, NF-kB       
 
Erythropoietin 
 
in vivo Ischemia, Optic Neuritis, 
Axotomy, Cytokines, DBA/2J 
(Digicaylioglu and Lipton, 2001;Junk et al., 
2002;Sattler et al., 2004;Kilic et al., 2005b;Zhong 
et al., 2007) 
 Unknown Nicotinamide in vitro Ischemia, Light insult 
 
(Ji et al., 2008) 
 PTP CoQ10 in vitro SS, Antimycin A, Ceramide, 
UVC, H2O2     
in vivo Ischemia, NMDA 
(Papucci et al., 2003;Nakajima et al., 2008) 
 
(Nucci et al., 2007b;Nakajima et al., 2008)                                                                                                                                    
Inflammation and 
immunological 
strategies 
Multiple Curcumin in vitro IS, NMDA,  H2O2 
in vivo ATM 
(Mandal et al., 2009;Teiten et al., 2009) 
(Lim et al., 2001) 
 
 ROS   Pitavastatin  in vivo NMDA (Nakazawa et al., 2007) 
 Myelin Basic 
Protein 
Cop-1 in vivo OHT,Optic Nerve Crush, 
Glutamate 
(Kipnis et al., 2000;Schori et al., 2001;Bakalash et 
al., 2003;Ben Simon et al., 2006;Li et al., 2008) 
 TNF-α  
 
GLC756   in vitro IS 
in vivo IS 
(Laengle et al., 2006) 
 Unknown Agmatine  in vitro Hypoxia, NMDA, TNF-α  (Wang et al., 2006;Hong et al., 2007;Hong et al., 
2009) 
 
  
 
 
 
47 
Pro-Apoptotic 
Mechanism 
Taeget      Compound   Model     References 
Excitotoxicity NMDR Memantine in vitro NMDA 
in vivo OHT, Optic nerve crush, 
UEG, DBA/2J, Ischemia 
(Pellegrini and Lipton, 1993) 
(WoldeMussie et al., 2002;Yucel et al., 2006;Ju et 
al., 2009) 
  MK801 in vitro Hypoxia, Glutamate     
 
(Tsuda, 2004) 
(Russelakis-Carneiro et al., 1996;Solberg et al., 
1997;Chaudhary et al., 1998;Guo et al., 
2006;Russo et al., 2008) 
  Flupritine in vitro  NMDA 
in vivo  Ischemia                  
(Nash et al., 2000) 
(Nash et al., 2000) 
 
   DXM in vitro Hypoxia 
in vivo Laser, OHT, SSP, Subdural 
Hematoma 
(Goldberg et al., 1987) 
(Duhaime et al., 1996;Calzada et al., 2002;Guo et 
al., 2006) 
  Eliprodil     
 
in vitro Glutamate 
in vivo NMDA, Ischemia 
(Kapin et al., 1999;Pang et al., 1999) 
(Kapin et al., 1999) 
  Ifenprodil in vitro Glutamate 
in vivo OHT,SSP       
(Tamura et al., 1993) 
(Guo et al., 2006) 
  P38 inhibitor in vivo Axotomy (Kikuchi et al., 2000) 
 AMPA/Kainate-R Topiramate                 in vitro Glutamate, Kainate 
 
in vivo Ischemia 
(Gibbs et al., 2000;Skradski and White, 
2000;Yoneda et al., 2003) 
(Yoneda et al., 2003) 
  DNQX   in vitro Glutamate 
in vivo Optic Nerve Crush 
(Otori et al., 1998) 
(Schuettauf et al., 2000) 
  Arachidonic Acid in vitro Glutamate 
 
in vivo Kainate 
(Miller et al., 1992;Kovalchuk et al., 
1994;Kawasaki et al., 2002) 
(Cunha et al., 2004) 
 mGluR2/mGluR3 LY354740  in vivo Ischemia, OHT, SSP  (Guo et al., 2006) 
  
 
 
 
48 
 
Pro-Apoptotic 
Mechanism   
Target      Compound   Model     References 
 Ca+2 Flunarizine in vitro NMDA 
in vivo Axotomy, Ischemia, NMDA                                                   
(Osborne et al., 2002) 
(Eschweiler and Bahr, 1993;Osborne et al., 
2002) 
  Diltiazem in vitro Glutamate 
in vivo  Ischemia   
(Vallazza-Deschamps et al., 2005) 
(Vallazza-Deschamps et al., 2005) 
  Riluzole in vivo  Axotomy (Ettaiche et al., 1999) 
  TRPV1 agonist in vitro  hydrostatic pressure   
in vivo  DBA/2 mouse 
(Sappington et al., 2009) 
(Sappington et al., 2009) 
 Na+ channels Phenytoin in vivo  Optic Nerve Crush, OHT (Naskar et al., 2002;Hains and Waxman, 2005) 
 
 ACh-R Galantamine in vivo  Axotomy, OHT  
 
(Tamura et al., 1993) 
Neurotrophin 
withdrawal 
TrkB, p75 BDNF in vitro  BDNF withdrawal 
in vivo Axotomy, Superior Colliculus 
remova, OHT 
(Johnson et al., 1986;Rodriguez-Tebar et al., 
1989) 
(Mansour-Robaey et al., 1994;Cui and Harvey, 
1995) 
  NT-1 in vivo  Optic Nerve Crush, NMDA (Senaldi et al., 1999;Schuettauf et al., 2005) 
 TrkB NT-4/5 in vivo Superior Colliculus removal (Cui and Harvey, 1995) 
 CNTF receptor CNTF in vivo OHT (Ji et al., 2004;Pease et al., 2009) 
 GFRA-1,GFRA-2 GDNF in vivo OHT (Jing et al., 1996;Naskar et al., 2000;Jiang et 
al., 2007;Ward et al., 2007) 
 TrkA NGF TrkA agonist in vivo OHT, axotomy (Lambiase et al., 2009;Lebrun-Julien et al., 
2009;Colafrancesco et al., 2010) 
Gene therapy RrkB, BIRC-4, 
GDNF 
Viral Vectors in vivo OHT, axotomy (Cheng et al., 2002;McKinnon et al., 
2002b;Pease et al., 2009) 
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NMDA= N-methyl-D-aspartic acid, OHT= Ocular Hypertension, UEG= Unilateral experimental glaucoma, DBA/2J= Mouse model of Glaucoma, MCAO= Middle Cerebral 
Artery Occlusion, SSP= staurosporine, DXM= Dextromethorphan, DNQX= 6,7-Dinitroquinoxaline-2,3-dione, ROS=Reactive Oxygen Species, MPTP= 1methyl-4-phenyl-
1,2,3,6-tetrahydropyridine, EGCG= Epigallocatechin Gallate, PTP= Mitochondrial Permeability Transition Pore, SS= Serum Starvation, UVC= Ultraviolet Subtype C, Aß = 
Amyloid-ß,  HSPs= Heat Shock Proteins, GGA= Geranylgeranylacetone, NOS= Nitric Oxide Synthase, IS= Immune Stimulated, TNF-α = Tissue Necrosis Factor α , 
ATM=Alzheimer transgenic mouse, SHRSP= stroke-prone spontaneously hypertensive rats, ACh-R= acetylcholine receptors. Taken from (Baltmr et al., 2010)
Pro-Apoptotic 
Mechanism 
Target      Compound   Model     References 
Multiple 
mechanisms 
Multiple Estrogen in vitro Glutamate 
in vivo Ovariectomy, DBA/2J 
(Sribnick et al., 2004;Kumar et al., 2005) 
(Nakazawa et al., 2006) 
  Brimonidine in vitro NMDA, Glyoxal, H2O2 
in vivo Ischemia, Optic Nerve Crush, 
OHT 
(Knels et al., 2008) 
(Wheeler et al., 1999;Donello et al., 
2001;WoldeMussie et al., 2001;Lai et al., 
2002;Dong et al., 2008;Hernandez et al., 2008) 
  Cannabinoids in vitro Potassium Chloride, 
Ischemia 
in vivo NMDA, Ischemia 
(El-Remessy et al., 2003;Nucci et al., 2007a) 
 
(Opere et al., 2006) 
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1.2 Ginkgo biloba 
 
 
Ginkgo biloba has been integral part of traditional medicine for centuries, for treating 
a wide range of neurodegenerative diseases including Alzheimer’s disease (Kanowski 
et al., 1996;Ahlemeyer and Krieglstein, 2003;Yancheva et al., 2009), AMD 
(Lebuisson et al., 1986)  and low-tension glaucoma (Quaranta et al., 2003). Ginkgo 
biloba has attracted considerable interest because it is believed to have several 
biological actions which combine to make it a potentially significant agent in 
neurodegenerative diseases including improvement of central and peripheral blood 
flow, reduction of vasospasm, reduction of serum viscosity, antioxidant activity, 
platelet activating factor inhibitory activity, inhibition of apoptosis, and inhibition of 
excitotoxicity (Ahlemeyer and Krieglstein, 2003;Chan et al., 2007). 
 
1.2.1 Plant Description and the available forms 
 
 
Ginkgo biloba tree is believed to be one of the oldest existing species, which has been 
used in non-conventional Chinese medicine since 3000BCE (Ritch, 2000) and it is  
amongst the most extensively studied plant–based drug nowadays (van Beek and 
Montoro, 2009).  
The Ginkgo biloba tree, which is also  known as Fossil tree, Kew tree and Maidenhair 
tree (Diamond et al., 2000), has short branches with two lobed, fan shaped leaves 
around 3 inches long with indigestible fruits. The fruit contains an inner seed (ibid). 
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Figure 1.7 Ginkgo biloba leaves and fruits 
Taken from (RAKSA THAI HERBS CO., 2010) 
 
The leaves of Ginkgo biloba are subjected to multistep extraction procedure to form a 
concentrated standardized extract, Ginkgo biloba extract (EGb761) (Chan et al., 
2007). EGb761 is a brown powder with a characteristic odor (van Beek and Montoro, 
2009), which contains two major pharmacologically active groups of compounds: 
24% flavone glycosides and 6% terpene trilactones (van Beek, 2002). Flavone 
glycosides are composed of quercetin, kaempferol and isorhamnetin glycosides (1–3) 
and the terpene trilactones are composed of A, B, C, and J ginkgolides and bilobalide. 
In addition, the extract also contains non-flavonol glycosides, proanthocyanidins, 
carboxylic acids that can be divided into non-phenolic and phenolic acids. The 
phenolic acid including ascorbic, D-glucaric acid, quinic acid and shikimic acid, and 
the phenolic acids includes 6-hydroxykynurenic acid (6-HKA). EGb 761 also contains 
alkylphenols, glucose, rhamnose and various other constituents (Ahlemeyer and 
Krieglstein, 2003;van Beek and Montoro, 2009). EGb761 constituents are illustrated 
  
 
 
 
52 
in table 1.4 and the chemical structure of the terpene trilactones fraction of Ginko 
biloba: Ginkgolides and Bilobalide, principle constituents of Ginkgo biloba, which 
have been used in this study are given in Figure 1.2 
Ginkgo biloba is available as the standardized extract EGb 761, in the form of 40-240 
mg tablets, 40 mg eye drops, fluid extract, alcoholic extract with 40-60% ethanol 
(tinctures), or fluid extract made with glycerites and as a dried leaf for tea (Chan et 
al., 2007). The recommended daily dose of EGb761 is 120-240 mg/day, with the 240 
mg having superior therapeutic effect (Diamond et al., 2000;Le Bars and Kastelan, 
2000).   
 
 
Table 1.4 Constituents of Ginkgo biloba extract EGb761Table  
Compound 
 
Percentage % 
Flavone glycosides: 
Quercetin, kaempferol and isorhamnethin 
24% 
Terpene trilactones: 
1. Bilobalide  
2. Ginkgolide A, B, C and  J 
6% 
2.9% 
3.1% 
Carboxylic acids  13% 
Proanthocyanidins 7% 
Non-flavonol glycosides 20% 
Water, solvent 3% 
Inorganic constituents 5% 
Various 3% 
Unknown 13% 
Alkylphenols ≤ 5 mg/kg 
 
 
 
 
  
 
 
 
53 
 
 
 
 
 
 
 
Figure 1.8 Chemical structure of Ginkgolide A and Bilobalide 
Taken from (Chan et al., 2007)     
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1.2.2 Pharmacokinetics of Ginkgo biloba 
 
 
 
The half-life of Ginkgo biloba extract after oral administration is around 4.5 hours 
(Diamond et al., 2000;Chan et al., 2007). The pharmacological effect of EGb 761 is 
believed to be mediated via its two main chemical constituents, flavone glycosides and 
terpene trilactones. Nevertheless, the poor lipid solubility of flavone glycosides 
remains the main reason for the poor bioavailability of EGb 761 (Chen et al., 2010), to 
overcome this obstacle a recent development of a novel formulation of flavone 
glycosides has been made by Chen et al (2010). This was through preparing Ginkgo 
biloba extract phospholipid complexes and Ginkgo biloba extract solid dispersions. 
The authors have shown that these formulation had superior bioavailability compared 
with the standardized EGb 761 (Chen et al., 2010). 
In an animal models, 21% of GBE is excreted in the urine and 29% is excreted in 
faeces, with an absorption estimated at 60% (Diamond et al., 2000;Chan et al., 2007). 
A summary of some of the pharmacokinetic studies that have been carried out in vitro 
and in vivo in experimental animals or in human is provided in table 1.5 
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Table 1.5 Pharmacokinetic studies on Ginkgo biloba  
Compound Model Half-life t 1/2 References 
Ginkgolide A, B, C and 
Bilobalide 
in vivo I/V, rat 0.97, 1.02, 0.67, 1.13 (Xie et al., 2008) 
Ginkgolide B in vitro rat urine, rat liver 
microsomes 
- (Wang et al., 2008) 
EGb 761 in vivo oral, humans, 
analysis of urine 
- (Wang et al., 2003) 
Quercetin, Kaempferol 
and Isorhamnetin 
in vitro human breast cancer 
cells 
- (Wang et al., 2005a) 
EGb761, bilobalide, 
Ginkgolide A and 
Ginkgolide B 
in vivo oral, humans, 
analysis of plasma 
2.33, 2.31, 2.34 (Woelkart et al., 2010) 
Ginkgolide B 
40mg/80mg 
in vivo oral, humans, 
analysis of plasma 
11.64 /4.31 (Drago et al., 2002) 
 
 
 
 
 
 
1.2.3 Pharmacological activities of Ginkgo biloba 
 
 
Ginkgo biloba has a broad spectrum of pharmacological activities, which are derived 
from its various constituents. The administration of each of these alone is expected to 
exert a different action, as compared to when it is given together with the other 
constituents of the extract (DeFeudis and Drieu, 2000). This range of pharmacological 
activities includes, effects on nitric oxide (Kobuchi et al., 1997;Bastianetto et al., 
2000b;Ahlemeyer and Krieglstein, 2003) and modulation of ROS (Szabo et al., 
1993;Oyama et al., 1996;Zhou and Zhu, 2000;Thiagarajan et al., 2002), preservation 
of mitochondrial function (Chandrasekaran et al., 2001;Tendi et al., 2002;Eckert et 
al., 2003;Wang et al., 2005b;Abdel-Kader et al., 2007) and platelet activating factor 
(Kobuchi et al., 1997) as well as the inhibitory action on some apoptosis related 
caspases (Luo et al., 2002;Smith et al., 2002;Massieu et al., 2004). Furthermore, 
Ginkgo biloba has demonstrated effects on cellular peptide such as APP and Aβ (Yao 
et al., 2001;Bastianetto and Quirion, 2002;Gong et al., 2005;Wu et al., 2006;Augustin 
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et al., 2009;Shi et al., 2009) and on inflammatory mediators (Jiao et al., 2005;Park et 
al., 2006;Zhou et al., 2006;Kotakadi et al., 2008;Tsao et al., 2008;Zhou et al., 2010). 
Ginkgo biloba appears also to influence an ionic channel such as the glutamate-gated 
cation channel (NMDA) (Zhu et al., 1997;Wang et al., 2005b;Xu et al., 2010;Li et al., 
2011), GABA-gated chloride channels (Kiewert et al., 2007), with modulatory action 
on  neurotransmitters such as glycine (Kiewert et al., 2008). 
 
The flavone glycosides including quercetin, kaempferol and isorhamnetin have the 
potential to modulate oxidative metabolism, and are believed by some authors to be 
responsible for the free radical scavenging effects of Ginkgo biloba. Oyama et al 
(1994) have investigated the antioxidant action of myricetin, quercetin and 
kaempferol, on oxidative metabolism of neuronal cells, and the authors found a 
significant reduction in oxidative metabolism in both resting and calcium loaded 
neurons in comparison with EGb 761, possibly via a reduction in the cellular content 
of superoxide anion (Oyama et al., 1994). Flavone glycosides have also been shown 
to protect and rescue rat hippocampal cells from nitric oxide-induced toxicity, via free 
radical scavenging effect, and blocking nitric oxide-induced stimulation of protein 
kinase C (Bastianetto et al., 2000b). 
 
The terpene trilactone fraction of Ginkgo biloba: Ginkgolides and Bilobalide is 
believed to mediate its anti-inflammatory effect. Park and colleagues (2006) 
compared the effect of EGb 761 and another Ginkgo biloba extract with a higher level 
of terpene, a lower level of flavonol glycosides, and none detectable 
proanthocyanidins, known as (GBB) on lipopolysacharide-induced nitric oxide (NO) 
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and prostaglandin (PGE2) release in the macrophage cell line RAW 264.7. They have 
shown that GBB was more potent than EGb 761 in blocking lipopolysacharide and 
TNF-α-induced expression of iNOS and COX-II via suppression of NF-κB (Park et 
al., 2006). Furthermore, treatment with terpene fraction extracted from EGb 761, 
showed a therapeutic effect parallel to treatment with indomethacin, an anti-
inflammatory agent, on Candida albicans-induced arthritic inflammation and 
suppressed NO production in lipopolysacharide-treated macrophages (Han, 2005). 
Ginkgo biloba extract enriched 10 times in terpene trilactones have been found to be 
more effective than EGb 761 in rescuing hippocampal neurons from Aβ-induced 
synaptic dysfunction and this protection is believed to be mediated mainly by 
Ginkgolide J (Vitolo et al., 2009). Another proposed mechanism for terpene 
trilactones is via antagonistic effects on the inhibitory glycine and GABA receptors 
(Ivic et al., 2003). 
 
Ginkgolides, particularly Ginkgolide B (GB), in addition to its anti-inflammatory 
action are selective agonists on platelet activating factor receptor (PAF-R), where it 
competes with the platelet activating factor (PAF) and acts as effective anti-platelet 
factor antagonists, therefore preventing platelet aggregation and thrombus formation 
(van Beek and Montoro, 2009;Chen et al., 2010). Ginkgolide B has also been shown 
to protect primary cultured neurons from glutamate-induced excitotoxicity. This 
protection was more pronounced than EGb 761 and inferior to MK-801 (Xu et al., 
2010). Another study has shown that Ginkgolide A (GA) has an inhibitory effect on 
Aβ oligomerization and Aβ-induced paralysis in transgenic caenorhabditis elegans 
(Wu et al., 2006).  
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The Bilobalide (Bil), which constitutes 2.9% of terpene trilactones (Chan et al., 2007), 
has been investigated by several in vivo and in vitro studies, and is believed to have 
anti-ischemic and anti-edematous effects on cerebral neurons, and to mediate the 
neuroprotective effects of ginkgo biloba (Defeudis, 2002). Kiewert et al (2007; 2008) 
investigated the interaction between bilobalide and neuronal transmission mediated by 
gamma-aminobutyric acid and glycine, in rat hippocampal slices exposed to NMDA 
(Kiewert et al., 2007;Kiewert et al., 2008). Other research studies have shown that 
bilobalide can modulate gene expression by enhancing expression of mRNA-encoded 
COX III subunit of cytochrome oxidase in the resistant hippocampal CA1 neurons, 
which are challenged by global brain ischemia (Chandrasekaran et al., 2001) and 
enhancing the level of mRNA for the mtDNA-encoded subunit 1 of NADH 
dehydrogenase in PC12 cells (Tendi et al., 2002). In addition, simultaneous treatment 
of PC12 cells with ROS and bilobalide has resulted in a dose dependent reduction in 
the apoptotic rate via reducing ROS-induced elevation of Bax and caspase-3 
activation (Zhou and Zhu, 2000). In another experiment, bilobalide, ginkgolides A 
and J have demonstrated anti-apoptotic effect in cultured chick embryonic neurons 
and in a mixed culture of hippocampal neurons subjected to staurosporine and serum 
deprivation, with more protection being observed with bilobalide (Ahlemeyer et al., 
1999).  
 
Although flavone glycosides and terpene trilactones fractions of EGb 761 are believed 
to be the neuroprotective constituents of Ginkgo biloba (Defeudis, 2002;Ahlemeyer 
and Krieglstein, 2003), other constituents are not devoid of pharmacological activity, 
and even though their precise contribution to the Ginkgo biloba neuroprotective effect 
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are not clear in literature, future research studies should be directed to elucidate their 
neuroprotective properties. Those include proanthocyanidins, which are antioxidant 
oligomers and polymers of monomeric flavans, forming  approximately 7% of EGb 
761 and they occur in Ginkgo leaves as well in the standardized extract (van Beek, 
2002).  
The phenolic acid 6-HKA, a derivative of kynurenic acid, is among the carboxylic 
acids occurring in EGb 761. It is believed to have low affinity, antagonistic activity at 
the NMD and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors 
(Weber et al., 2001). In comparison to other derivatives of kynurenic acid, 6-HKA 
displayed superior affinity to AMPA receptors in hippocampal CA1 neurons. In 
addition its affinity to the NMDA receptors was half that of the parent compound, 
which reduces the side effects of the 6-HKA as compared with the high affinity 
antagonist, and adds to its therapeutic potentials (Weber et al., 2001). 
There are six different types of alkylphenols that have been reported to occur in leaves 
of Ginkgo biloba (ginkgolic acids, ginkgols, bilobols, urushiols, isourushiols and α-
hydroxycardanols), which constitute only less than 5 part per million of EGb 761 
because of their allergic, cytotoxic and mutagenic side effects (van Beek, 2002;van 
Beek and Montoro, 2009). 
Ginkgo biloba is generally a safe compound; however, there are some reported 
adverse effects including  spontaneous hyphema (Rosenblatt and Mindel, 1997), 
spontaneous subdural hematoma (Rowin and Lewis, 1996)mild GIT upset and 
headache. 
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1.2.4 Ginkgo biloba in clinical trials  
 
Ginkgo biloba has been advocated for the potential treatment of acute mountain 
sickness (Bartsch et al., 2004), tinnitus (Smith et al., 2005), diabetic nephropathy (Lu 
and He, 2005), bleeding disorders (Jiang et al., 2005) and intermittent claudication 
(Pittler and Ernst, 2000). However, there has been no substantial evidence of its 
therapeutic efficacy in these conditions. 
The potential efficacy of Ginkgo biloba in alleviating memory impairment and other 
cognitive disorders associated with Alzheimer’s and age related dementia, are widely 
suggested (DeFeudis and Drieu, 2000;Chan et al., 2007). However, clinical trials 
showed contradictory results about the benefits of Ginkgo biloba supplement in 
treating those conditions. A randomized clinical trial conducted for 6 weeks on 
patients with memory impairment, indicated that the Ginkgo biloba group did not 
differ from the controls, and that Ginkgo biloba supplement provided no enhancement 
in memory or related cognitive function (Solomon et al., 2002). Conversely, Le Bars 
et al (2002) documented improvement in the cognitive and social function in patients 
with mild and moderate Alzheimer’s disease (Le Bars et al., 2002). These conflicting 
results in fact necessitate the need for clinical trials with large sample sizes and long 
follow-up periods.  
Compared with the large number of clinical trials conducted to evaluate the effect of 
EGb 761 in other neurodegenerative diseases, only a few trials were conducted to 
evaluate its ophthalmic potential. EGb 761 has a demonstrated vasomodulatory effect 
on blood vessels, where it increases the ocular blood flow velocity by a mean of 24% 
compared to placebo (Chung et al., 1999). However, a randomized, double-masked, 
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placebo-controlled study was conducted over 2 years to investigate the effect of oral 
administration of 240 mg EGb 761 on ocular blood flow. This study on 15 healthy 
male volunteers failed to confirm a significant association between administration of a 
single dose of EGb 761 and the ocular blood flow (Wimpissinger et al., 2007), 
however, this result should not preclude its use in conditions with impaired ocular 
perfusion such as glaucoma, because it could be due to the small sample size, or the 
selected dose, or another possible neuroprotective mechanism for Ginkgo biloba. This 
is supported by an earlier prospective, randomized, placebo-controlled, double-
masked trial, which was conducted in a sample of 27 patients with normal tension 
glaucoma, to evaluate the effect of EGb 761 on preexisting visual field damage, and 
reported improvements in automated visual field indices, with no significant changes 
in IOP, blood pressure or heart rate (Quaranta et al., 2003).  
A summary of clinical trials that have demonstrated the effects of Ginkgo biloba 
supplementation in Alzheimer’s dementia and in the eye is provided in Table 1.6 
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Table 1.6 Clinical trials on Ginkgo biloba  
Neurodegenerative 
diseases 
Main outcome measure  Outcome 
 
Dose/Route  
of administration 
Duration/ No of 
participant 
References 
Alzheimer’s Psychopathological and 
cognitive function tests 
Improvement of dementia 
and cognitive impairment 
were same as cholinesterase 
inhibitors. 
 
160 mg EGb 761 per day, 
5mg donepezil 1x1/ oral 
 
24 weeks, 
76 patients 
(Mazza et al., 2006) 
Cognitive function and 
activity of daily living tests 
Decrease risk of developing 
Alzheimer’s dementia. 
 
- 7 years, 1462 
elderly women 
(Andrieu et al., 2003) 
Neuropsychological tests 
of cognitive functions 
Improve cognitive and social 
functions.  
40 mg EGb 761, 1x 3/oral 52 weeks, 168 
patients 
(Le Bars et al., 1997;Le 
Bars et al., 2002) 
 
Neuropsychological tests 
of cognitive functions 
No beneficial effects were 
observed. 
 
40 mg EGb 761, 1x 3/ 
oral 
 
6 weeks, 230 
elderly volunteers 
 
(Solomon et al., 2002) 
 
Neuropsychological tests Sig. improvement in memory 
and congnation. 
120mg per day/ oral 3o days, 61 
participants 
(Stough et al., 2001) 
Psychopathological 
neuropsychological,  and 
electrophysiological tests 
Sig. improvement of 
attention and memory 
function. 
 
40 mg EGb 761, 2x 3/ 
oral 
3 months, 20 
patients 
(Maurer et al., 1997) 
Psychopathological and 
neuropsychological tests of 
cognitive and behavioral  
functions 
Sig. improvement of 
attention and memory 
performance. 
 
120 mg EGb 761, 1x 2/ 
oral 
24 weeks, 216 
patients 
(Kanowski et al., 1996) 
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Ocular disease Main outcome measure Outcome 
 
Dose/Route of 
administration 
Duration/ No of 
participant 
References 
Glaucoma VF and any ocular or 
systemic complications 
Sig. improvement in VF 
parameters, no Sig. changes 
in IOP, BP or HR. 
 
40 mg EGb 761, 1x 3/ 
oral 
 
4 weeks/27 patients (Quaranta et al., 2003) 
Doppler imaging to 
measure EDV in OA 
Sig. increase in EDV in OA. 40 mg EGb 761, 1x 3/ 
oral 
2 days/11 
volunteers 
(Chung et al., 1999) 
Doppler imaging to 
measure OBF  
No Sig changes in ocular and 
systemic hemodynamics 
compared to controls. 
 
240 mg EGb 761,1x 1/ 
oral 
1 day/ 15 healthy 
volunteers 
(Wimpissinger et al., 
2007) 
PVCRD, RD Plasma and tear lipid 
peroxidation and 
antioxidative activity, 
Visual function 
Decrease lipid peroxidation 
and increase antioxidant 
activity in tear and plasma 
and improve visual function. 
 
- -/33 Patients with 
PVCRD, 135 with 
operated RD, 32 
with non-operated 
dystrophic RD, 22 
healthy volunteers. 
(Karazhaeva et al., 
2004) 
AMD Visual function Improve long distant visual 
acuity. 
 
- -/10 patients (Lebuisson et al., 1986) 
DM Anatomical and Visual 
function 
Improve colour vision. 40 mg EGb 761, 1x 3/ 
oral 
3 months/ 15 
patients. 
(Bernardczyk-Meller et 
al., 2004) 
 
SKT (Syndrome Kurz test), CGI (Clinical Global Impression), MMSE (Mini-Mental State Examination), Visual field (V/F), Significant (Sig.), intraocular pressure (IOP), 
blood pressure (BP), heart rate (HR), end diastolic velocity (EDV), ophthalmic artery (OA), Ocular blood Flow  (OBF), peripheral vitreochoreoretinal dystrophies (PVCRD), 
retinal detachment (RD), Age related macular degeneration (AMD), Diabetes Mellitus (DM). 
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1.2.5 Neuroprotective effects of Ginkgo biloba and its potential mechanisms of 
action 
 
1.2.5.1 In the Central Nervous System (CNS) 
 
 
 
Several of the above-mentioned clinical trials in section 1.2.4 as well as recent 
experimental evidence suggest neuromodulatory effect of Ginkgo biloba in the CNS 
and reported its benefit  in improving the symptoms of Alzheimer’s disease and other 
cognitive disorders (Wu and Zhu, 1999;Le Bars et al., 2002;Mazza et al., 
2006;Augustin et al., 2009).  
 
Many research studies attributed the neuroprotective effect of Ginkgo biloba to its 
outstanding antioxidant capacity (DeFeudis and Drieu, 2000). This was observed in 
aged brain and liver where EGb 761 protected mitochondrial DNA from free radical 
attack (Sastre et al., 2002), and from nitric oxide induced toxicity (Bastianetto et al., 
2000b).  The neuroprotective effect has also been observed  in cerebellar neurons 
stressed by H2O2 (Oyama et al., 1996). Bastianetto et al have shown that 100 µg/ml 
EGb 761 protects rat primary mixed hippocampal culture from sodium nitroprusside 
(SNP) induced neuronal loss which is believed to be mediated through blockade of 
Protein Kinase C (PKC) activity and superoxide scavenging properties (Bastianetto et 
al., 2000b).  
 
Aβ-induced neuronal death has been attributed in part to increased ROS production 
by Aβ and the resultant oxidative damage (Shi et al., 2009). An in vitro study looking 
at Aβ-induced apoptosis in a pheochromocytoma neuronal cell line (PC12) 
demonstrated that exposure to Aβ1-42 has increased ROS levels and that simultaneous 
administration EGb 761 completely prevented the toxic effect of Aβ (Yao et al., 
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2001). Furthermore, in the same experiment, higher concentrations of EGb 761 were 
associated with increased cell viability measured using 3-4,5-dimethyithiazol-2-yl-
2,5-diphenyl-tetrazolium bromide (MTT) and trypan blue assays. The mechanism of 
this neuroprotection of EGb 761 is thought to be through its inhibitory effect on Aβ 
derived diffusible neurotoxic ligands, presumably dimmer and tetramer of Aβ 
oligomer. This experiment also pointed out that flavone glycosides and terpene 
trilactones-free extract prepared from EGb 761 did not confer any protection against 
Aβ-induced apoptosis (Yao et al., 2001). 
 
The effect of EGb 761 and its constituents, the flavone glycoside quercetin, and the 
terpene trilactone ginkgolide B, were tested against 100 µg Aβ1-42-induced ROS 
accumulation and mitochondrial dysfunction in human neuroblastoma (SH-SY5Y) 
cells (Shi et al., 2009). The result showed mitochondrial protection mainly by EGb 
761 and to a lesser extent by ginkgolide B. This reduction in Aβ-induced 
mitochondrial dysfunction is believed to be mediated via modulation of downstream 
effectors in the apoptotic pathway such as JNK, ERK1/2 and Akt signalling pathways. 
Moreover, it was found that, EGb761 prevented both H2O2 and platelet activating 
factor-induced apoptosis (Shi et al., 2009). Constitutes of Ginkgo biloba have shown 
protective effects even on Aβ25-35 induced cytotoxicity. PC12 cells treated with 100 
µM/l Aβ25-35  for 24 hours were associated with cell loss, which was attenuated in a 
dose dependent manner by adding 25-100 µM/l bilobalide (Zhou et al., 2000). 
Furthermore, the inhibitory effect of ascending concentrations from 0.01-1 µM    
Aβ25-35, on cholinergic transmission in a rat hippocampal slices, was examined by Lee 
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et al. (2004). This inhibition was blocked by addition of Ginkgolide B 0.01-10 µM, 
possibly via suppressing potassium-evoked acetylcholine release (Lee et al., 2004). 
 
Augustin et al (2009) have investigated APP as a molecular target of Ginkgo biloba 
neuroprotective effects. The authors examined the effect of dietary supplementation 
with 300 mg/kg of EGb 761 for 1 and 16 months, on APP protein levels in a 
transgenic human APP (Tg2576), model of Alzheimer’s disease. Up to a 50% 
reduction in the APP level in the cortex of the 16 months group was reported by this 
group, whereas no such reductions were observed in the hippocampus or in young 
mice (Augustin et al., 2009). To examine the effect of EGb 761 on the α-secretase 
pathway, another study using a daily dose of 80 and 150mg/kg/day EGb 761 was 
administered orally for 5 days to normal Sprague-Dawley (SD) rats. 5 days after 
commencement of treatment, western blot analysis was used to measure soluble α 
APP in the cortex and hippocampus. EGb 761 at 150mg/kg/day was found to 
significantly increase α APP secretion (Colciaghi et al., 2004). Furthermore, the 
authors examined the effect of increasing concentration from 5-200 µg/ml of EGb 761 
on acute hippocampal slice for 30 min. They found that the dose response curve to 
increasing EGb 761 dosage was bell shaped, where immunoreactivity of α APP 
observed with the lowest concentrations and was not seen at higher doses (ibid). 
 
Accumulating evidence suggests a link between Aβ deposition, oxidative stress, and 
apoptosis. Luo et al have looked at the antioxidative, antiamyloidogenic and 
antiapoptotic effects effect of EGb 761 on Aβ accumulation and caspase-3 activation 
using a neuroblastoma cell line (Luo et al., 2002). In this experiment, 40µM Aβ1-40 
was incubated either alone or in the presence of 100g/ml of EGb 761. 
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Immunohistochemical labelling of Aβ showed that EGb 761 prevented Aβ 
accumulation both in vitro and in medium of Aβ producing cells. Furthermore, using 
Mitosensor, the authors have shown that EGb 761 attenuated caspase-3 activity (ibid).  
The effect of EGb 761 on cochlear caspase level has also been investigated as a 
possible mechanism in age related hearing loss. EGb 761 administered orally at a dose 
of 100mg/kg daily to 4 and 12 months old SD rats were associated with a significant 
reduction in age related caspase-3 and caspase-9 activation, an increase in ATP levels, 
and modulation of superoxide dismutase activity in rat cochlea (Nevado et al., 2010). 
 
Ginkgo biloba is proposed to have multiple protective effects on mitochondrial 
function and apoptotic pathways, including stabilization of mitochondrial membrane 
potential, and enhancing respiratory chain energy production as well as down 
regulation of executor caspases. Abdel-Kader et al have investigated the effects of 
EGb 761 in vitro on mitochondrial functions in the PC12, dissociated mice brain cells, 
as well as on isolated mitochondria exposed to serum deprivation, SNP and complex 
inhibitors such as Sodium Azide (NaN3) (Abdel-Kader et al., 2007). They used ATP 
levels and mitochondrial membrane potential as indicators of mitochondrial function; 
and showed enhancement of mitochondrial function even with the lowest EGb 761 
concentration 0.01 mg/ml. Additionally in vivo, the authors found that treating two 
different age groups of mice with EGb 761 100mg/kg for 14 days was associated with 
beneficial effects on complexes I, IV and V of the mitochondrial respiratory chain 
(Abdel-Kader et al., 2007). Furthermore, Eckert and associates have demonstrated 
that EGb 761 protected PC12 cells mitochondria from H2O2, antimycin (complex III I 
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inhibitor) and Aβ-induced MTT reduction, and that 2 weeks treatment with EGb 761 
reduced ROS induced apoptosis in mice lymphocytes (Eckert et al., 2003).  
To examine the effect of Ginkgo biloba on the mitochondrial respiratory chain, one 
study looked at the effect of oral administration of 25-100mg/kg/day EGb 761 and 3 
and 6 mg/kg/day bilobalide on the level of mitochondrial DNA (mtDNA)-encoded 
cytochrome Oxidase COX subunit III in hippocampal CA1 neurons. The result 
showed that both EGb 761 and bilobalide fraction confer protection against ischemia-
induced reduction in COXIII mRNA and neuronal loss (Chandrasekaran et al., 2001). 
Furthermore Tendi et al reported that 100 µg/ml EGb 761 and 10 µg/ml bilobalide 
increases NADH Dehydrogenase (complex I) mRNA level and mitochondrial 
respiratory control ratio in PC12 cells (Tendi et al., 2002). 
 
The anti-inflammatory effect of Ginkgo biloba and its modulation of key-
inflammation related molecules in the CNS have been investigated by several 
research studies. Jiao et al (2005) studied the effect of Ginkgo biloba extract on 
protein and mRNA expression of pro and anti-inflammatory cytokines in the brain of 
a rat model of atherosclerosis. This group found that 100mg/kg/day EGb 761 for 8 
weeks inhibited the production of pro-inflammatory cytokines: IL-1β and TNF-α and 
up regulate the anti-inflammatory cytokines: IL-10 and IL-10R (Jiao et al., 2005). 
Another experiment looked at activated human T lymphocytes, isolated from whole 
blood and was conducted by Tsao and associates in 2008. This research reported that 
pretreatment with 25-100 µg Ginkgo biloba extract protected human T lymphocyte 
from TNF-α and H2O2 induced damage (Tsao et al., 2008). 
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 Recent studies have looked at the anti-inflammatory activity of Ginkgo biloba in 
inflammatory bowel disease, chronic relapsing inflammatory conditions mediated by 
overactive immune system, and have shown that EGb 761 suppresses the activation of 
inflammatory markers (iNOS, Cox-2 and TNF-α) and reduces the number of effector 
T cells (Kotakadi et al., 2008;Zhou et al., 2010).  
 
EGb761 has been reported to prevent glucose induced accumulation of ECM in rat 
mesengial cells cultured in hyperglycemic conditions, and this is believed to be 
mediated via multiple mechanisms including decreasing the level of transforming 
growth factor-ß1 (TGF-ß1), insulin-like growth factor-1 (IGF-1), connective tissue 
growth factor (CTGF) and decreasing the expression of collagen IV and laminin (Ji et 
al., 2009).     
 
The effect of Ginkgo biloba on excitotoxicity has also been investigated, and EGb761 
has been shown to reduce glutamate-induced elevation of calcium concentrations, 
enhance neuronal viability in primary cultures from mouse cerebral cortex (Zhu et al., 
1997), and prevent impairment of the Na/K-ATPase activity in a mouse model of 
focal cerebral ischemia (Pierre et al., 1999;Pierr et al., 2002). 
Xiao et al (2006) investigated the effect of EGb 761 pretreatment against 
excitotoxicity induced by NMDA receptor over-activation and focal cerebral 
ischemia. In this study EGb 761 enhanced cell viability and showed lower affinity to 
NMDA receptors compared with MK-801 (Xiao et al., 2006).  Furthermore, Li et al 
(2011) have investigated the modulatory effects of Ginkgo biloba on the NMDA 
receptor in acutely isolated hippocampal neurons. The authors showed that in addition 
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to antioxidation and free radical scavenging effect, Ginkgo also inhibited calcium 
influx via the NMDA receptors (Li et al., 2011). 
 
The potential neuroprotective effect of EGb 761, ginkgolides A and B administration 
in Parkinson’s disease has also been investigated in a 1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) induced mouse model. The result showed that EGb 761, 
compared to Ginkgolides A and B, effectively protects against MPTP-induced 
nigrostriatal dopaminergic neuronal death, possibly via inhibition of Monoamine 
Oxidase (MAO) (Wu and Zhu, 1999). 
 
Ginkgo biloba has also been used to improve cerebral insufficiency and enhances the 
cerebral blood flow, through inhibition of NO, PAF and catechol-O-methyltransferase 
(Diamond et al., 2000), and to recover the peripheral circulation and ameliorate 
peripheral vascular diseases such as intermittent claudication (Kleijnen and 
Knipschild, 1992). 
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1.2.5.2 In the Eye 
 
 
There are several reported ophthalmic beneficial effects of Ginkgo biloba both in 
experimental models and in patients, which encourage its use in the treatment of 
ischemic and neurodegenerative ocular diseases.  
As seen in the previous section (1.2.5.1), in studies on neuronal cells both in vivo and 
in vitro, mechanisms of oxidative stress, inhibition of the inducible pathological form 
of the NO synthase enzyme (iNOS), possible effect on the caspase-3 and Aβ pathway 
have all been proposed. In fact, in vivo and in vitro experiments conducted on Ginkgo 
biloba in the CNS thus far (summarized in table 1.7) appears suggestive of its 
potential in targeting mechanisms implicated in RGCs apoptosis in glaucoma.  
Ginkgo biloba has been shown to increase the ocular blood flow velocity in young 
healthy volunteers compared to a placebo (Chung et al., 1999) and improves visual 
field parameter in patients with normal tension glaucoma and preexisting visual field 
damage (Quaranta et al., 2003). Furthermore, a case report published in 2007, on a 
patient with primary OAG, reduced visual field and acuity, an IOP between a 15-32 
mmHg and on maximal tolerated medical therapy, showed that EGb 761 dramatically 
improved visual acuity over months, from counting finger occulus dexter (OD) and 
20/50 occulus sinister (OS), with -8.00 sphere OD and -7 sphere Os to 20/40 OD and 
20/30 OS after 30 months of follow-up. Although no improvement was observed in 
the visual field, the improvement in  visual acuity was believed to be mediated either 
through enhancement of the ocular blood flow or via an EGb 761 neuroprotective 
effect (Dorairaj et al., 2007). 
To investigate whether Ginkgo biloba usage could confer any protection against 
development of glaucoma over  a 12 month period, the National Health Interview 
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study was conducted, in which self-reported information was collected from 30,964 
participants over the age of 50 years and at risk of glaucoma. EGb 761 
supplementation was not associated with reducing risks of developing glaucoma in 
the study group, where patients who reported having glaucoma were 26% less likely 
to report EGb 761 usage (Khoury et al., 2009). However, no clear association between 
EGb 761 and glaucoma was demonstrated, possibly because of the cross sectional 
design and the lack of information on the duration of Ginkgo biloba use and glaucoma 
(ibid), which necessitate the need for prospective randomized clinical trial to see if 
prophylaxis supplement of EGb 761 could prevent glaucoma development.  
 
In a rat model of unilateral chronic glaucoma, Hirooka et al (2001) investigated the 
neuroprotective effects of EGb 761, and demonstrated that pretreatment and early post 
treatment with 100 mg/kg/day EGb 761 twice weekly protected and rescued RGCs. 
Although the exact mechanism of this protection was not investigated in this study, 
the authors attributed it to the antioxidant activity of EGb 76 (Hirooka et al., 2004).  
 
In a model of OHT in rabbits, EGb 761 was associated with multiple beneficial 
effects including: inhibition of dexamethasone-induced IOP elevation, accumulation 
of extracellular materials within the cribriform layers of the trabecular meshwork as 
well as improving meshwork cellularity (Jia et al., 2008). The authors further 
explored its mechanism of action in cultured human trabecular cells; EGb761 was 
shown to significantly reduce anti-Fas ligand-induced apoptosis and dexamethasone- 
induced myocilin expression (ibid). This suggests another possible mechanism for 
Ginkgo biloba via modulation of gene expression.  
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The effect of a mixture of herbal extracts including Ginkgo biloba have been shown to 
enhance viability of axotomized RGCs, although separate treatment with any single 
constituent did not confer such protection (Cheung et al., 2002). To further explore 
the possible mechanism of this neuroprotection in adult hamsters, the same group has 
confirmed recently the antioxidant effect of this herbal mixture, where they found a 
substantial decrease in the endogenous NO content in axotomized RGCs without any 
effect on the NOS activity, confirming the free radical scavenging activity of this 
mixture. In addition, this herbal mixture showed inhibitory effect on the caspase-3 
independent apoptotic pathway in RGCs (Cheung et al., 2008b). 
 
In a rat model of optic nerve crush, intraperitoneal injections of EGb 761 before and 
after the injury enhanced RGCs viability in comparison to the controls (Ma et al., 
2010). An earlier experiment by the same group in the same animal model showed a 
dose related enhancement  in RGC survival even when EGb 761 was administered 
intragastrically after the injury (Ma et al., 2009). Using the optic nerve transection 
model in guinea pigs, intraperitoneal administration of  EGb 761 showed anti-
apoptotic effects and improved RGCs function on electoretinograms (Xie et al., 
2009). 
 
The neuroprotective effect of EGb 761 on RGCs is perhaps due to its broad spectrum 
of pharmacological activities including its promising antioxidant activity which was 
advocated by Ritch in 2000 as the basis of its use as anti-glaucoma medication (Ritch, 
2000). The observed antioxidant activity of EGb 761 is believed to account for its 
beneficial effect not only in glaucoma, but also in other neurodegenerative diseases 
such as AMD (Rhone and Basu, 2008). This beneficial effect was also observed in a 
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double-blind trial comparing Ginkgo biloba extract with a placebo control in 10 
patients with AMD (Lebuisson et al., 1986), and in patients with peripheral vitreo-
chorioretinal dystrophies and dystrophic retinal detachment (Karazhaeva et al., 2004). 
 
Ginkgo biloba has been observed to modulate many inflammatory mediators (Jiao et 
al., 2005;Park et al., 2006;Kotakadi et al., 2008;Tsao et al., 2008;Zhou et al., 2010), 
and in glaucoma, there are several proposed stress factors for RGC apoptosis  (Mittag 
et al., 2000;Tatton et al., 2001;Tezel and Yang, 2004), including  the involvement of 
the immune system (Tezel, 2009). Glaucoma-related stimuli such as hypoxia, TNF-α 
and oxidative stress can trigger the mitochondrial-mediated RGC death pathway 
(Cheung et al., 2008a).  
An interesting study looked at the free radical scavenging effect of Ginkgo biloba on 
aged mitochondria. This study, which was performed on retinal Muller cells from 
guinea pigs, has confirmed that EGb761 treatment considerably enhanced 
mitochondrial membrane potential and preserved mitochondrial ultrastructure of the 
aged cells (Paasche et al., 2000). EGb761 has also been observed to protect primary 
cultured rat retinal neurons against glutamate-induced ischemic injury and  improve 
mitochondrial membrane potential (MMP), thus making it an effective antioxidant at 
the mitochondrial level (Wang et al., 2005b).  This ability to counteract the glutamate-
mediated neurotoxicity further enhances its potential as a possible ophthalmic drug in 
glaucoma management as these pathways have already been implicated in the 
apoptotic RGCs death in glaucoma (Osborne et al., 1999;Casson, 2006).  
 
 
Another interesting study, was conducted in the rat insulinoma cell line and the rabbit 
corneal cell line by Thiagarajan et al (2002). This group confirmed the potentials of 
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EGb 761 on alloxan and dexamethasone induced apoptosis and Photo-Fenton reagent 
induced hydroxyl radicals. Furthermore, in vivo EGb 761 halted the progression of 
selenite-induced cataract in rat through its antioxidant property (Thiagarajan et al., 
2002). 
 
Researches on retinal photoreceptor and EGb 761 have also been carried out; 
intraperitoneal injection of EGb761 protects photoreceptors against light induced 
injury, possibly by inhibiting apoptosis and preventing oxidative stress in rat retinas 
(Xie et al., 2007). Similar protection with intragastric administration of EGb761 on 
photoreceptors after light-induced injury has also been demonstrated using 
electrophysiological test (Ranchon et al., 1999). EGb761 has been found to 
significantly reduce the ischemia-reperfusion induced Na
+ 
and Ca
2+
 accumulation and 
K
+
 loss in ischemic-reperfused retinal tissue (Szabo et al., 1993). 
 
A summary of different molecular targets of Ginkgo biloba that have been identified 
in literature in CNS and Eye and the experimental work performed thus far are shown 
in Table 1.7 
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Table 1.7 Summary of different pro-apoptotic molecular targets of Ginkgo biloba   
Pro-Apoptotic 
Mechanism  
Target      Compound Model     References 
Oxidative stress NOS EGb 761, Ginkgolide B, 
Bilobalide and CP 205 
in vitro LPS, IFN-γ, SNP, 3-
morpholinosydnonimine 
 
(Kobuchi et al., 1997;Bastianetto et 
al., 2000b;Ahlemeyer and Krieglstein, 
2003) 
 ROS 
 
GBE, EGb 761, Ginkgolides 
A, B,Bilobalide, quercetin, 
kaempferol and isorhamnetin 
EGb 761 
in vitro H2O2, alloxan or 
dexamethasone SS, SSP 
 
in vivo ischemia-reperfusion, 
selenite cataract  
(Oyama et al., 1994;Oyama et al., 
1996;Ahlemeyer et al., 1999;Zhou and 
Zhu, 2000;Thiagarajan et al., 2002) 
(Szabo et al., 1993;Thiagarajan et al., 
2002) 
 MDA, T-SOD, GSH-Px, 
CAT 
EGb 761 in vivo LIRD (Xie et al., 2007) 
Mitochondrial 
Dysfunction 
Mitochondrial Respiratory 
Chain 
EGb 761, Bilobalide in vitro H2O2, glutamate, NaN3 
SNP, SS, antimycin, ischemia 
 
in vivo young and old mice, 
gerbil ischemia 
(Zhou and Zhu, 2000;Tendi et al., 
2002;Eckert et al., 2003;Wang et al., 
2005b;Abdel-Kader et al., 2007) 
(Chandrasekaran et al., 2001;Abdel-
Kader et al., 2007) 
 Caspases 1,3 and 9 EGb 761, Ginkgolides A, B, 
C, and J and Bilobalide.  
 in vitro  Aß (1-40), SS, SSP 
 
in vivo aged SD rats, Axotomy 
in hamster 
(Luo et al., 2002;Smith et al., 
2002;Massieu et al., 2004) 
(Cheung et al., 2008b;Nevado et al., 
2010) 
 ROS EGb 761, Ginkgolide B, 
quercetin 
in vitro Aß (1-42), H2O2, PAF 
 
(Shi et al., 2009) 
Protein Misfolding  Aß EGb761, Ginkgolide A, B 
and  J, Bilobalide,HE 208 
and CP 205, quercetin 
in vitro  Aß (25-35),  Aß (1-40) 
and (1-42) 
 
in vivo  Aß , transgenic 
Caenorhabditis elegans, 
transgenic mice for APP 
(Zhou et al., 2000;Yao et al., 
2001;Bastianetto and Quirion, 
2002;Luo et al., 2002;Shi et al., 
2009;Vitolo et al., 2009) 
(Wu et al., 2006;Augustin et al., 2009) 
 APP and caspase-3 GBE In vivo aluminum-treated rats (Gong et al., 2005) 
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Pro-Apoptotic 
Mechanism   
Target Compound Model References 
 α-secretase  
 
EGb 761 in vitro hippocampal slices 
in vivo SD rats 
(Colciaghi et al., 2004) 
 
Multiple MYO 
anti-Fas ligand-induced 
apoptosis, HSPs 
GBE in vitro DEX treatment 
in vivo  DEX induced OHT 
rabbit 
(Jia et al., 2008) 
 
Excitotoxicity NMDA-R 
 
 
 
GBE, EGb 761, Ginkgolide 
B,  Bilobalide 
 
GBE 
in vitro Glutamate, NMDA  
 
 
in vivo MCAO model 
(Zhu et al., 1997;Wang et al., 
2005b;Xiao et al., 2006;Kiewert et al., 
2008;Xu et al., 2010;Li et al., 2011) 
(Xiao et al., 2006) 
 Na/K ATPase EGb 761 in vivo mouse model of FCI (Pierre et al., 1999) 
 GABA-R, Glycine-R 
 
Ginkgolide, A, B, C and 
Bilobalide 
in vitro GABA, NMDA (Ivic et al., 2003;Kiewert et al., 
2007;Kiewert et al., 2008) 
 Unknown 
 
EGb 761, Bilobalide in vitro hypoxia-induced 
release of choline. 
(Klein et al., 1997) 
 ACh-R Ginkgolide A and B in vitro  Aß (25-35) (Lee et al., 2004) 
 MAO EGb761, Ginkgolide A and 
B 
in vivo C57 mouse treated with 
MPTP 
(Wu and Zhu, 1999) 
Inflammation and 
immunological 
strategies 
iNOS, Cox-2 TNF-α, IL-1 
beta,  IL-6, IL10,  IL-
10R,NF-κBp65, SOD, 
MDA  
GBE, EGb 761 in vitro  TNF-α 
in vivo TNBS-Induced Colitis, 
AS model, DDS mouse model 
(Kotakadi et al., 2008) 
(Jiao et al., 2005;Zhou et al., 
2006;Kotakadi et al., 2008) 
 NO, PGE2  
 
 Ecb 761, GBB, terpene in vitro   LPS, TNF-α 
in vivo C.albicans-induced 
inflammation in mouse 
(Han, 2005;Park et al., 2006) 
(Han, 2005) 
 AP-1 GBE in vitro H2O2, TNF-α  (Tsao et al., 2008) 
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CP 205= flavonoid fraction, LPS = Lipopolysaccharide, IFN-γ= interferon-gamma, SNP= Sodium nitroprusside,  NaN3= sodium azide, GBE= Ginkgo biloba extract, MDA= 
malondialdehyde, T-SOD= total superoxide dismutase, GSH-Px= glutathione peroxidase, CAT=catalase, LIRD= light-induced retinal damage SS= Serum Starvation, 
antimycin= complex III inhibitor, SSP= Staurosporin, PAF=platelet activation factor, MYOC= myocilin, HSPs= Heat shock proteins, FCI mouse model= focal cerebral 
ischemia mouse model, HE 208= terpene and flavonoid-free EGb 761, MAO= Monoamine Oxidase,  IL=interleukin, TNF-α= tumor necrosis factor-alpha, NF-κBp65 = 
nuclear factor-κBp65, SOD= Superoxide dismutase, MDA= malondialdehyde, TNBS = 2,4,6-trinitrobenzene sulfonic acid, ACh-R= acetylcholine receptors, AS= 
atherosclerosis, MCAO model= middle cerebral artery occlusion model, FCI= focal cerebral ischemia, GBB= Ginkgo biloba  extract with higher levels of terpene and 
biflavonoid than EGb, PGE2= prostaglandin E , SD rats= Sprague Dawley rats, AP1= activator protein-1,  DDS mice model=Dextran sulfate sodium mouse model of colitis, 
DEX treatment= Dexamethasone treatment.  
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Aims 
 
 
 
 
Ginkgo biloba has demonstrated neuroprotective effects in animal models of 
neurodegenerative disease such as Alzheimer’s disease, and experimental glaucoma. 
However, the exact mechanism of this neuroprotection is still unknown. The literature 
established Ginkgo biloba as targeting several neuroprotective pathways implicated in 
RGCs apoptosis in glaucoma, including the abnormal processing of amyloid precursor 
protein (APP) and amyloid-beta (Aß) deposition, abnormal mitochondrial function, 
modulation of the TNF-α pathway and regulation of apoptosis-related caspases such 
as caspase-3. The purpose of this study was:  firstly to perform histological 
assessment of known molecular targets of Ginkgo biloba related to RGCs apoptosis in 
an experimental glaucoma model (specifically the expression of APP, Aß, 
cytochrome c, caspase-3 and TNF-α protein); and secondly, to investigate 
neuroprotective effects of Ginkgo biloba targets in vitro, including assessment of  
Ginkgolide A, Ginkgolide B and Bilobalide against different apoptotic inducers 
(namely DMSO, UV40, the mitochondrial toxin Sodium Azide and Aß25-35) in 
cultured RGC-5 cells. 
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Chapter two: 
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2 Materials and Methods 
 
2.1 Immunohistochemistry for Pro-Apoptotic target related to RGCs in OHT 
model 
2.1.1 Animals 
 
All conditions and experimental procedures were carried out in accordance with the 
UK Animals (Scientific Procedures) Act 1986 and associated guidelines. Animals 
were housed in a 12 hours light /dark cycle with unlimited access to food and water. 
2.1.1.1 OHT Rat Model 
 
Dr Li Guo, Senior Research Associate in the department performed all surgery to 
achieve elevated IOP in the Ocular Hypertension (OHT) model used in this study. 
OHT induction was performed in the left eye of 15 Adult Dark Agouti (DA) rats, 
weighing 150-200 g, using method established in the group, in which IOP was 
elevated by injecting 1.80 M of hypertonic saline solution into two episcleral veins 
(Cordeiro et al., 2004;Guo et al., 2005a;Guo et al., 2005b;Guo et al., 2006;Guo et al., 
2007a). This OHT rat model is modified from the previously described techniques by 
Morrison et al (Morrison et al., 1997;Morrison, 2005). The unoperated right eyes 
served as controls. IOP measurements of both eyes were performed at regular interval 
using a Tono lab Tonometer (Tiolat OY, Heisinki, Finland). Animals were deeply 
anaesthetized with intraperitoneal (IP) injection of Ketamix: ketamine (Ketaset 
37.5%, Fort Dodge Animal Health Ltd., Southampton, UK)/medetomidine (Dormitor 
25%, Pfizer Animal Health, Pfizer limited, Kent, UK)/ sterile water (37.5%, Pfizer 
Animal Health, Exton, PA) solution (0.75ml ketamine, 0.5 ml medetomidine, and 
0.75 ml sterile water) at 0.2 ml/100g. Animals were sacrificed at 1, 3 and 12 weeks 
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time points after IOP elevation. The eyes were rapidly enucleated and kept in 4% 
Paraformaldehyde (Sigma-Aldrich, UK). 
2.1.2 Preparation of Retinal Slices 
 
Expression of Amyloid Precursor Protein (APP), Aβ, the mitochondrial apoptosis 
related marker cytochrome-c, caspase 3 and TNF Receptor I was studied in OHT rat 
eyes using immunohistochemistry. Eyes were enucleated by making an incision 
posterior to the limbus; the cornea, iris and lens were removed. The retina and uveal 
tissue were dissected from the surrounding tissues and embedded in paraffin. 
Sequential 5µm thick paraffin-embedded retinal sections from OHT and age matched 
controls (n=5 per time point) were acquired and cut using the (MSE Ltd, Maidstone, 
UK) cutting microtome. Three sections were collected from each paraffin block and 
transferred to onto SuperFrost Plus microscope slides (VWR International bvba) for 
immunostaining. 
 
2.1.3 Immunohistochemical staining 
 
 
Retinal sections of OHT and age-matched controls at 3 time points: 1 week, 3 weeks 
and 12 weeks of IOP elevation were used. Sections were incubated with each of the 
following primary antibodies: goat polyclonal primary antibody to APP (Abcam 
ab2084) 1:1000 concentration, rabbit polyclonal to Aβ (Abcam ab68896) 1:750 
concentration, rabbit polyclonal to cytochrome c (Cell Signaling 4272) 1:400 
concentration, rabbit polyclonal to cleaved caspase-3 (Cell Signaling 9661) 1:300 
concentration and rabbit polyclonal to TNF-R1 Abcam (ab58436) 1:100 
concentration. 
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The following secondary antibodies directed against each primary were used, Donkey 
polyclonal anti-goat (FITC) to detect APP, Donkey anti-rabbit IgG (Cy3) to detect Aβ 
and cytochrome c, biotinylated goat anti-rabbit IgG to detect caspase-3 and TNFR1. 
A list of antibodies used in the study are shown in Table 2.1 
The final working concentration of APP, Aβ and cytochrome c were determined by 
prior titration of the antibodies by Shereen Nizari in the group, and the titration of 
active caspase-3 and TNF-R1 was performed by the writer using the manufacturers 
recommended dilution range.  
 
Table 2.1 Primary and Secondary antibodies used in the study 
Primary antibody Dilution Source Secondary 
antibody 
Dilution Source 
Polyclonal primary 
antibody to APP  
1:1000 Abcam (ab2084) Donkey polyclonal 
anti-goat (FITC) 
1:100 Abcam (ab6881) 
Anti-beta Amyloid  1:750 Abcam (ab68896) Donkey anti-rabbit 
IgG (Cy3) 
1:100 JacksonImmuno-
research Lab 
Anti-cytochrome c 1:400 Cell Signaling (4272) Donkey anti-rabbit 
IgG (Cy3) 
1:100 JacksonImmuno-
research Lab 
Cleaved Caspase-3 
 
1:300 
 
Cell Signaling (9661) 
 
Biotinylated goat 
anti-rabbit IgG  
DAB anti-rabbit kit 
 Abcam (ab64261) 
 
TNF R I  1:100 Abcam (ab58436) Biotinylated goat 
anti-rabbit IgG  
DAB anti-rabbit kit 
 Abcam (ab64261) 
 
 
 
2.1.3.1 Immunohistochemistry on retinal cross sections for APP, Aβ and 
cytochrome c using immunofluorescence staining technique 
 
The same immunohistochemical technique was used to stain retinal section with APP, 
Aβ and cytochrome c. 90 sections of OHT and age matched controls (n=5) were used 
in the study for each antibody, with 30 section per each time point 1 week, 3 weeks 
and 12 weeks of IOP elevation.  
 Retinal sections were de-waxed with Xylene 3 x for 5 minutes each and re-hydrated 
through a series of ethanol washes with descending concentration (100%-90% and 
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70%, 5 minutes each) before applying a final wash of running tap water for 5 minutes. 
Sections were then blocked by incubation in a 3% Hydrogen peroxide solution for 25 
minutes at room temperature (rtp). To permeabilize cell membranes for antigen 
retrieval and to enhance antibody staining, sections were placed in 10 mM Citrate 
buffer pH 6.0 (10 mM Citric acid, 25 mM Sodium Hydroxide in  1 L distilled water) 
and irradiated in a microwave at 650 W 2x for 2.5 minutes. Slides were then washed 
with water and Phosphate buffered saline (PBS) (Sigma-Aldrich, UK) for 5 minute 
each. Slides were then incubated in a 5% solution of normal donkey serum (Jackson 
Immuno Research) diluted in PBTA (1000 ml PBS, 0.5% w/v BSA, 0.1% v/v Tween, 
0.1% w/v Sodium Azide) for one hour at rtp to block non-specific binding. Sections 
were then rinsed with PBS containing 0.1% Triton to relieve surface tension and 
further permeabilize the cytoplasmic membrane and incubated with the primary 
antibodies. 
 
Goat polyclonal primary antibody to APP (Abcam ab2084), at a dilution of 1:1000, 
rabbit polyclonal to Aβ (Abcam ab68896) at a dilution of 1:750, and rabbit polyclonal 
to cytochrome c (Cell Signaling 4272) at a dilution of 1:400 were applied to retinal 
slides of OHT and age matched controls. Sections were incubated with Primary 
antibodies over night at 4°C in a humidified chamber. Sections were washed in PBS 
Triton for 5 minutes and incubated with secondary antibodies diluted in PBTA for one 
hour at rtp. Fluorescein isothiocyanate (FITC) Donkey polyclonal anti-goat antibody 
(abcam ab6881) at 1:100 concentrations was used as secondary antibody to detect 
APP, Cy3 donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories, INC) at 
1:100 concentrations was used to detect Aβ and cytochrome c. Sections were then 
washed with PBS Triton, PBS and water for 5 minutes each. 
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To stain the nuclear DNA retinal sections were stained with the fluorescent stain 4′, 6-
Diamidino-2-phenylindole dihydrochloride (DAPI) (D9542 Sigma-Aldrich) at 1:2500 
concentrations for 30 seconds then washed with PBS and water. Sections were then 
incubated in ascending concentration of ethanol (70%, 90%, 100%) 30 seconds each 
and then in Xylene for 5 minutes. Sections were then mounted with the glycerol-
based mounting medium Citifluor, to avoid possible dehydration –induced changes in 
retinal sections and dye bleaching (Citifluor Ltd, UK). The slides were then labeled 
and kept in the fridge, protected from light until imaging. 
 
Leica Microscopic Imaging 
 
Fluorescent images were taken using the Leica Image Capture Microscope and x40 
lens. Fluorescent signal of DAPI (excited at 358), Cy-3 (excited at 514 nm) was 
detected using the blue channel whereas FITC, (excited at 488nm) was detected by 
the green channel. 
 
2.1.3.2 Immunohistochemistry on retinal cross sections for Active caspase-3 and 
TNFR1 using Immunoperoxidase staining technique 
 
 Retinal sections were de-waxed with three Xylene washes (5 minutes each) before re-
hydrating through a descending serious of 5 minute ethanol (100%, 90% and 70%) 
washes followed by a wash under running tap water for 5 minutes. Sections were then 
blocked as described in section (2.1.3.1) and incubated with primary antibodies. 30 
retinal slides per time point were then incubated with cleaved caspase-3 antibody 
(Cell Signaling 9661) 1:300 concentration, and 18 retinal slides per time point were 
stained with TNF R1 Abcam (ab58436) a dilution of 1:100 overnight in a humidified 
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chamber. Slides were washed 4 times in PBS triton (5 minutes each) before 
incubating with biotinylated goat anti-rabbit IgG (Abcam ab64261) for 10 min at rtp. 
Excess IgG was removed by washing a further four times with PBS before; slides 
were incubated with Streptavidin Peroxidase complex (Abcam ab64261) for 10 min at 
rtp. Slides were subject to x4 PBS washes before incubating with substrate-
chromogen (Abcam ab64261) for 4 min. Finally, the slides were rinsed with water, 
dehydrated through a graded alcohol series (100%, 90% and 70 %) before staining 
with Hematoxylin and mounting in DPX. Slides were examined under Nikon Eclipse 
80i microscope. 
 
Nikon Eclipse Microscopic Imaging 
 
Light micrographs of the retinal sections were taken using the Nikon Eclipse 80i 
upright microscope under a x40 objective. 
 
2.1.4 Data Analysis and statistics 
 
Sections were graded for staining by three independent and masked observers on the 
basis of the presence and the intensity of immunoreactivity, thickness and the 
homogenous or heterogeneous character of staining as in table 2.2 positive (+) 
indicated brightest than control slide, and negative (–) stand for no labeling in 
comparison with the control. 
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Table 2.2 Grading of Retinal Micrographs 
Scale intensity 
+4 76-100% positive control 
+3 51-75% positive control 
+2 26-50% positive control 
+1 1-25% positive control 
0 Same as negative control 
-1 1-25% negative control 
-2 26-50% negative control 
-3 51-75% negative control 
-4 76-100% negative control 
 
           
This grading system and the method of analysis was originally described by Shah et al 
(Shah et al., 1994) and validated by the group (Cordeiro et al., 1999a;Cordeiro et al., 
1999b;Cordeiro et al., 2003;Guo et al., 2005a). 
 
Statistical analysis was performed using SPSS 14 software. One-way ANOVA was 
applied to compare grading among glaucoma and age-matched controls at 3 time 
points, *P < 0.05 was considered to be significant. 
 
 
2.2 Neuroprotective effects of Ginkgolide A, Ginkgolide B and Bilobalide in 
vitro against DMSO, UV40, NaN3, and Aβ toxicity in RGC-5  
 
2.2.1 Retinal ganglion cell (RGC-5) culture 
RGC-5, a rat ganglion cell line transformed using E1A virus (Krishnamoorthy et al., 
2001), was generously gifted to Prof. M F Cordeiro by Dr. Neeraj Agarwal (UNT 
Health Science Centre, Fort Worth, TX, USA). This cell line is used extensively in 
glaucoma research as an alternative to the primary RGCs because of the similarities 
between both cell lines and the troubles of culturing primary RGCs (Hu and Ritch, 
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1997). RGC-5 was identified on the basis of the selective expression of RGC markers 
such as Thy-1 (Krishnamoorthy et al., 2001), RGC-5 was cultured in T75 flasks and 
was maintained in filtered DMEM containing 10% FBS, 100U/ml penicillin, and 
100μg/ml streptomycin under a humidified atmosphere with 5% CO2 at 37 °C. The 
RGC-5 was grown to 80-90% confluence before washing with PBS and passaged by 
trypsinization using 3ml of 0.05% Trypsin-EDTA solution as described previously 
(Krishnamoorthy et al., 2001). Trypsin was then neutralized with 7 ml filtered DMEM 
and RGCs were centrifuged at ~200g for 3 minutes to pellet the cells. Pellets were 
then resuspended in filtered DMEM and split into new T75 flask at a 1×10
6 
concentration. These flasks were fed every other day by fresh filtered DMEM (Harper 
et al., 2009). 
 
2.2.2 Reagents 
Dulbecco's modified Eagle's medium (DMEM) from Lonza Walkersville, Inc., Fetal 
Bovine serum (FBS) from GIBCO invitrogen, Penicilline/Streptomycine by the cell 
culture company PAA-laboratories Gmbh, Trypsin-EDETA from GIBCO invitrogen, 
Dimethyl sulfoxide (DMSO), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), N,N-Dimethylformamide (DMF) and Soduim Azide (NaN3) were 
purchased from Sigma-Aldrich, Company Ltd. UK, Aβ  peptides corresponding to the 
sequence of human Aβ 1-42 and Aβ 25-35  were obtained from Sigma-Aldrich, Company 
Ltd. UK, Ginkgolide A, Ginkgolide B and Bilobalide were purchased from (Sigma-
Aldrich, Company Ltd. UK), Hoechst 33342 and Trypan Blue from invitrogen, 
ApopTag® Fluorescein Direct In Situ Apoptosis Detection Kit from CHEMICON, 
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Paraformaldehyde and Propidium iodide solution (PI) from Sigma-Aldrich, UK. 
Ethanol and Acetic acid were purchased from Fisher Scientific, UK. 
 
2.2.3   Toxicity and pharmacological treatment of RGC-5 
 
For each of the following experiments RGC-5 was seeded at a density of 1×10
5
 viable 
cells per well into 96-well plates. This density was chosen from the published 
densities in literature (Munemasa et al., 2008) and based on the writer’s Preliminary 
experiments during this cell culture work to give 80-90% confluency in the 96 well 
plates after 24 hours incubation. Cell population counts were determined using a 
Haemocytometer with trypan blue exclusion assay. To plate the cells at 1×10
5
 viable 
cells per well into 96-well plates, 10µl Pellet (mass of cells after centrifuging) are 
mixed with 10µl Trypan Blue dye to mark dead cells which stain dark blue due to 
Trypan Blue uptake, this 20 µl of cells are then taken onto a hemocytometer, covered 
with a cover slide and counted under a light microscope. To minimize random errors, 
cells are counted in the four quadrants of the hemocytometer paying attention to count 
only cells which intersect two of the boundaries. The total number of counted cells are 
then divided by 4 and multiplied by 2 (to compensate for trypan blue cell dilution) 
and this should give the number of cells in 0.1µl of the original pellet, the 
concentration of the cells (how many cells) in the whole volume of the pellet can be 
then calculated and using the equation C1V1=C2V2, where C1= is the concentration of 
the cells in the original pellet, V1 is the volume to take from this pellet, V2 is the 
volume to be plated into the 96 well plate i.e 9600 µl if the whole 96 well plate are to 
be used and C2 is 1×10
5
. 
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Cells were then incubated in humidified atmosphere of 95% air and 5% CO2 at 37 °C. 
After 24 hours cells were examined under microscope to check their shape and 
confluence and pretreated for 2 hours before the insult with ascending concentration 
(0.5-25 µg) of Ginkgolide A, B and Bilobalide diluted in sterile filtered DMEM. After 
this pretreatment, the entire medium was replaced with the indicated concentration of 
the insult (1% DMSO, 1mM NaN3 and 50µM Aβ25-35 diluted in 0.5-25 µg 
Ginkgolide A, B and Bilobalide) or exposed to UV40. In every experiment 0.5% 
Triton was used as a negative control and filtered DMEM as positive control, 
furthermore, equal number of wells (n=5 in all experiment unless otherwise indicated) 
have been treated by 0.5-25µg Ginkgolide A, B and Bilobalide alone to make sure no 
toxicity is encountered from these drugs. RGC-5 viability in all experiment was 
measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay. 
 
2.2.3.1 DMSO treatment of RGC-5  
Dimethyl sulfoxide (DMSO) is a widely used pharmaceutical solvent, has also been 
used to induce time and concentration dependent apoptotic effect in various cells 
(Trubiani et al., 1996;Liu et al., 2001). To examine the effects of increasing 
concentration of DMSO,  RGC-5 cells were seeded at a density of 1 × 10
5
 viable cells 
per well into 96-well plates, then incubated with filtered DMEM in a humidified 
atmosphere of 95% air and 5% CO2 at 37 °C. After 24 hours the entire media was 
replaced by filtered DMEM mixed with 1%, 2.5%, 5% and 10% DMSO and 
incubated for a further 24 hours. 
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To examine the neuroprotective effect of 0.5-25 µg of Ginkgolide A, B and Bilobalide 
on the RGC-5 death induced by 1% DMSO, RGC-5 were seeded as described above 
and incubated in filtered DMEM for 24 hours. Cells were next pre-treated with 0.5-25 
µg of Ginkgolide A, B and Bilobalide for 2-hours, following which the media was 
replaced with ascending concentrations of 0.5-25 µg of Ginkgolide A, B and 
Bilobalide mixed with 1% DMSO for a period of 24 hours. 
 
2.2.3.2 UV treatment of RGC-5  
 
UV light has been used by several researchers to induce ROS mediated apoptotic 
damage. It has been shown to produce a dose dependent reduction in the viability of 
RGC-5 (Dunkern et al., 2001;Balaiya et al., 2010). To investigate the cytotoxic effect 
of shortwave UV-C energy on RGC-5, cells were plated as described above in four 96 
well plates. In one 96 plate unexposed cells were used as control, and the other three 
plates were exposed to 40, 60 and 80 mj/cm
2
 UV-C light (254nm) for 2 minutes using 
CL-1000 Ultraviolet Crosslinker (Ultra Violet Products Ltd. Cambridge).  
 
To examine the neuroprotective effect of 0.5-25 µg Ginkgolide A, B and Bilobalide 
on UV40 stressed RGC-5; cells were pretreated with the indicated concentration of 
the potential neuroprotective agents for 2 hours before UV40 mj/cm2 exposure. RGC-
5 was then incubated for another 24 hours before an MTT assay was conducted. 
 
2.2.3.3  Sodium Azide (NaN3) treatment of RGC-5  
 
 
The mitochondrial failure induced by NaN3 has been used to investigate the 
mechanisms of ischemic and neurodegenerative diseases, and been advocated to 
screen potential neuroprotective agents (Selvatici et al., 2009). For this reason, NaN3 
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is employed in this study. Stock solution of 20mM of the mitochondrial toxin NaN3 
was prepared by dissolving 13mg of NaN3 in 10ml DMEM and titrated to prepare the 
desired concentrations (1mM, 2.5mM, 5mM and 10mM), RGC-5 were treated with 
the indicated concentration of NaN3 for 24 hours prior to MTT, based on the result of 
this experiment 1mM NaN3 was chosen to stress RGC-5 before Ginkgolide A, B and 
Bilobalide treatments.  
 
2.2.3.4  Aβ1-42 treatment of RGC-5  
 
To assess Aβ1-42 induced neuronal cell death RGC-5 was treated with concentration 
range of 10-100 µM Aβ1-42 for 24 hours. Stock solution of 1mM Aβ1-42 was prepared 
by dissolving 0.1mg Aβ1-42 powder in 22.15µl DMSO and stored in aliquots at -20 °C. 
On the day of experiment Aβ1-42 aliquots were thawed for 5 minutes in sonicating 
water bath and centrifuged for 15 minutes at 12.300 RPM then diluted to the final 
concentration in DMEM. RGC-5 were pre-incubated with DMEM containing the 
indicated concentration of Aβ1-42 (10,25,50 and 100 µM) for 24 hours following 
which an  MTT assay was performed to assess cell viability. 
 
2.2.3.5 Aβ25-35 treatment of RGC-5  
 
A stock solution of 5mM Aβ25-35 was prepared by dissolving 1mg Aβ25-35 in 200µl 
sterilized distilled water which was then stored at -20 °C and incubated at 37 °C for 3 
days to aggregate before usage (Ban et al., 2006c;Tsuruma et al., 2010). 
To investigate the toxicity of Aβ25-35 on RGC-5 line, cells were treated with 
5,10,25,50 and 100µM Aβ25-35 for 24 hours before MTT cell viability assay was 
performed. RGC-5 pretreated for 2 hours with 0.5-25µg Ginkgolide A, Ginkgolide B 
and Bilobalide were then insulted with 50µM Aβ25-35 mixed with the indicated 
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concentration of Ginkgolide A, B and Bilobalide for 24 hours. MTT assay was then 
performed.  
 
2.2.3.6 Neuroprotective Drugs  
 
Stock solution of 20mg/ml Ginkgolide A was prepared by dissolving 50mg 
Ginkgolide A powder in 2500 µl DMF and stored as 50µl aliquots.  Ginkgolide B 
stock solution of 50 mg/ml was prepared by dissolving 10mg Ginkgolide B in 200µl 
DMSO, aliquoted and stored at -20 °C whereas a stock solution of 25mg/ml 
Bilobalide was prepared by dissolving 10 mg Bilobalide in 400µl acetone and stored 
at  -20 °C as 40µl aliquots. 
 
 
2.2.4 Assessment of cell viability and cell injury 
 
2.2.4.1 MTT cell viability assay 
24 hours following each of the above experiments MTT assay was conducted. This 
test is commonly used for assaying cell viability and depends on the reduction of the 
MTT, a yellow tetrazolium salt into crystalline blue formazan in live cells, by the 
action of the mitochondrial enzyme oxidoreductase (Ban et al., 2006b). The amount 
of formazan produced is proportional to the number and activity of the viable cells 
(Mosmann, 1983). After incubating the cells with the allocated treatment, 10 µl of 
MTT (0.5mg/ml) were added to each well of the 96 well plate containing 100µl of 
media. After 2-4 hours incubation period at 37 °C, equal volume of MTT stop 
solution (5 g SDS+ 50 ml DMF) were added into each well and left for 2 hours at 37 
°C to dissolve the formazan crystal. The optical densities (absorbance) of the media in 
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the 96 well plates were determined using the (Safire II, Tecan, Switzerland) 
microplate reader at a wavelength of 570 nm with a reference wavelength of 630 nm. 
 
2.2.4.2 In Situ Apoptosis Detection 
A cell viability kit, usually referred to as the TUNEL assay, ApopTag® Fluorescein 
Direct In Situ Apoptosis Detection Kit; Chemicon was used in this study to detect 
apoptotic RGC-5 cells insulted by DMSO. This assay which is usually known as 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, 
detect apoptotic cells by specific staining by modifying fragmented DNA utilizing 
terminal deoxynucleotidyl transferase (TdT). RGC-5 was cultured in five of the 
35mm glass bottom microwell petri dishes (MatTek corporation) for 24 hours, after 
that cells were exposed to 1%, 2.5%, 5% and 10% DMSO, one petri dish was used as 
a control in which RGC-5 were treated by DMEM only. 24 hours later TUNEL assay 
was started by fixing the cells by adding 2ml of 1% fresh paraformaldehyde to each 
petri dish for 10 min at 37°C, then wash twice in PBS for 5 min. RGC-5 cells were 
then post fixed by adding 2ml of cooled ethanol: acetic acid 2:1 for 5 min at -20 °C. 
Before applying equilibrium buffer cells washed again twice in PBS for 5 min each 
wash, aspirate off excess and added 50 µl equilibrium buffers to each petri dish for 10 
sec. Excess liquid were gently taped and 30 µl of working concentration of TdT 
enzyme (105 µl reaction buffer and 45 µl TdT enzyme were applied to the central part 
of each petri dish and cells then incubated in humidity chamber for one hour at rtp. 
Later working concentration of stop buffer (1ml stop buffer in 34 ml d H2O) was 
applied, cells were agitated for 15 seconds and incubated at rtp for 10 min. The final 
step in this assay was to counterstain and mounts after fluorescence staining, so 
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excess liquid gently tapped and 1.5 µl mounting media (1 µl of 1mg/ml PI in 1ml 
vector shield) was applied, glass cover slip then placed over and petri dishes placed in 
foil and stored at -20 °C until they were imaged using Leica Image Capture 
Microscope. 
2.2.4.3 Hoechst 33342 staining 
 
 
Hoechst 33342 is a trihydrochloride trihydrate blue fluorescent dye, capable of 
penetrating plasma membrane and staining the DNA of the apoptotic cell without 
needing permeabilization (Ban et al., 2006b). Compared to normal cells, the densely 
condensed chromatin of the apoptotic cells will uniformly take up the Hoechst 33342 
and can be visualized by fluorescent microscopy. In these studies, this vital stain was 
used to examine DMSO-induced morphological changes in the nuclei of apoptotic 
RGC-5. After treating the cells in the 12 well plates with 1% DMSO and ascending 
concentrations of Ginkgolide A, Ginkgolide B and bilobalide for 24 hours as 
described before, RGC-5 was gently washed with PBS then fixed with fresh 4% 
Paraformaldehyde for 25 minutes at room temperature. Cells were then stained with 
Hoechst 33342 dye at a concentration of 5µl/ml for 5 minutes, washed with PBS and 
stored at -20 °C until they were examined under the Leica Image Capture Microscope 
and x40 lens. RGC-5 with high fluorescence intensity due to chromatin condensation 
or nuclear fragmentation were considered to be apoptotic.  
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2.2.5 Data Analysis and statistics 
 
Data of the MTT reduction were expressed as the mean and 95% CI, statistical 
significance was further assessed by One-way ANOVA, *P < 0.05,  **P < 0.01 were 
considered to be significant. Dose-response curves of Ginkgolide A, Ginkgolide B 
and Bilobalide were fitted using Origin 8.5 (OriginLab, Northampton, MA). 
 
Data of Hoechst 33342 staining of DMSO-induced apoptotic nuclei was shown as 
apoptotic neurons as a percentage of total neurons (Massieu et al., 2004;Ban et al., 
2006b;Santiago et al., 2007). 
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3 Results:  
 
3.1 Investigation of pro-apoptotic targets in OHT model 
 
As discussed in section 1.2.5 several possible targets were identified as potentially 
modifiable by Ginkgo biloba and were investigated. Immunohistochemistry was used 
in this study to examine several of the potential targets for Ginkgo biloba in OHT rat 
eyes. 
3.1.1  Immunohistochemistry for Cytochrome c  
 
In this study the pattern of cytochrome c expression and the effect of IOP elevation    
was investigated in an OHT model that has been established by our group. OHT and           
age-matched controls at 1, 3 and 12 weeks after IOP elevation were assessed. 
 
Results of cytochrome c deposition on paraffin-embedded retinal sections, as 
presented in (figure 3.1 a-f, red), showed marked up-regulation of cytochrome c 
immunoreactivity one week post OHT surgery (arrow head), reaching a peak at three 
weeks (P < 0.05). The level of cytochrome c activity in normal retina was almost 
undetectable at all time points. As illustrated in (figure 3.1 g) masked grading of 
retinal sections showed that cytochrome c level in the OHT retina dropped after 3 
weeks to reach statistically non-significant level at 12 weeks, which is possibly due to 
the fact that mitochondrial damage is an early event in the apoptotic process, will lead 
to cytochrome c release, which then potentially contributes to RGCs apoptosis by 
activating caspases.  
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Leica Image Capture of Cytochrome c in OHT model and age–matched controls  
 
 
                        
Cytochrome c stained OHT retina                                          Cytochrome c stained control retina    
 at 1 week                                                                                 at 1 week 
                        
Cytochrome c stained OHT retina                                         Cytochrome c stained control retina    
 at 3 weeks                                                                               at 3 weeks 
                               
Cytochrome c stained OHT retina                                       Cytochrome c stained control retina    
at 12 weeks                                                                           at 12 weeks 
 
 
Figure 3.1 Cytochrome c Immunohistochemistry 
(Figure 3-1 a-f, red): shows cytochrome c immunoreactivity in the RGCs and NFL on paraffin-
embedded cross sections in the OHT retina and age-matched controls at 3 time points. Note that 
immunoreactivity was highest at 3 weeks in OHT eyes, with minmal changes in the controls, in (figure 
3-1 g): comparison of cytochrome c level in OHT and age-matched controls at 3 time points. n=30 
slide/time point. (All treatment groups were compared to each other and the control by one-way 
ANOVA followed by post hoc comparisons * P < 0.05, * * P < 0.01). 
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3.1.2 Immunohistochemistry for Active caspase-3 level  
 
Immunoreactivity of activated caspase-3, the ultimate executioner caspase, was next 
investigated in this study. There was an apparent increase in caspases-3 deposition 
(figure 3.2 a-f, brown) in the retina of OHT at all of the time points observed (arrow 
head), compared with age-matched controls, caspase-3 up-regulation in the OHT eyes 
was statistically significant at 3 and 12 weeks (P < 0.01) as illustrated in ( figure 3.2 
g). 
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Nikon Eclipse 80i Image Capture of active caspase-3 in OHT model and age–
matched controls  
 
                           
Caspase-3 stained OHT retina at 1 week                         Caspase-3 stained control retina at 1 week         
 
                        
Caspase-3 stained OHT retina at 3 weeks                     Caspase-3 stained control retina at 3 week 
    
                      
Caspase-3 stained OHT retina at 12 weeks                   Caspase-3 stained control retina at 12 week        
 
 
Figure 3.2 Active caspase-3 Immunohistochemistry 
(Figure a-f, brown) shows caspase-3 immunoreactivity on paraffin-embedded cross sections in the 
OHT retina and age-matched controls at 3 time points. Note labeling of the RGCs and NFL which was 
maximum at 3 weeks in the OHT eyes compared with the controls, (figure 3-2 g) shows histological 
grading of active caspase-3 level in OHT and age-matched controls at 3 time points. n=18 slide/time 
point (All treatment groups were compared to each other and the control by one-way ANOVA 
followed by post hoc comparisons * * P < 0.01). 
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3.1.3 TNF-R1 level in OHT model and age –matched controls 
  
To explore TNF expression in OHT eyes, retinal sections were then stained with 
TNF-R1 antibodies and the results are displayed in (figures 3.3 a-g, brown). Intense 
immunostaining of TNF-RI was observed in the ganglion cell layer as well as in the 
inner plexiform layer (arrow head) in OHT eyes, which peaked at 3 weeks after IOP 
elevation (P < 0.05 or P < 0.01) (figure 3.3, g), although positive immunoreactivity 
was seen in the control eyes as well, the intensity of the staining was lower in age 
matched controls.  
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Nikon Eclipse 80i Image Capture of TNF-R1 in OHT model and age–matched 
controls  
 
                     
TNF-R1 stained OHT retina at 1 week               TNF-R1 stained control retina at 1 week         
 
                 
TNF-R1 stained OHT retina at 3 weeks                TNF-R1 stained control retina at 3 weeks   
 
                   
TNF-R1 stained OHT retina at 12week             TNF-R1 stained control retina at 12 week         
 
Figure 3.3 TNF-R1 Immunohistochemistry 
(Figure a-f, brown) shows TNF R1 immunoreactivity on paraffin-embedded cross sections in the OHT 
retina and age-matched controls at 3 time points. Note labeling of the RGCs and inner plexiform layer. 
(Figure 3-3, g) illustrate comparison of TNF-R1 in OHT and age-matched controls, n=18 slide/time point 
(All treatment groups were compared to each other and the control by one-way ANOVA followed by 
post hoc comparisons * P < 0.05, * * P < 0.01). 
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3.2 Investigation of Aß in OHT 
 
To examine the potential role of Aß in RGCs apoptosis in glaucoma, APP and Aß 
expression in the same experimental glaucoma (OHT) model was examined in this 
study.  
3.2.1 Immunohistochemistry for APP and Aß  
 
 
 Leica image capture of APP in OHT eyes and age–matched controls are shown in 
(figure 3.4 a-f, green), enhanced expression of APP (arrow head) was found in the 
inner retinal layers (RGCs and nerve fiber layer) of OHT retinal sections while 
minimal immunoreactivity were observed in age-matched control; masked grading of 
the retinal sections (figure 3.4, g) illustrate significant reduction in APP expression in 
OHT rats over time (P < 0.05 or P < 0.01) to reach the lowest level at 12 weeks of 
OHT elevation. There was no apparent difference in APP labeling in the control 
sections. 
 
We have observed enhanced Aß immunohistochemical expression in RGCs of all 
OHT rats in comparison with the control, as shown in (figure 3.5 a-f) (arrow head). 
Aß accumulation in the OHT retinal sections increased gradually during the observed 
time points, and the maximum deposition was evident at 12 weeks after OHT surgery. 
The graph displayed in (figures 3.5, g) shows the masked grading of this retinal 
sections and the statistically significant Aß accumulation at 3 and 12 weeks time 
points in comparison with the control (p < 0.01).  
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Leica Image Capture of APP in OHT model and age –matched controls  
 
                  
 APP stained OHT retina at 1 week                                APP stained control retina at 1 week   
 
                       
APP stained OHT retina at 3 weeks                              APP stained control retina at 3 weeks   
  
                     
APP stained OHT retina at 12 weeks                            APP stained control retina at 12 weeks   
 
 
Figure 3.4 APP Immunohistochemistry 
(Figure 3-4 a-f, green) shows apparent reduction in APP immunoreactivity in RGC layer on paraffin-
embedded cross sections of the OHT retina compared to age-matched controls at 3 time points. Notice 
intense labelling of the RGCs and NFL in the OHT whereas no intensity observed in the age-matched 
controls, (figure 3-4 g) statistically significant reduction in APP level of OHT and age-matched 
controls at 3 time points, n=30 slide/time point. (All treatment groups were compared to each other and 
the control by one-way ANOVA followed by post hoc comparisons * P < 0.05, * * P < 0.01). 
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 Leica Image Capture of Aß in OHT model and age–matched controls  
 
  
Aß stained OHT retina at 1 week                                 Aß stained control retina at 1 week         
 
                     
Aß stained OHT retina at 3 weeks                               Aß stained control retina at 3 weeks         
 
 
Aß stained OHT retina at 12 weeks                             Aß stained control retina at 12 weeks    
 
 
Figure 3.5 Aß Immunohistochemistry 
(Figure 3-5 a-f, red) shows enhanced Aß immunoreactivity (red) in RGC and NFL on paraffin-
embedded cross sections in the OHT retina and age-matched controls at 3 time points. Notice increased 
immunofluorescence intensity of Aß over time in OHT eyes, whereas minimum increase observed in 
the age-matched controls, (figure 3-5, g) comparison of Aß level among glaucoma rats and age 
matched controls at 3 time points, n=30 slide/time point. (All treatment groups were compared to each 
other and the control by one-way ANOVA followed by post hoc comparisons * P < 0.05, * * P < 0.01). 
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3.3 Investigation of RGC apoptosis in vitro  
 
To mimic RGCs mitochondrial injury occurring in glaucoma, RGC-5 were exposed to 
the apoptotic inducers: DMSO, UVC and Na N3, and their effect on RGC-5 viability 
were examined using the MTT assay.  
3.3.1 Effect of DMSO on RGC-5 survival 
 
 
RGC-5 were treated with 1%, 2.5%, 5% and 10% DMSO, DMEM and 0.5% Triton 
and an MTT assay was performed 24 hours later to assess cell survival. Results 
showed all concentrations of DMSO significantly reduced RGC-5 viability compared 
to control (figure 3.6). DMSO treatment resulted in a dose dependent reduction in cell 
survival (MTT reduction) in comparison with the control (DMEM), 1% DMSO 
resulted in 27% reduction in RGC-5 viability, 57% cell survival reduction observed 
with 2.5% DMSO, 69% with 5% DMSO and 86% with 10% DMSO. Statistical 
analysis showed significant effects between different concentrations of DMSO and in 
comparison with the control (DMEM) (P < 0.01).                                                              
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Figure 3.6 DMSO-induced RGC-5 death 
Treating RGC-5 with a concentration range of 1-10% DMSO were associated with a dose dependent 
reduction in cell survival as confirmed by MTT assay, in comparison with base line DMEM the 
indicated concentration of DMSO has resulted in 27%, 57%, 69% and 86% reduction in RGC-5 
viability, data are expressed as mean ± 95% CI, n=8. (All treatment groups were compared to each 
other and the control by one-way ANOVA followed by post hoc comparisons * * P < 0.01). 
 
 
 
3.3.2 Effect of UVC on RGC-5 survival 
 
Figure 3.7 shows the influence of UVC exposure on the viability of cultured RGC-5. 
There was a dose dependent reduction in RGC-5 viability following exposure to 40, 
60 and 80 mj/cm
2
, compared with cells incubated without UV treatment; RGC-5 
viability has been reduced by 20% following UV40 and 47% after increasing the dose 
to 60 mj/cm
2
, while doubling the radiation to 80 mj/cm
2
 has resulted in 67% reduction 
in RGC-s viability by MTT assay. Compared with the control (DMEM), the effect of 
all UVC exposure on RGC-5 viability was statistically significant (P < 0.01).                                                              
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Figure 3.7 UV-induced RGC-5 toxicity 
RGC-5 exposed to 40, 60 and 80 mj/cm
2
 UV, were associated with a dose dependent reduction in cell 
survival as confirmed by MTT assay, in comparison with base line DMEM the indicated exposure of 
UV,  has resulted in 20%, 47% and 67% reduction in cell survival, data are expressed as mean ± 95% 
CI, n=8. (All treatment groups were compared to each other and the control by one-way ANOVA 
followed by post hoc comparisons * * P < 0.01). 
 
 
                                                                                                                                                                                                                    
    
3.3.3 Effect of NaN3 on RGC-5 survival 
 
As shown in figure 3.8, 24 hours exposure of RGC-5 to 1, 2.5, 5 and 10mM NaN3 
resulted in a concentration dependent decline in cell survival. Exposing RGC-5 to the 
indicated concentration of NaN3 had the effect of reducing viability on MTT assay to 
35%, 49%, 51% and 62% of control level respectively. In comparison with the control 
(DMEM) this effect was statistically significant at all used concentrations of NaN3 
(P < 0.01 or P < 0.05).                                                              
                                                             
 
 
 
 
** 
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Figure 3.8 NaN3-induced RGC-5 toxicity 
RGC-5 treated with 1, 2.5, 5 and 10mM NaN3, were associated with a dose dependent reduction in cell 
survival as confirmed by MTT assay, in comparison with base line DMEM RGC-5 exposure to the 
indicated concentration of NaN3 has resulted in 35%, 49%, 51% and 62% reduction in cell survival, 
data are expressed as mean ± 95% CI, n=8. (All treatment groups were compared to each other and the 
control by one-way ANOVA followed by post hoc comparisons * P < 0.05, * * P < 0.01). 
 
 
 
 
3.4 Effect of Ginkgolide A, Ginkgolide B and Bilobalide on RGC-5 
viability 
 
From the previous section, it has been shown that all 3 pro-apoptotic insults decreased 
RGC survival, and before carrying on these investigations, it was necessary to 
examine and compare effects of Gingko biloba constituents alone on RGC-5 viability. 
RGC-5 were incubated with different concentrations (0.5-25µg/ml) of GA, GB and 
Bil alone for 24 hours to access any possible cytotoxicity using these agents alone 
might have on RGC-5 viability. As shown in (figure 3.9), toxicity was observed with 
higher doses of GA (5, 10, and 25 µg/ml). These doses has largely reduced RGC-5 
viability leading to 78%, 65% and 55% reduction in cell viability respectively in 
comparison with the control (DMEM), whereas lower doses (0.5, 1 and 2.5µg/ml) of 
GA appear to have no significant differences in comparison to control (DMEM) 
** 
** 
** ** 
** 
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(P < 0.01), and were associated with 99%, 92% and 88% reduction in cell viability, 
suggesting that GA is not cytotoxic at lower doses. 
  
 
 
 
 
 
 
Figure 3.9 Effects of Ginkgolide A on RGC-5 
RGC-5 treated with a concentration range (0.5-25µg) Ginkgolide A, and MTT assay to access cell 
viability was performed after 24 hours, as in (figure 3.9) in comparison with baseline DMEM the 
indicated concentration of GA were associated with dose dependent reduction in the mitochondrial 
activity of living RGCs with no apparent toxicity at the lower doses in comparison with control 
(DMEM), data are expressed as mean ± 95% CI, n=5, Y axis= Abs 570nm. (All treatment groups were 
compared to each other and the control by one-way ANOVA followed by post hoc comparisons * * 
P < 0.01). 
 
Looking at the effect of Ginkgolide B (Figure 3.10), it is visible that higher RGC-5 
viability than the control (DMEM) were observed with (0.5, 1 and 2.5µg/ml) GB 
leading to 134%, 115% and 107% higher RGC-5 survival in comparison with the 
control while (5, 10, and 25 µg/ml) GB were found to be associated with 100%, 91% 
and 85% reduction in RGC-5 survival. No toxicity was evident with (0.5-10 µg/ml) 
GB. Statistical analysis revealed significant difference between the control and the 
lowest and the highest used concentration (P < 0.01).  
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Figure 3.10 Effect of Ginkgolide B on RGC-5 
A concentration range (0.5-25µg) Ginkgolide B was used to treat RGC-5 and MTT assay was 
performed 24 hours later. (Figure 3.10) displays RGC-5 viability in comparison with baseline DMEM, 
higher cell viability  than the control (DMEM) were observed with (0.5, 1 and 2.5µg/ml) GB with no 
apparent toxicity at the doses (0.5-10µg/ml), data are expressed as mean ± 95% CI, n=5, Y axis= Abs 
570nm. (All treatment groups were compared to each other and the control by one-way ANOVA 
followed by post hoc comparisons * * P < 0.01). 
 
 
 
 
The comparison of the effect of Bilobalied and the control (DMEM) are illustrated in 
(figure 3.11). Bil application has resulted in enhancement of cell survival at the lower 
dose and then dose dependent reduction in RGC-5 viability in comparison with the 
control, 0.5 µg/ml Bil were associated with 104% higher viability than the control 
while Bil at (1, 2.5, 5, 10 and 25 µg/ml ) were associated with about 99%, 89%, 86%, 
82% and 58% reduction in cell viability respectively, no significant difference 
(P < 0.01) was observed with the control at (0.5, 1, 2.5 and 5 µg/ml) Bil suggesting 
lack of cytotoxicity at these concentrations.  
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Figure 3.11 Effect of Bilobalide on RGC-5 
Treating RGC-5 with a concentration range of (0.5-25µg) Bilobalide has resulted in enhancement of 
cell survival at the lower dose and then dose dependent reduction in RGC-5 viability in comparison 
with the control. No significant difference was observed at (0.5, 1, 2.5 and 5 µg/ml) Bil and the control 
suggesting lack of cytotoxicity at these concentrations, data are expressed as mean ± 95% CI, n=5, Y 
axis= Abs 570nm. (All treatment groups were compared to each other and the control by one-way 
ANOVA followed by post hoc comparisons * * P < 0.01). 
 
 
 
 
3.5 Neuroprotective effect of Ginkgolide A, Ginkgolide B and Bilobalide 
against DMSO, UV40 and NaN3 toxicity 
 
To screen neuroprotective potential of Ginkgolide A, Ginkgolide B and Bilobalide on 
RGC-5 exposed to those apoptotic inducers discussed in section 3.3, the following 
studies were then performed at doses where RGC-5 viability was 20-35%. Hence, for 
DMSO, 1% was identified as UV40 and 1mM NaN3 were chosen as the average 
reduction in RGC-5 viability using these protocols was between 20-35% and using 
higher concentrations of those insults would result in massive reduction in RGC-5 
viability where cell damage may not be prevented by GA, GB and Bil.  
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3.5.1 Effects of Ginkgolide A, B and Bilobalide on 1% DMSO-induced RGC-5 
death 
3.5.1.1 Effects of Ginkgolide A, B and Bilobalide on DMSO-induced toxicity 
using MTT assay  
 
From the results illustrated in the previous section 3.4, no cytotoxicity was observed 
with (0.5, 1 and 2.5 µg/ml) GA, (0.5, 1, 2.5, 5 and 10 µg/ml) GB and (0.5, 1, 2.5 and 
5 µg/ml) Bil. However, all the following experiments were conducted using the full 
range of (0.5-25 µg/ml) of these compounds to examine their EC50 on dose response 
curve. In these investigations, the effect of GA was dose dependent, and it appeared 
that the lowest doses of GA (0.5 and 1µg/ml) were the most effective in enhancing 
cell viability, however, no statistically significant difference was observed in 
comparison with baseline 1% DMSO (figure 3.12). In comparison with baseline 
1%DMSO, 0.5 and 1µg/ml GA had resulted in 10% and 9% enhancement in cell 
viability compared to baseline 1% DMSO respectively. The reduction in RGCs 
survival at higher doses is most probably related to the toxicity of the drug by itself as 
shown earlier in figure 3.9 in which toxic effect was observed at 5, 10 and 25µg/ml 
GA. 
 
 
 
 
 
 
 
 
 
  
Figure 3.12 Effects of Ginkgolide A on 1% DMSO-induced RGC-5 death 
0.5-25 µg/ml Ginkgolide A was applied to RGC-5 for 2 hours before DMSO treatment. MTT 
absorbance at 570nm was performed 24 hours later, as seen in (figure 3-12). There is a trend for 0.5-1 
to induce RGC survival, this was statistically not significant, the effects of 1% DMSO on RGC-5 was 
dose dependent, and in comparison with baseline1% DMSO, 0.5 and 1 µg/ml GA were associated with 
10% and 9% enhancement in RGC-5 viability, each experiment was performed five times and the 
result is expressed as mean ± 95%CI, Y axis= Abs 570nm. (All treatment groups were compared to each 
other and the control by one-way ANOVA followed by post hoc comparisons  * * P < 0.01). 
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Ginkgolide B treatment in presence of 1%DMSO was associated with neuroprotective 
effect at 0.5-2.5 µg/ml (P < 0.01), and the best protection was seen at the lowest 
concentration tested (0.5 µg/ml) as displayed in (figure 3.13 a). The range of used 
concentration of GB of 0.5, 1, 2.5, 5, 10 and 25 µg/ml was associated with about 52%, 
30%, 29%, 19%, 17% and 14% higher RGC-5 viability respectively in comparison  
with baseline 1% DMSO. GB effect on RGC-5 was dose dependent with EC50 of 
2.21µM as shown in (figure 3.13, b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Protective effect of Ginkgolide B on 1% DMSO-induced RGC-5 toxicity 
Ginkgolide B 0.5-25 µg/ml was applied to RGC-5 2 hours before 1% DMSO treatment. 24 hour later 
cell viability was assessed using MTT assay. In (figure 3-13 a) there was a significant inhibition in 
RGC-5 viability by 1%DMSO, which was blocked by 0.5-2.5 µg/ml GB. GB enhancement of cell 
viability ranged between 52% with 0.5 µg/ml and 14% with 25µg/ml GB. (Figure 3-13 b) illustrate 
dose response curve of GB+1%DMSO showing dose dependent effect with an EC50 of 2.21µM. Each 
experiment was performed five times and the result is expressed as mean ± 95%CI, Y axis= Abs 570nm. 
(All treatment groups were compared to each other and the control by one-way ANOVA followed by 
post hoc comparisons  * * P < 0.01). 
** 
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The profile of protection observed with Bilobalide was similar to GA as displayed in 
(figure 3.14) 0.5 and 1µg/ml Bil had the most pronounced effect on 1%DMSO 
neurotoxicity in cultured RGC-5, however, the effect was statistically not significant 
(P < 0.01). In comparison with baseline 1%DMSO, those doses enhanced RGC-5 
survival by 23% and 18%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 Effects of Bilobalide on 1% DMSO-induced RGC-5 death 
0.5-25 µg/ml Bilobalide were applied to RGC-5 for 2 hours before1% DMSO treatment. MTT 
absorbance was performed 24 hour later. As seen in (figure 3-14) the DMSO induced reduction in cell 
viability was attenuated by 0.5 and 1 µg/ml Bil. Each experiment was performed five times and result 
is expressed as mean ± 95%CI, Y axis= Abs 570nm. (All treatment groups were compared to each other 
and the control by one-way ANOVA followed by post hoc comparisons * * P < 0.01). 
                       
 
3.5.1.2 Effects of Ginkgolide A, B and Bilobalide on DMSO-induced toxicity 
using Hoechst 33342 staining  
 
 
To examine the apoptotic potential of DMSO in cultured RGC-5 and to further assess 
the neuroprotective effect of Ginkglide A, Ginkgolide B and Bilobalide on 1% DMSO 
induced RGC-5 death; cells were stained by Hoechst 33342. This viable dye allows 
condensation of DNA, a feature of apoptosis, to be detected. After 24 hours of 1% 
DMSO, GA, GB and Bil treatment, cells were fixed and stained with Hoechst 33342 
dye at a concentration of 5µl/ml for 5 minutes. On observing the 12 well plates under 
the Leica Image Capture Microscope, as seen in figures 3.15-3.17, the majority of 
** 
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RGC-5 in the control culture (DMEM) had normal cell density, whereas the density 
of RGC-5 reduced markedly in the 1% DMSO treated culture with higher percentage 
of apoptotic nuclei. The apoptotic cells in all wells with condensed chromatin and 
fragmented DNA take up the Hoechst 33342 stain and fluorescence typical for 
apoptotic nuclei (arrows head). Apoptotic cells were counted from 5 field per well and 
their proportion was calculated and the results are shown as apoptotic cells as a 
percentage of the total number of cells (Massieu et al., 2004;Ban et al., 
2006b;Santiago et al., 2007).  
In figure 3.15 the effect of GA on the 1% DMSO treated cells was illustrated, when 
RGC-5 was exposed to DMEM only (figure 3.15 a) this resulted in 3.9% apoptosis 
whereas 1% DMSO (figure 3.15 e) increased the number of apoptotic cells to 5%, 
among the used concentration of GA 0.5, 1 and 2.5 µg/ml showed neuroprotective 
effect as measured by reduction in RGC apoptosis (figure 3.15 b, f, c). These doses 
had the lowest proportion of apoptosis of 3.4%, 3.7% and 4% respectively and 
reversed the DMSO-induced cytotoxicity, on the other hand 5, 10 and 25 µg/ml 
(figure 3.15 d, g, h) were associated with 5.5%, 5.9%, and 6.8% apoptotic nuclei 
respectively. 
 
 It was clearly evident on examining those plates that 0.5, 1 and 2.5 µg/ml GA had 
remarkably reduced the number of condensed and apoptotic nuclei; quantitative data 
of apoptotic cells as a percentage of the total number of cells are displayed in (figure 
3.15, i). At 0.5, 1 and 2.5 µg/ml GA was found to be neuroprotective (P < 0.01). This 
result using the Hoechst 33342 staining to measure reduction in RGC apoptosis, was 
different from the previous MTT assay results of the effect of 0.5, 1 and 2.5µg/ml GA 
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against 1% DMSO-induced cytotoxicity, because each assay has different implication 
for cell death.  
 
Figure 3.16 illustrates the neuroprotective effects of GB on 1% DMSO-induced 
toxicity. From this data it is apparent that cell density of the GB treated RGC-5 was 
maintained at all concentration range 0.5-25 µg/ml used in the study. The control 
culture (DMEM) in (figures 3.16, a) shows the majority of cells with apparently 
normal nuclear morphology resulting in only 2.9% apoptosis, while 1% DMSO 
treated RGC-5 (figures 3.16, e) led to 4.6% apoptotic cells. Pretreatment with 0.5, 1, 
2.5, 5, 10 and 25 µg/ml GB two hours before DMSO exposure (figures 3.16 b, c, d, f, 
g, h) reduced nuclear condensation (arrow head) and the percentage of apoptotic 
nuclei to 1.8%, 1.9%, 2%, 2.5%, 2.8%, and 2.6% respectively. Figures 3.16, i 
illustrate that, at 0.5 and 1 µg/ml GB was found to be neuroprotective P < 0.01 as 
measured by a reduction in RGC apoptosis. 
 
Figure 3.17 shows the Hoechst 33342 staining of Bil and 1% DMSO treatment. In 
(figures 3.17, a) the control culture with 2.9% apoptosis and maintained cellular 
density was displayed. Figures 3.17, e shows 1% DMSO treatment, which resulting in 
4.4% apoptosis with visible reduction in cell density. In (figures 3.17 b, f, c) the effect 
of 0.5, 1, 2.5 µg/ml of Bil on DMSO treated RGC-5 was shown, which has inhibited 
the percentage of apoptotic RGC-5 to 2.3%, 3.4%, 3.9%, while Hoechst staining of 5, 
10, 25 µg/ml Bil treated cultures failed to reduce the apoptosis and increased the 
apoptotic cells to 4.7%, 5.5 and 5.5% respectively. Nevertheless, at all concentrations 
Bil effect on RGC apoptosis was statistically not significant. 
 
 119 
 
  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Fluorescent microscopy images of Hoechst 33342 staining of GA and 1% DMSO 
treated RGC-5 
RGC-5 were pre-treated with the indicated concentration of GA, 2 hours later 1% DMSO was added 
and cells were incubated for 24 hours, after that RGC-5 stained with Hoechst 33342. Five fields for 
each indicated concentration were counted and tabulated using Microsoft excel software, the brightly 
stained RGCs with condensed nuclei were considered to be apoptotic whereas the lightly stained 
smooth RGCs were considered as normal non apoptotic cells. The apoptotic degree was calculated by 
dividing the number of counted apoptotic cells over the total number of visible cells in the field and 
displayed as percentage. (Figure 3.15, a) shows normal RGC-5 density and fewer apoptotic cells in the 
control culture, (figure 3.15, e) RGC-5 loss with higher number of apoptotic nuclei in 1% DMSO 
treated cells, (figures 3.15, b, c, f) reduced nuclear condensation with 0.5, 1 and 2.5 µg/ml GA 
treatment, (figures 3.15, d, g, h) RGC-5 loss with higher percentage of apoptotic nuclei with 5, 10 and 
25 µg/ml, quantitative data are displayed in (figure 3.15, i) as shown in the graph At 0.5, 1 and 2.5 
µg/ml GA was found to be neuroprotective. Each column represents mean ± 95%CI. (All treatment 
groups were compared to each other and the control by one-way ANOVA followed by post hoc 
comparisons * * P < 0.01).                 
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+ 1% DMSO b
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+ 1% DMSO g
25 µg/       ml 
GA +1% DMSO h
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Figure 3.16 Fluorescent microscopy images of Hoechst 33342 staining of GB and 1% DMSO 
treated RGC-5 
Representitive fluorescence microscopy of Hoechst 33342 after 1% DMSO and Ginkgolide B 
treatment. RGC-5 were pretreated with the indicated concentration of GB and two hours later 1% 
DMSO was added, after 24 hours incubation, RGC-5 stained with Hoechst 33342. Five fields for each 
indicated concentration were counted and tabulated using Microsoft excel software, fluorescent cells 
were counted and expressed as a percentage of the number of Hoechst positive cells. (figure 3.16, a) 
shows maintained cell density and fewer apoptosis in the control culture, (figure 3.16, e) RGC-s loss 
and higher apoptosis percentage, (figures 3.16 b, c, d, f, g, h) relatively maintained density and 
reduction in apoptosis with all the used concentration of GB. Quantitative data are displayed in (figures 
3.16, i), at 0.5 and 1µg/ml GB was found to be neuroprotective, each column represents mean ± 
95%CI. (All treatment groups were compared to each other and the control by one-way ANOVA 
followed by post hoc comparisons * * P < 0.01). 
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2.5 µg/ml GB 
+1% DMSO c
10 µg/  ml GB 
+1% DMSO d
1% DMSO e
1 µg/ml GB
+ 1% DMSO f
5 µg/ml GB
+1% DMSO g
25 µg/  ml GB 
+1% DMSO h
 
( i ) 
 
** 
** 
( i ) 
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Figure 3.17 Fluorescent microscopy images of Hoechst staining of  Bil and 1% DMSO treated 
RGC-5 
Hoechst 33342 after 1% DMSO and Bilobalide treatment. RGC-5 were pre-treated with the indicated 
concentration of Bil and 2 hours later 1% DMSO was added and cells were incubated for 24 hours, 
after that RGC-5 stained with Hoechst 33342. Five fields for each indicated concentration were 
counted and tabulated using Microsoft excel software, cells were counted and expressed as percentage 
of the number of Hoechst positive cells. In (figure 3.17, a) the control culture displays normal cells 
density with 2.9% apoptosis, (figure 3.17, e) 1% DMSO treatment with resultant reduction in RGC-5 
density and increasing the percentage of apoptotic cells to 4.4%, applying 0.5, 1 and 2.5 µg/ml Bil as in 
(figures 3.17 b, c, f) has inhibited the percentages of apoptosis. No protection was observed with the 
higher doses of Bil which failed to reduce the apoptosis as in (figures 3.17 d, g, h).  Quantitative data 
are displayed in (figures 3.17, i) at all concentrations Bil effect on RGC apoptosis was statistically not 
significant, the apoptotic degree was calculated by dividing the number of counted apoptotic cells over 
the total number of visible cells in the field and displayed as percentage. Each column represents mean 
± 95% (All treatment groups were compared to each other and the control by one-way ANOVA 
followed by post hoc comparisons). 
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To detect DNA fragmentation and identify the apoptotic features of DMSO toxicity in 
RGC-5 line, the TUNEL assay was performed on cells treated with the indicated 
concentration of DMSO for 24 hours using the protocol described previously in 
section 2.2.4. Micrographs of DMSO treated RGC-5 were taken using Leica Image 
Capture microscope and the number of The TUNEL-positive cells were counted. No 
quantitative evidence of apoptosis in the DMSO treated RGC-5 was detected with the 
TUNEL assay (data not shown). 
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3.5.2 Effects of Ginkgolide A, B and Bilobalide on UV40-induced RGC-5 death 
 
 
UVC light is a known apoptotic inducer in several cell lines and has been associated 
with oxidative cellular damage. In these experiments RGC-5 survival fell significantly 
following two minutes exposure to 40 mj/cm
2
 of UVC light (254nm) and Ginkgolide 
B and Bilobaliode were able to significantly restore cell viability. As displayed in 
(figure 3.18), UV40 has reduced RGC-5 viability, Ginkgolide A at concentration (0.5-
2.5 µg/ml) was respectively associated with 10%, 17 % and 14% enhancement in 
RGC-5 survival in comparison with baseline UV40. However, this enhancement was 
not significant using one way-ANOVA. 
 
Figure 3.18 Effect of Ginkgolide A on UV40-induced RGC-5 death 
 
Pre-exposing RGC-5 cells to 0.5, 1 and 2.5 µg/ml GA for 2 hours before UV40 treatment has 
increased RGC-5 survival in comparison with baseline UV40, n=6 and the result is expressed as mean 
± 95%CI, Y axis= Abs 570nm.  (All treatment groups were compared to each other and the control by 
one-way ANOVA followed by post hoc comparisons). 
 
 
 
Figure 3.19 shows the MTT assay result of incubating RGC-5 with Ginkgolide B 
prior to UV40 mj/cm2 exposure. As illustrated in figure 3.19, a the decline in RGC-5 
viability was significantly blocked by (0.5-5µg/ml) GB with maximal effect at 0.5 
µg/ml (P < 0.01), which has resulted in 22%, 21%, 21% and 12% enhancement in cell 
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viability respectively. The dose response curve of GB protective effect is illustrated in 
(figure 3.19, b) with an EC50 of 15μM. 
 
 
 
  
 
 
 
 
Figure 3.19 Effect of Ginkgolide B on UV40-induced RGC-5 toxicity 
0.5-25 µg Ginkgolide B were applied to RGC-5 for 2 hours before exposure to UV40. MTT absorbance 
was performed 24 hours later; there was a decline in RGC-5 viability after UV-C exposure which was 
dose dependently blocked by (0.5-10 µg/ml) GB (figure 3.19, a). Figure 3.19, b displays dose response 
curve of GB with an EC50 of 1.53 µM. n=6 and result is expressed as mean ± 95% CI, Y axis= Abs 
570nm. (All treatment groups were compared to each other and the control by one-way ANOVA 
followed by post hoc comparisons * * P < 0.01). 
 
The effect of Bilobalide on UV40 treated RGC-5 is displayed in (figure 3.20), and as 
seen UV40-induced cell death was significantly (P < 0.01) reversed by 0.5 and 
1µg/ml Bil, with the best protection observed at 1µg/ml Bil. The illustrated 
concentration range of 0.5-5 µg/ml Bil in (figure 3.20), has resulted in 18%, 23%, 
17% and 12% enhancement of cell viability as compared with baseline UV40.  
** ** 
** 
** 
( a ) 
 
( b ) 
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Figure 3.20 Protective effect of Bilobalide on UV40-induced RGC-5 death 
0.5-5 µg Bilobalide were applied to RGC-5 for 2 hours before exposing RGC-5 to UV40, MTT 
absorbance was performed 24 hours later; (figure 3.20) shows significant reduction in RGC-5 survival 
which was totally and dose dependently blocked by the applied Bil, the percentage of RGC-5 
protection by  (0.5-5 1µg/ml) Bil in comparison with baseline UV40 was 18%, 23%, 17% and 12% 
respectively, n=6 and result is expressed as mean ± 95% CI, Y axis= Abs 570nm.  (All treatment groups 
were compared to each other and the control by one-way ANOVA followed by post hoc comparisons * 
* P < 0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
** ** 
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3.5.3 Effects of Ginkgolide A, B and Bilobalide on 1Mm NaN3-induced RGC-5 
death 
 
Applying 1mM NaN3 to RGC-5 has resulted in a significant fall in cell viability as 
estimated by MTT assay and Ginkgolide A, B and Bilobalide pretreatment failed to 
demonstrate a protective effect. Interestingly, the reduction in RGC-5 viability 
following NaN3 treatment was attenuated by GA, GB and Bil at 0.5µg/ml 
concentration. However, the result of ANOVA revealed that this effect was not 
significant (P < 0.01). 
As shown in (figure 3. 21) pre-incubating RGC-5 with the lowest concentration used 
0.5µg/ml GA led to 24% enhancement in RGC-5 viability as compared with baseline 
1 mM NaN3, GA at 1 and 2.5 µg/ml GA were associated with dose dependent 
reduction in RGC-5 viability.  
 
Figure 3.21 Effect of Ginkgolide A on NaN3-induced toxicity 
Ginkgolide A 0.5-2.5 µg/ml was applied to RGC-5 for 2 hours before 1Mm NaN3 treatment. MTT 
assay was performed 24 hours later; as shown in (figure 3.21) there was a reduction in RGC-5 survival 
with 1 mM NaN3 that is attenuated by 0.5 µg/ml GA.  In comparison with baseline 1Mm NaN3, 0.5 
µg/ml GA were associated with 24% increase in RGC-5 viability, whereas, GA at 1 and 2.5 µg/ml GA 
were associated with dose dependent reduction in RGC-5 viability, n=5, result is expressed as mean ± 
95% CI, Y axis= Abs 570nm.  (All treatment groups were compared to each other and the control by one-
way ANOVA followed by post hoc comparisons). 
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The profile of Ginkgolide B on NaN3 treated RGC-5 was similar to GA as displayed 
in (figure 3.22), GB at 0.5µg/ml was associated with statistically not significant 
enhancement in RGC-5 viability of 1% compared to baseline NaN3, whereas (1-
25µg/ml) were associated with dose dependent reduction in RGC-5 viability. 
 
Figure 3.22 Effect of Ginkgolide B on NaN3-induced RGC-5 toxicity 
0.5-25 µg/ml Ginkgolide B was applied to RGC-5 for 2 hours before 1 mM NaN3 exposure. MTT 
absorbance was performed 24 hours later; as seen in (figure 3.22) there is a decline in RGC-5 survival 
with 1 mM NaN3, this was attenuated by 0.5 µg/ml GB leading to 1% enhancement in cell viability in 
comparison with baseline1 mM NaN3. Other doses 1-25µg/ml GB failed to improve RGC-5 survival, 
the effect of GB on 1Mm NaN3-induced cytotoxicity was dose dependent and statistically not 
significant (P < 0.01), n=5 and result is expressed as mean ± 95% CI, Y axis= Abs 570nm. (All treatment 
groups were compared to each other and the control by one-way ANOVA followed by post hoc 
comparisons). 
 
The effect of Bilobalide on 1mM NaN3-induced cytotoxicity in RGC-5 line was 
interestingly similar to GA and GB as displayed in (figure 3.23). Only the smallest 
used concentration of 0.5 µg/ml Bil was able to rescue RGC-5 increasing the cellular 
viability by 10% in comparison to baseline 1mM NaN3. Other doses (1-5 µg/ml Bil) 
were associated with 6%, 22% and 24% reduction in RGC-5 viability respectively.  
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Figure 3.23 Effect of Bilobalide on NaN3-induced RGC-5 toxicity 
0.5-5 µg/ml Bilobalide was applied to RGC-5 for 2 hours before applying1 mM NaN3. MTT 
absorbance was performed 24 hours later; as displayed in (figure 3.23) there is a significant fall in 
RGC-5 survival with 1 mM NaN3 which is attenuated by 0.5 Bil. (figure 3.23) in comparison with 
baseline1 mM NaN3, 0.5 µg/ml Bil were associated with 2% enhancement in RGC-5 survival while 
other doses failed to protect the cell resulting in 4%, 11%, 12%, 14% and 4% reduction in RGC-5 
survival. Each experiment was performed five times and result is expressed as mean ± 95% CI, Y axis= 
Abs 570nm. (All treatment groups were compared to each other and the control by one-way ANOVA 
followed by post hoc comparisons * * P < 0.01). 
 
 
 
3.6 Aβ toxicity in RGC-5 line 
  
 
Since Aβ expression in the retinal sections from the OHT model established in the 
group has been demonstrated, using immunohistochemistry (section 3.2). The effect 
of the full length peptide Aβ1-42 and Aβ25-35 on RGC-5 survival in vitro was next 
examined in the following experiments. 
3.6.1 Effect of Aβ1-42 on RGC-5 survival 
 
To investigate the ability of the full length peptide Aβ1-42 to induced RGC-5 death, 
RGC-5 was incubated with 10, 25, 50 and 100 µM Aβ1-42, cell viability assay which 
was performed 24 hours after the insult failed to show significant reduction in RGC-5 
survival, as shown in figure 3.24. Interestingly, in comparison with the control 
(DMEM) addition of 10 µM Aβ1-42 led to 6% increase in RGC-5 survival, other 
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doses were associated with 6%, 5% and 4% reduction in RGC-5 viability 
respectively.  
 
Figure 3.24 Effect of Aβ1-42 on RGC-5 survival 
The effect of 10, 25, 50 and 100µM Aβ1-42 on RGC-5 viability was measured after 24 hours. Aβ1-42 25-
100µM Aβ1-42 resulted in mild insignificant reduction in cell viability as determined by MTT assay, 
absorbance was measured at 570nm. There has been 6%, 5% and 4% reductions in cell survival 
compared with baseline DMEM. Result is expressed as mean ± 95% CI, n=8, Y axis= Abs 570nm. (All 
treatment groups were compared to each other and the control by one-way ANOVA followed by post 
hoc comparisons). 
 
 
3.6.2 Aβ25-35 leads to RGC-5 death 
 
The apoptotic effect of Aβ25-35 has been demonstrated in vitro in many neuronal cell 
lines. Thus in this experiment RGC-5 was challenged with a concentration range of 
Aβ25-35 up to 100µM that has been used by other researchers to stress PC12 cell line 
(Zhou et al., 2000) as displayed in figure 3.25. The colorimetric MTT assay was 
performed to investigate the effect of 24 hours exposure to concentration range of 5-
100µM Aβ25-35 on RGC-5. A concentration dependent decrease in RGC-5 survival 
was observed on treating RGC-5 with 5µM, 10µM, 25µM, 50µM and 100µM Aβ25-35, 
which led to a 16%, 17%, 18%, 27% and 60% reduction in survival respectively, in 
comparison with the control (DMEM). One way-ANOVA showed significant 
reduction in RGC-5 viability (P < 0.01) compared with the control (DMEM). The 
 
 130 
50µM Aβ25-35 was associated with nearly 30% reduction in cell viability and was used 
in the next experiment for the determination of neuroprotective effect of Ginkgolide 
A, Ginkgolide B and Bilobalide on Aβ25-35-induced RGC-5 cytotoxicity. 
 
 
 
 
 
 
 
 
 
 
Figure 3.25 Effect of AB25-35  on RGC-5 survival 
RGC-5 was exposed to concentration range of 5-100µM Aβ25-35 and MTT assay done 24 hours later. 
There was a concentration dependent reduction in RGC-5 viability which was statistically significant 
at all used concentration; absorbance was measured at 570nm. Results are expressed as mean ± 95% 
CI, Y axis= Abs 570nm.  (All treatment groups were compared to each other and the control by one-way 
ANOVA followed by post hoc comparisons * * P < 0.01). 
 
 
 
 
3.7 Effects of Ginkgolide A, Ginkgolide B and Bilobalide aganist Aβ25-35-
induced toxicity in RGC-5 
 
 
To examine the effect of Ginkgolide A, Ginkgolide B and Bilobalide on RGC-5 death 
induced by 50µM Aβ25-35, RGCs were pretreated with various doses (0.5-25µg) GA, 
GB and Bil for 2 hours, followed by simultaneous administration of the indicated 
concentration of Aβ25-35, cells were then incubated for 24 hours. As estimated by 
MTT assay, the result of these experiments showed that 1 µg/ml GA and 0.5µg/ml 
** 
** 
** 
** 
** 
** ** 
** 
** 
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GB had a protective effect on RGCs and were able to significantly reverse the 
neuronal toxicity of 50µM Aβ25-35. 
(Figure 3.26) shows that, Ginkgolide A at 1µg/ml had significantly (P < 0.01) 
prevented 50µM Aβ25-35-induced RGC-5 death. Applying 0.5, 1 and 2.5µg/ml GA to 
RGC-5 resulting in 21%, 28% and 11% enhancement in cell viability in comparison 
with the baseline Aβ25-35, higher doses of GA (5, 10 and 25 µg/ml) were associated 
with reduction in cell viability (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26 Protective effect of Ginkgolide A on AB25-35-induced RGC-5 toxicity 
RGC-5 were pre-treated with 0.5-2.5 µg/ml Ginkgolide A for 2 hours and then exposed to 50µM Aβ25-
35.  MTT absorbance was performed after 24 hours to access cell viability, in (figure 3.26) as displayed 
the reduction in cell viability after exposure to 50µM Aβ25-35 was reversed by 1 µg/ml GA.  At 0.5, 1, 
2.5 and 5 µg/ml GA there was 11%, 15% and 6% enhancement in cell survival in comparison with the 
control. Each experiment was performed five times and the result is expressed as mean ± 95%CI, Y 
axis= Abs 570nm. (All treatment groups were compared to each other and the control by one-way 
ANOVA followed by post hoc comparisons * * P < 0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
** 
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Figure 3.27 illustrates the dose dependent effect with 0.5-25µg/ml GB on Aβ-induced 
toxicity. In comparison with baseline, 50µM Aβ 25-35, pre-treating RGC-5 with these 
concentrations of GB was associated with 27%, 21%, 13% and 11% enhancement of 
cell viability. However, one-way ANOVA showed significant protective effect only at 
0.5 µg/ml concentration (P < 0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.27 Protective effect of Ginkgolide B on Aβ25-35-induced Rgc-5 toxicity 
0.5-25µg/ml Ginkgolide B were applied to RGC-5 for 2 hours before insulting the cells with 50µM 
Aβ25-35.  MTT absorbance was performed after 24 hours and seen in (figure 3.27) GB enhanced RGC-5 
survival resulting in 27%, 21%, 13%, 11% increase in cell viability at 0.5, 1, 2.5 and 5 µg/ml 
concentration whereas 10 and 25 failed to protect RGC-5. However, the protective effect was observed 
at 5µg/ml. Each experiment was performed five times and the result is expressed as mean ± 95% CI, Y 
axis= Abs 570nm.  (All treatment groups were compared to each other and the control by one-way 
ANOVA followed by post hoc comparisons * * P < 0.01). 
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The effect of Bilobalide on Aβ25-35-induced toxicity in RGC-5 is displayed in (figure 
3.28), among the used concentrations only 1 µg/ml Bil was able to enhance cell 
viability by 16%, as compared with baseline Aβ 25-35, Nevertheless, this enhancement 
was statistically not significant (P < 0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28 Protective effects of Bilobalide on AB25-35-induced RGC-5 toxicity 
 
RGC-5 was incubated with 0.5-25 µg/ml Bilobalide for 2 hours before 50µM Aβ25-35 exposure.  MTT 
absorbance was performed after 24 hours and as displayed in (figure 3.28, a) 1 µg/ml Bil reversed Aβ 
toxicity resulting in 16%, reduction in RGC-5 apoptosis as compared with 50µM Aβ25-35. Each 
experiment was performed five times and the result is expressed as mean ± 95% CI, Y axis= Abs 570nm.  
(All treatment groups were compared to each other and the control by one-way ANOVA followed by 
post hoc comparisons * * P < 0.01). 
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4 Discussion 
 
 
In glaucoma, the major cause of global irreversible blindness (Quigley and Broman, 
2006), there is an urgent need for treatment modalities that directly target RGCs 
(Cheung et al., 2008a;Baltmr et al., 2010). The discovery of an alternative therapeutic 
approach, independent of IOP reduction, is highly sought after, due to the indirect 
nature and limited effectiveness of IOP lowering therapy in preventing RGC loss 
(Oliver et al., 2002;Leske et al., 2007). As discussed in the introduction (section 
1.1.4), several mechanisms have been implicated in initiating the apoptotic cascade in 
glaucomatous retinopathy, and numerous drugs have been shown to be 
neuroprotective in animal models of glaucoma. Ginkgo biloba, a naturally occurring 
herb, has been advocated as a neuroprotective agent for several years in progressive 
glaucoma, especially when IOP-lowering strategies are ineffective (Ritch, 2000). 
However, the mechanism by which Ginkgo biloba exerts its action is not well 
established, although several pathways have been implicated (Diamond et al., 
2000;Ahlemeyer and Krieglstein, 2003). These include reduction of oxidative stress 
via Aβ (Yao et al., 2001;Bastianetto and Quirion, 2002;Luo et al., 2002;Shi et al., 
2009), mitochondrial dysfunction (Tendi et al., 2002;Abdel-Kader et al., 2007), and 
regulation of apoptosis-related caspases (Luo et al., 2002;Massieu et al., 2004;Gong et 
al., 2005). All of these mechanisms ultimately lead to programmed cell death with 
loss of RGCs (Osborne et al., 1999;Tatton et al., 2001;McKinnon et al., 2002a;Tezel, 
2006).  
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4.1 Summary of immunohistochemical findings  
 
The aim of the immunohistochemical work in this thesis was to examine several of 
the potential molecular targets of Ginkgo biloba related to RGC-5 apoptosis in OHT 
retinal sections and their correlation with IOP elevation. Immunohistochemistry 
showed cytochrome c and TNF-R1 expression peaking at 3 weeks (Fig 3.1 and 3.3), 
and active caspase 3 activity at 12 weeks after IOP elevation (Fig 3.2). Furthermore, 
the results have revealed a strong inverse correlation between Aß and APP in OHT 
animals, with APP and Aß accumulation peaking at 1 and 12 weeks after IOP 
elevation respectively (Fig 3.4 and 3.5). 
4.2 Interpretation 
 
4.2.1 Mitochondrial dysfunction and RGC apoptosis in OHT 
 
Mitochondrial dysfunction has previously been described as one of the key 
intracellular lesions associated with the pathogenesis of glaucoma (Mittag et al., 
2000;Tatton et al., 2001;Tezel and Yang, 2004), and many experimental studies have 
demonstrated the protective effect of Ginkgo biloba on mitochondrial function (Tendi 
et al., 2002;Eckert et al., 2003;Abdel-Kader et al., 2007). Literature does not show a 
direct link between Ginkgo biloba treatment and cytochrome c, nevertheless, Cheung 
et al (2003) who correlated mitochondrial failure with cytochrome c release and 
subsequent activation of the executor caspase, caspase-3, have observed cytochrome c 
release in RGCs post axotomy (Cheung et al., 2003). The activation of the death 
receptors TNF-R1 can also lead to caspase-3 activation in RGCs (Tezel and Yang, 
2004). Therefore, in these experiments, the expression of those molecular targets has 
been investigated in retinal sections of OHT and age-matched controls at different 
time points following IOP elevation. 
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4.2.1.1 Cytochrome c release in RGCs  
 
Work in this study provides evidence that cytochrome c, a water soluble protein 
located in the mitochondrial intermembrane space (Cheung et al., 2003), is detected in 
the cytoplasm of RGCs in OHT eyes. The results displayed in section 3.1.1, showed 
marked up-regulation of cytochrome c  immunoreactivity 1 week post OHT surgery 
to reach a peak at 3 weeks’ time point, which coincides with the development of peak 
RGC apoptosis in the same model as previously described (Cordeiro et al., 2004;Guo 
et al., 2005a). The diffuse cytoplasmic staining pattern of cytochrome c in RGCs post 
IOP elevation and the absence of obvious nuclear chromatin condensation in this 
study was similar to those described in RGCs post axotomy (Cheung et al., 2003;He 
et al., 2004). Relocation of cytochrome c from the inner mitochondrial membrane to 
the cytoplasm has also been reported in neuronal cells post transient focal cerebral 
ischemia (Fujimura et al., 1998), post cold injury induced brain trauma (Morita-
Fujimura et al., 1999) and in traumatic axonal brain injury (Buki et al., 2000).  
 
Cytochrome c expression in the normal control retinas was nearly undetectable in 
substantial agreement with Cheung et al (2003), who looked at cytochrome c in 
normal and axotomized RGCs (Cheung et al., 2003) and in the control cortex of post 
cold injury induced brain trauma (Morita-Fujimura et al., 1999). The decline in 
cytochrome c immunoreactivity in the OHT retinal sections after 3 weeks may be 
explained by considering the fact that mitochondrial damage is an early event in the 
apoptotic process in glaucoma, and will lead to cytochrome c release, which then 
potentially contributes to RGCs apoptosis by activating caspases (Tezel and Yang, 
2004). Additionally cytochrome c expression appears to be related to the type and 
duration of insult. While work in this thesis has shown cytochrome c expression to be 
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inconstant at different time points of IOP elevation (Fig 3.1), Cheung et al (2003) 
documented localized cytochrome c immunoreactivity increasing in one day to reach 
a peak at three days post axotomy (Cheung et al., 2003). Furthermore, in a study, 
which was conducted on adult hamsters, He et al 2004, who also looked at caspase-3 
as will be shown later, have observed more RGCs death and a significantly higher 
number of RGCs releasing cytochrome-c when optic nerve transection was performed 
closer to the optic disc (He et al., 2004). Released cytochrome-c has been shown to 
activate Apaf-1 and procapse-9 resulting in caspase-3 activation, ending in nuclear 
DNA fragmentation in an experimental model of traumatic brain injury (Morita-
Fujimura et al., 1999). In addition, the balance between Bcl-2/Bax also appears to be 
essential in the activation of cytochrome c (Ow et al., 2008). 
 
4.2.1.2 Active caspase-3 level in RGCs 
 
In addition to cytochrome c, activation of caspases has also been shown to be 
involved in the death of cultured RGCs exposed to different apoptotic stimuli (Tezel 
and Wax, 1999, 2000), in optic nerve axotomy induced RGC death (Chaudhary et al., 
1999;Kermer et al., 1999), and in rat models of experimental glaucoma (McKinnon et 
al., 2002a). Moreover, gene therapy conveying a potent caspase inhibitor, in a rat 
glaucoma model has been found to promote optic nerve axon survival (McKinnon et 
al., 2002b).  
 
Caspases, cysteine-aspartic proteases, are naturally occurring as proenzymes, which 
are activated in response to apoptotic insult (Tezel and Wax, 1999). Among them, 
activated caspase-3 is believed to be the primary effecter enzyme in neuronal 
apoptosis (Cheng et al., 1998;Thornberry and Lazebnik, 1998;Wang et al., 2007). In 
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this study, as shown in section 3.1.2, there was gradual enhancement in active 
caspase-3 expression over time in the retinal sections of OHT animals peaking at 12 
weeks of IOP elevation compared to age-matched controls. The intense labeling of 
active caspase-3 in RGC layer after IOP elevation was similar to that observed in 
RGCs after axotomy, additionally, the level of caspase-3 in the control retina was 
similar, indicating the presence of baseline level of caspase-3 in control retinas  
(Kermer et al., 1999). This result was also consistent with previous research 
conducted by McKinnon et al (2002), who examined the involvement of active 
caspase-3 in experimental glaucoma model, using several assays including 
immunohistochemistry. In that experiment, an active caspse-3 antibody was detected 
in the RGC layer of OHT retinas more extensively than the control retinas. However, 
unlike work presented in this thesis, the animals were observed for a period of 4 
weeks only after IOP elevation (McKinnon et al., 2002a).  
 
The peak of caspase-3 expression at 12 weeks of IOP elevation in this study was 
rather delayed. This is in agreement with previous groups who suggested activation of 
caspase-3 may be a delayed event in traumatic and ischemic brain injury (Buki et al., 
2000) and in RGCs after optic nerve transection (He et al., 2004). This delay is 
probably due to the presence of other effectors downstream of cytochrome c such as 
caspase-9 which might affect the activation of caspase-3 (Tezel and Yang, 2004). 
 
Caspase-3 activation has also been considered as the underlying mechanism of 
Ginkgo biloba’s neuroprotective effect in age related hearing loss (Nevado et al., 
2010), and in Aß treated neuroblastoma cell line (Luo et al., 2002;Nevado et al., 
2010), which could be via either the mitochondrial or the death receptor pathway. 
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 A similar mechanism could therefore be involved in RGCs apoptosis in the OHT 
model established by the group, caspase-3, similar to other caspases is produced as 
proenzyme and is usually sliced after its activation to smaller subunits of 12 kDa and 
17 kDa (Liu et al., 1999). A higher level of the 12 kDa subunit of caspase-3 was 
observed using immunoblotting analysis in the retina of transgenic rats with 
Rhodopsin mutation than in age-matched controls (ibid). 
 
Activation of apoptotic pathways in AD brains has been widely reported, where 
caspase activation was implicated in neurofibrillary tangle formation (Rohn et al., 
2001b;Rohn et al., 2002b). Furthermore, the brain section from Down Syndrome 
patients showed extensive Aß deposition and neurofibrillary tangle formation which 
was associated with accumulation of caspase-3 cleavage products of fodrin (Head et 
al., 2002). Gervais et al (1999) have previously shown APP cleavage by caspases 
during apoptosis, resulting in elevated Aß production in hippocampal neurons 
(Gervais et al., 1999).  
There appears to be more than one way of involving activated caspase-3 in apoptosis: 
one is through APP cleavage which is supported by substantial elevation of caspase-3 
and its implication in APP cleavage in Alzheimer's disease (Gervais et al., 1999) and 
the other is as a key executor of the mitochondrial pathway (Tezel and Yang, 2004). 
 
4.2.1.3 TNF-R1 in RGCs 
 
 
Up-regulation of pro-inflammatory cytokines and excessive expression of TNF-α has 
been documented in RGCs incubated in ischemic conditions (Fuchs et al., 2005), as 
well as in coculture of RGCs and glial cells exposed to elevated hydrostatic pressure 
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(Tezel and Wax, 2000). Further evidence to support this hypothesis was provided by 
Kitaoka et al (2006) who observed substantial RGC loss following intravitreal 
injection of TNF-α in rat model of optic nerve axonal degeneration (Kitaoka et al., 
2006). Moreover, TNF-R1 was also found to be localized to RGCs in glaucomatous 
eyes (Tezel et al., 2001;Tezel, 2008) and TNF-α and its subsequent binding to the 
death receptor, TNF-R1, in RGCs has been proposed to trigger a caspase-dependent 
and a caspase-independent component of the mitochondrial death pathways in 
glaucoma (de Kozak et al., 1997;Tezel, 2008). 
 
Immunohistochemical staining of TNF-R1 (section 3.1.3), documented enhanced 
TNF-RI receptor expression on the RGC’s surface and in the cytoplasm, that peaked 
at 3 weeks after IOP elevation. This appears to follow a similar profile of developing 
RGC apoptosis in the OHT model, leading to the assumption that blockade of TNF-
R1 signaling could be an effective strategy to protect RGCs in glaucoma. 
 
 Ginkgo biloba is known to suppress expression of TNF-α in the brain of 
atherosclerotic rats (Jiao et al., 2005). It also inhibits TNF-α and H2O2 activated 
primary human T lymphocytes through down-regulation of activator protein-1 signal 
transduction (Tsao et al., 2008). As TNF-α pathway has been implicated in initiating 
RGCS apoptosis (Tezel, 2008), this result highlights its neuroprotective potential in 
glaucoma.   
 
In this study, positive immunoreactivity for TNF-R1 was observed in the cytoplasm in 
addition to the RGCs surface, and was more intense in OHT eyes in comparison to 
control (Fig 3.3). This observation further indicates that binding of TNF-α to the 
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death receptor is essential for signaling the apoptotic pathway (Tezel et al., 2001). The 
result of this study was in agreement with previous observations on cultured RGCs 
exposed to ischemia or elevated hydrostatic pressure (Tezel and Wax, 2000) and on 
retinal section from 20 eyes of glaucoma patients, in which excessive expression of 
TNF-α and TNF-R1 was observed in glaucoma eyes compared to age-matched normal 
subjects (Tezel et al., 2001). 
 
The role of the TNF-R1 and TNF-R2 has been investigated, with substantial evidence 
that TNF-R1 promotes neurodegeneration (Tezel et al., 2001), whereas TNF-R2 is 
neuroprotective (Fontaine et al., 2002). In mice deficient for TNF, TNF-R1 and TNF-
R2, TNF has been observed to aggravate cell death, and absence of TNF-R1 was 
associated with reduction of neurodegenerative process, furthermore, selectively 
activating TNF-R2 was found to promote neuroprotection, in the ischemia–
reperfusion model. This was associated with the presence of activated Akt/protein 
kinase B (Fontaine et al., 2002).  
 
Receptor mediated death of RGCs through TNF-R1 has been observed and it is 
believed to involve a caspase-dependent and caspase–independent component of the 
mitochondrial cell death pathway (Tezel et al., 2001). In this process caspase-8 
cleaves a proapoptotic member of the Bcl-2 family, Bid, and the activated Bid 
consequently participates in the activation of the mitochondrial cell death pathway (Li 
et al., 1998;Luo et al., 1998). 
 
Rohn et al (1999) examined the role of TNF-R1 activation in Alzheimer’s disease and 
found that receptor activation can initiate the apoptotic cascade by recruiting adaptor 
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proteins that activate the proximal effector caspase, caspase-8 (Rohn et al., 2001a), 
and caspase-8 in turn activates the final executor caspase, caspase-3 (Stadelmann et 
al., 1999). Inhibition of caspase-8 in RGCs exposed to TNF-α has resulted in a 
relatively greater protection than in RGCs exposed to hypoxia. This enhancement in 
RGC survival was, however, temporary and caspase inhibition was not sufficient to 
block RGC death if the mitochondrial membrane potential was depleted and 
mitochondrial mediators including cytochrome c and AIF were released (Tezel and 
Yang, 2004).  
 
TNF- R1 and c-Jun N-terminal protein kinase (JNK) signaling have been implicated 
in the secondary degeneration of RGCs following optic nerve injury, where RGCs 
loss was remarkably lower in TNF-R1 deficient mice compared to controls (Tezel et 
al., 2004). In addition, this RGC loss was more prominent two weeks after optic nerve 
crush. This time period was correlated with the period of glial activation and 
increased glial immunoreactivity for TNF-α in these eyes (ibid). 
 
4.2.2 Aß and RGC apoptosis in OHT 
 
Apoptosis of RGCs has been demonstrated in experimental animal models of 
glaucoma as well as in human glaucoma. Many mechanisms have been implicated in 
initiating RGCs apoptosis in literature as in section 1.1.4, and it is believed that more 
than one mechanism might be involved in different glaucoma patients at different 
stages of disease progression (Yin et al., 2008).  
 
Colocalization of Aß and RGC apoptosis in experimental glaucoma has been shown 
earlier by the group in vivo, where a dose and time dependent apoptosis has been 
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confirmed with Aß administration (Guo et al., 2007a). Aß, polypeptide of 39-43 
amino acids that is generated by proteolytic cleavage of APP, is believed to play a 
significant role in RGC apoptosis, and blocking Aß cytotoxicity may help to prevent 
the occurrence or progression of glaucoma (McKinnon et al., 2002a). This work 
showed a strong inverse correlation between Aß and APP immunohistochemistry in 
retinal cross sections of OHT animals, and in the in vitro section of this study as 
shown in the next section, Aß 25-35-induced toxicity in RGC-5 was confirmed, which 
was blocked by Ginkgolide A and Ginkgolide B treatment. This converse association 
between Aß and APP is believed to be due to an increase in APP proteolysis and Aß 
formation that accompanies neuronal apoptosis in glaucoma. This is consistent with 
Aß colocalization with apoptotic RGCs, that was previously investigated by the group 
in vivo in experimental glaucoma (Guo et al., 2007a).  
 
In section 3.2.1, the presence of APP in the inner retinal layers (RGCs and nerve fiber 
layer) of OHT rats and age-matched control was demonstrated, however, more intense 
labeling was observed in the OHT eyes. This observation is in agreement with 
previous studies that examined APP and Aß in the OHT model (McKinnon et al., 
2002a;Guo et al., 2007a). McKinnon et al (2002), using immunoblots, confirmed 
significant reduction in the level of APP and elevation in Aß in hypertensive eyes in 
comparison with the controls (McKinnon et al., 2002a). In partial disagreement with 
this result, however, is the work of, Goldblum et al 2007 who documented higher 
intensity of both APP and Aß labeling in retinal sections of old DBA/2J glaucomatous 
mice than young and old controls (Goldblum et al., 2007). This study showed a 
reduction in APP immunoreactivity in OHT rats over time, which was highest at 12 
weeks of OHT elevation. This is postulated to be due to cleavage of APP into Aß by 
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caspase-3 during apoptosis (Gervais et al., 1999;McKinnon et al., 2002a). The 
predominant site of caspase-mediated proteolysis of APP in hippocampal cells was 
found to be within its cytoplasmic tail, and two mechanisms have been proposed to be 
responsible for caspases mediated processing of APP: the cleavage of APP at 
endogenous caspase sites and, probably interfering with the normal intracellular 
processing of APP that would otherwise prevent it from Aß formation (Gervais et al., 
1999). The result in this study has also showed minor increases in APP 
immunohistochemistry in all age-matched controls over time, which could be 
attributed to the physiological aging changes (Loffler et al., 1995). 
 
Abnormal metabolism of APP, a neuronal transmembrane precursor of Aß, has been 
implicated in the pathogenesis of several neurodegenerative diseases such as 
Alzheimer’s disease (Anandatheerthavarada and Devi, 2007). Accumulation of APP 
and Aβ in the mitochondria has been proposed as a causative role in impairing 
mitochondrial functions (ibid). Furthermore, knocking down of APP inhibited Aß-
induced RGCs death (Tsuruma et al., 2010). APP which is believed to play a critical 
role in growth (Saitoh et al., 1989) and synaptogenesis (Moya et al., 1994) is hugely 
synthesized in RGCs and then transported into the optic nerve in small transport 
vesicles, from where it is then transferred to the axonal plasma membrane, as well as 
to the nerve terminals and metabolized (Morin et al., 1993). A reduction in APP level 
on chronic administration of EGb 761 have been reported by Augustin and associates 
(2009) in the cortex of transgenic mouse model of AD (Augustin et al., 2009) which 
indicated that APP is an important molecular target of Ginkgo biloba. Furthermore, 
Colciaghi et al  (2004) have reported that EGb 761 was capable of inducing the 
metabolism of APP toward the non amyloidogenic pathway in hippocampal slices 
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therefore blocking the formation of Aß (Colciaghi et al., 2004). 
 
Using immunohistochemical techniques Gong and colleagues (2005) have observed 
that EGb 761 treatment reduced the content of APP and caspase-3 in the hippocampus 
of aluminum-treated rats in a dose dependent manner (Gong et al., 2005). Conversely, 
Luo et al (2003) using immunohistochemistry have shown that EGb 761 raises the 
levels of caspase-3 and APP in the hippocampus of a normal rat (Luo et al., 2003), 
and this could be due to the controversial effect of Ginkgo biloba on the normal and 
degenerated tissues. 
 
Atypical processing of APP has been implicated in the pathogenesis of glaucoma as 
well (McKinnon et al., 2002a;Goldblum et al., 2007), additionally, elevated levels of 
Aß either due to intracellular accumulation or extracellular administration possibly via 
interaction with the death receptor, has been suggested to act as a stimulus to initiate 
the apoptotic pathway within neurons (Du and Yan, 2010).  This triggers the 
activation of caspases that subsequently cleave fodrin, a neuronal cytoskeletal protein 
and known molecular target for caspase-3, APP tau and protein (Head et al., 2002), 
which is supported by the strong association between Aß deposition and caspase-3 
activation that has been observed in neuronal section from patients with Down 
syndrome, where neuronal cells found to be positive for caspase-3 cleavage product 
of fodrin (Head et al., 2002), and in patients with Alzheimer’s disease (Stadelmann et 
al., 1999). 
 
This study has observed enhanced Aß immunohistochemical expression in RGCs of 
all OHT rats, with maximum deposition at 12 weeks after OHT surgery. A similar 
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pattern of Aß accumulation was found in the rat ocular hypertensive model by others 
(McKinnon et al., 2002a). The strong inverse correlation between Aß and APP 
immunohistochemistry observed in this work is believed to be due to an increase in 
APP proteolysis and Aß formation that accompanies neuronal apoptosis in glaucoma. 
This is consistent with Aß colocalization with apoptotic RGCs, that was previously 
investigated in vivo in experimental glaucoma (Guo et al., 2007a). 
 
4.3 Summary of in vitro experimental findings 
 
 
Table 4.1 Neuroprotective effects of Ginkgolide A, B and Bilobalide on RGC-5 
 
Apoptotic 
Inducers 
Assay Ginkgolide A 
Effect/Dose 
Ginkgolide B 
Effect/Dose 
Bilobalide 
Effect/Dose 
1%  DMSO 
 
MTT assay 
 
- +/ 0.5,1 and 
2.5µg/ml 
- 
 Hoechst 33342 +/ 0.5,1 and 
2.5µg/ml 
+/ 0.5 and 
1µg/ml 
- 
 
UV40 MTT assay - 
 
+/ 0.5,1, 2.5 and 
5µg/ml 
+/ 0.5 and 1µg/ml 
1mM NaN3 
 
MTT assay 
 
- 
 
- 
 
- 
 
50µM Aβ25-35          MTT assay +/ 1µg/ml +/ 0.5µg/ml - 
 
 
 
 
In the in vitro section of this study, RGC-5 was exposed to different concentrations of 
DMSO, UVC, NaN3 and Aβ25-35. This has led to a dose dependent reduction in cell 
viability at 24 hours. To screen the neuroprotective potential of Ginkgolide A, 
Ginkgolide B and Bilobalide on RGC-5, 1% DMSO, UV40, 1mM NaN3 and 50µM 
Aβ25-35 were used as apoptotic inducers, as the average reduction in RGC-5 viability 
using these concentrations was between 20-35% and using higher concentrations of 
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those insults would result in a loss of RGC-5 viability that may not be recovered by 
Ginkgo biloba treatment. 
To prove the apoptotic potential of 1% DMSO, Hoechst 33342, which is capable of 
penetrating plasma membranes and staining the DNA of apoptotic RGCs has been 
used on DMSO treated RGCs. While all three compounds showed a dose-related 
response on RGC-5, some intrinsic toxicity was observed with GA. As shown in table 
4.1 using the MTT assay, the significant protective effect of Ginkgolide A was 
observed only against 50µM Aβ25-35 at 1µg/ml concentration. Although GA failed to 
rescue RGCs from DMSO toxicity on the MTT assay, Hoechst 33342 staining 
showed that 0.5,1 and 2.5µg/ml of this compound was able to reduce the percentage 
of apoptotic RGCs after DMSO treatment. 
 
Work in this thesis shows that Ginkgolide B had the most profound neuroprotective 
effects, against different apoptotic inducers in the majority of assays at a 
concentration range of 0.5-5µg/ml. Using the MTT assay, 0.5- 2.5µg/ml GB treatment 
was found to significantly enhance RGC viability after 1% DMSO insult. In addition, 
on Hoechst staining, the lower two doses 0.5-1µg/ml were able to reduce DMSO-
induced apoptosis in RGCs.  The protective potential of GB was also observed against 
UV40 at 0.5-5µg/ml and against 50µM Aβ25-35 at 0.5µg/ml, whereas Bilobalide was 
effective only against UV40 at a concentration of 0.5-1µg/ml. Interestingly, none of 
the Ginkgo biloba constituents tested in this work were able to rescue RGC-5 from 
the toxic effect of sodium azide in both assays. 
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4.4 Interpretation 
 
4.4.1 1% DMSO and the effects of Ginkgolide A, Ginkgolide B and Bilobalide  
 
DMSO, a widely used solvent, has been reported to have a multitude of actions both  
in vivo and in vitro (Santos et al., 2003) and it has been implicated in apoptotic death 
in several cell lines (Trubiani et al., 1996;Marthyn et al., 1998;Liu et al., 2001;Koiri 
and Trigun, 2011). In section 3.3.1 of this study, applying ascending concentrations of 
1-10% DMSO to RGC-5, resulted in a dose dependent decline in cell survival as 
accessed by the MTT assay. In this study DMSO was found to cause significant 
toxicity to RGCs even with the smallest used concentration of 1%. This is consistent 
with an earlier finding by Cao et al 2007, who found ≥ 10% reduction in cell viability 
and increased cellular apoptosis in human lens epithelial cell line (HLECs) line 
treated with 1% DMSO in addition to up regulation of Bax expression in HLECs (Cao 
et al., 2007). In another study, which was conducted in the EL-4 murine lymphoma 
cell line, Liu et al (2001) found no apoptotic changes with 0.5% and 1.5% DMSO 
treatment but with 2.5% DMSO (Liu et al., 2001). This could be due to variable 
sensitivity of different cell lines to DMSO. Furthermore, the previous research has 
confirmed that, DMSO-induced apoptosis in the EL-4 murine lymphoma cell line is 
mediated via caspase cascade of the mitochondrial death pathways (ibid). 
 
DMSO has been observed to promote death receptor mediated apoptosis in human 
myeloid leukemia cell line via enhancement of mitochondrial membrane 
depolarization (Vondracek et al., 2006).  Involvement of the mitochondrial pathway 
in DMSO-induced toxicity through stimulation of TNFα-p53 in vitro has also been 
investigated (Brown et al., 2007) and more recently in Dalton lymphoma cells in vivo, 
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DMSO-induced apoptosis have been found to be mediated via inducing TNFα-p53 
mitochondrial apoptotic pathway and caspase-9 activation (Koiri and Trigun, 2011),  
 
To evaluate the neuroprotective potential of Ginkgo biloba constituents against 1% 
DMSO, cells were pre-treated with GA, GB and Bil for two hours before DMSO 
treatment at a dose range chosen based on previous descriptions in various cell lines 
and disease models as will be shown in section 4.4.5. Using the MTT assay, GA 
failed to demonstrate significant protective effects on RGCs viability at all used 
concentrations, which was expected at higher doses as this cannot be attributed only 
to DMSO toxicity, but as displayed in section 3.4 at 5, 10 and 25 µg/ml GA was also 
toxic to RGC. However, lower doses of GA were also insufficient to rescue RGCs. 
GB treatments on the other hand were associated with significant neuroprotective 
effects on RGCs, observed at 0.5,1 and 2.5 µg/ml with the greatest protection seen at 
the smallest used concentration. This protection was dose dependent with an EC50 of 
2.21µM. 
 
As the MTT assay relies on activity of the mitochondrial succinate dehydrogenase 
enzyme of living cells, any drug that affects cellular mitochondrial function could 
unduly influence the result. This possibility could be ruled out using a more sensitive 
mitochondrial test such as direct evaluation of the mitochondrial membrane potential 
(Tezel and Yang, 2004;Abdel-Kader et al., 2007) and the mitochondrial ROS level 
using fluorescence dyes, bioluminescent measurement of ATP level and measurement 
of caspase-9 activity (Abdel-Kader et al., 2007). 
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To demonstrate that apoptosis occurred after 1% DMSO treatment and to assess the 
anti-apoptotic potential of GA, GB and Bil on these cells, Hoechst 33342 staining was 
used as displayed in section 3.5.1.2. The morphological changes of apoptotic RGCs 
on Hoechst 33342 staining, such as chromatin condensation seen in this study was the 
same confirmed by others in different cell lines (Massieu et al., 2004;Griffin et al., 
2007;Santiago et al., 2007). In this study, Hoechst 33342 staining of 1% DMSO 
treated RGC-5 was associated with higher level of apoptosis and contrasting the MTT 
results 0.5, 1 and 2.5 µg/ml GA treatment significantly reduced the percentage of 
apoptotic RGCs. A significant reduction of apoptotic RGCs number was also 
observed on treatment with 0.5 and 1 µg/ml GB. However, surprisingly no significant 
protective effect was observed with Bil using both MTT and Hoechst assays. 
 
To confirm the apoptosis inducing potential of DMSO on RGC-5, the TUNEL assay 
was carried out. However, no quantitative data of apoptotic RGCs were obtained. This 
failure to obtain positive results with the TUNEL assay in this study might be 
attributed to cell line resistance or the used protocol.  
 
4.4.2 UV40 and the effects of Ginkgolide A, Ginkgolide B and Bilobalide 
 
UV light induced apoptosis has been linked to several cytoplasmic and membrane 
bound molecular targets (Schwarz, 1998). Several other research studies have 
investigated whether UV light-induced DNA damage was associated with apoptotic 
or necrotic process. In a study which looked at DNA repair deficient and proficient 
isogenic cells, UVC (200-280nm) induced DNA damage has been found to be mainly 
due to apoptotic pathway (Dunkern et al., 2001). 
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UVB (280-320nm) has also been found to induce apoptosis in RGC-5. In the RGCs, 
UVB induced a dose dependent reduction in cell viability, which was also associated 
with enhanced expression of cytochrome c, Bax and absence of bcl2 (Balaiya et al., 
2010). A similar observation was reported by another group who documented 
caspase-3 and Bax activation after exposing RGC-5 culture to visible light (more than 
400nm) for 48 hours (Wood et al., 2008). 
 
The duration of UVC exposure in this experiment was 2 minutes in all treated RGCs, 
but another group (Balaiya et al., 2010) have exposed RGC-5 to a different time 
period of UVB light, and they have observed a dose dependant reduction in cell 
viability corresponding with increased cytochrome c expression in cultured RGC-5. In 
1994 Sachsenmaier et al investigated the involvement of growth factor receptors in 
UVC induced apoptosis in HeLa cells. This group found that UVC and growth factor 
have common signal transduction pathway to the nucleus, which involves Ras, Raf, 
Src and MAP kinases (Sachsenmaier et al., 1994).  
 
In this study, the MTT assay indicated that the viability of RGC-5 culture was 
significantly and dose dependently declined after exposure to 40, 60 and 80 mj/cm
2
 
UVC light, which is likely due to chronic oxidative damage in those cells. The 
protective effect of Ginkgolide A, Ginkgolide B and Bilobalide against UV40 was 
further accessed.  As shown in table 4.1, no significant effect was observed with GA, 
whereas GB at 0.5, 1. 2.5, and 5 µg/ml, and Bil at 0.5 and 1 µg/ml were associated 
with significant enhancement in cell viability, which is probably mediated via their 
antioxidant potential (Ahlemeyer et al., 1999;Zhou and Zhu, 2000). This result is in 
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line with a recent observation by Liu and Yu, 2008, who used UVC as an apoptotic 
inducer in a primary culture of rat cortical neurons. Here; significant increase in MTT 
absorbance and neuroprotective effect was observed with green tea polyphenols (Liu 
and Yu, 2008). 
 
4.4.3 NaN3 and the effects of Ginkgolide A, Ginkgolide B and Bilobalide 
 
 
Examining the effects of 24 hours exposure of RGC-5 to 1, 2.5, 5 and 10mM of the 
mitochondrial complex inhibitor NaN3, it has been observed that concentration 
dependent reduction in RGC-5 viability was produced, which is in agreement with 
another group who had dose dependent reduction in cellular viability and 
mitochondrial membrane potential of primary cortical neuron, using 1, 3 and 10 mM 
NaN3 (Selvatici et al., 2009). In that study, Selvatici and coworkers confirmed that 
MK801, trolex, N-acetyl-L-carnitine, and the nitric oxide synthase inhibitor, L-
NAME were able to prevent the cytotoxicity of 10 minutes exposure to NaN3, which 
disagree with the result of this experiment in which no neuroprotection was achieved 
with Ginkgolide A, B and Bilobalide. However, the protective effect of EGb 761 on 
mitochondrial respiratory chain function in PC 12 cells using complex inhibitors 
including NaN3 has been documented (Abdel-Kader et al., 2007). Possible 
explanations for this effect is NaN3, which is known to cause irreversible loss of 
cytochrome c oxidase activity (Leary et al., 2002), and is also known to cause 
mitochondrial failure leading to both apoptotic and necrotic effects depending on dose 
and duration of exposure to NaN3 as well as on the type of cultured cells (Selvatici et 
al., 2009). As mentioned in section 3.3.3 in this thesis RGCs were exposed to NaN3 
for 24 hours. 
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 It is conceivable to assume that RGCs death after NaN3 treatment in this experiment 
was via non-apoptotic pathway. That is why on using the same assay (MTT), RGC-5 
viability was reduced after NaN3 exposure and GA, GB and Bil failed to reuse them. 
This is actually supported by the absence of a significant increase in annexin V-FITC 
labeling of phosphatidyl serine (PS) which is believed to signal early apoptosis on the 
external surface of cortical neurons after NaN3 (Selvatici et al., 2009). Additionally, 
as mentioned earlier our assessment of neuroprotective potential of Ginkgo biloba 
constituents was through the MTT assay which is a measure of mitochondrial 
function, so its validity may be criticized. 
 
4.4.4 Aß and the effects of Ginkgolide A, Ginkgolide B and Bilobalide 
 
In these experiments RGC-5 were resistant to 10-100 µM Aß 1-42 treatment, unlike 
human neuroblastoma SH-SY5Y cells which showed significant apoptosis and its 
viability dropped to around 50% after exposure to 100µg/ml Aß 1-42 (Shi et al., 2009). 
One possible explanation is that RGC-5 are much more resistant cell line with ability 
of survival in the presence of high level of ROS (Maher and Hanneken, 2005). The 
result of these experiments was also partly inconsistent with Bastianetto et al 2000 
who observed reduction in hippocampal primary cells survival on MTT assay after 
exposure to 5 µM Aß 1-40, 25 µM Aß 1-42 and 25 µM Aß 25-35 (Bastianetto et al., 
2000a). The authors also found that the whole extract EGb 761 and the flavonoid 
fraction of the extract were able to rescue rat hippocampal primary cells from the 
indicated concentrations of Aß toxicity, interestingly; with Aß 25-35. This protection 
was significant even if EGb 761 was applied 8 hours after Aß 25-35 treatment. On the 
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other hand, in the same research Ginkgolide B and Bilobalide failed to protect 
neuronal cells from Aß-induced neurodegenerative process (Bastianetto et al., 2000a).  
 
In the present in vitro study Aß 25-35 caused significant reduction in RGC-5 viability in 
agreement with previous observation showing similar effect at similar concentrations: 
at 5-20 µM Aß25-35 in RGC-5 (Tsuruma et al., 2010), at 10 µM Aß 25-35 in cultured rat 
cerebral cortical neurons (Ban et al., 2006a) and finally at  50 µM Aß 25-35 (Zhang et 
al., 2010) and at 100 µM Aß 25-35 (Zhou et al., 2000) in PC 12 cell line. 
 
In this work, the protective effect of 1µg/ml GA and 0.5µg/ml GB against 50 µM Aß 
25-35-induced death in RGC-5 was confirmed, while Bilobalide failed to confer any 
protection. Krieglstein et al (1995) hypothesised that Ginkgolides exert their action on 
neurons possibly via PAF receptors, whereas bilobalide could act on both neurons and 
astrocyte (Krieglstein et al., 1995). Despite this, the exact mechanism of protection by 
the Ginkgolides against Aß 25-35 toxicity was not addressed in this thesis and remains 
to be elucidated. Ginkgolides especially Ginkgolide B have demonstrated protective 
effects against apoptotic inducers known to target mitochondrial pathway such as 
DMSO, given the fact that the mitochondrial permeability transition pore (mPTP) is 
believed to be involved in Aß-induced toxicity (Du and Yan, 2010). It is possible that 
this Ginkgolid’s neuroprotection was mediated via this pathway. 
 
In literature, there are several proposed mechanisms through which Aß exert its 
apoptotic effect including: oxidative stress and Ca
2+
 influx (Abramov et al., 2011), 
mitochondrial dysfunction (Du and Yan, 2010) and modulation of apoptosis related 
caspases (Troy et al., 2000;Rohn et al., 2002a). Moreover, Tsuruma and coworkers 
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2010 strongly suggested that Aß 25-35 up-regulation of APP is the leading cause for 
RGC-5 death (Tsuruma et al., 2010). A recent research on mixed culture of 
hippocampal neurons and astrocytes has implicated astrocyte membrane cholesterol 
content in mediating Aß neurotoxicity (Abramov et al., 2011). This recent work might 
provide an explanation for an earlier finding by Yao and colleagues 2004 in PC12 
cells where they observed that EGb 761 inhibited overproduction of APP and Aß 
induction by free cholesterol (Yao et al., 2004).   
 
 Ginkgo biloba has exerted its protective effect on Aß treated cells via several 
mechanisms including a direct inhibitory effect against Aß aggregation and Aß 
induced apoptosis in neuronal cell culture (Yao et al., 2001;Shi et al., 2009). This 
property of EGb 761 is believed to be mediated via direct interaction with Aß in 
neuroblastoma cell line expressing AD-associated double mutation (Luo et al., 2002). 
In that experiment, EGb 761 and Bilobalide were more powerful than GA and GB in 
inhibiting Aß aggregation. Furthermore, EGb 761 significantly attenuates 
mitochondrial initiated apoptotic pathway and decreased the activity of caspase-3 in 
neuroblastoma cells (Luo et al., 2002). 
 
4.4.5 Comparison of in vitro effects of Ginkgolide A, Ginkgolide B and 
Bilobalide 
 
Despite having certain structural and chemical properties in common, especially three 
lactone groups and a tertiary-butyl group (Krieglstein et al., 1995;Ivic et al., 2003), 
the pharmacological activity of  Ginkgolide A, Ginkgolide B and Bilobalide  is 
different as shown in section 1.2.3, and the effective neuroprotective concentration of 
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GA, GB and Bil on RGC-5 in these experiments was also variable in different 
experimental conditions as displayed in table 4.1  
 
In this work, overall the most profound neuroprotective effects were observed with 
Ginkgolide B against 1% DMSO, UV40, and 50µM Aβ25-35 at a concentration range 
of 0.5-5 µg/ml, with the best protection against all apoptotic inducers observed at 0.5 
µg/ml. This raises a question of whether doses lower that 0.5µg/ml would confer 
greater protection, however, the dose range used in these experiments was based on 
previous work by (Ahlemeyer et al., 1999;Bastianetto et al., 2000b;Shi et al., 2009) in 
different neuronal cells. Similar neuroprotective effect by GB was observed at 0.25-1 
µg/ml, in iNOS producing THP-1 macrophages which were treated with 
lipopolysaccharide and TNF-α (Cheung et al., 2001) which is believed to be mediated 
via the anti-oxidant property of GB. Conversely, Bastianetto et al (2000) have 
observed a negative effect with 1–5 µg/ml GB in hippocampal cells, treated with the 
NO donor SNP (Bastianetto et al., 2000b).  
 
 GB has also demonstrated neuroprotective anti-oxidant effects against serum 
deprivation and staurosporine-induced ROS production and apoptosis in chick 
embryonic neurons and in mixed cultures of neurons and astrocytes from neonatal rat 
hippocampus, however, higher concentrations were used to achieve anti-apoptotic 
effects (Ahlemeyer et al., 1999). In those experiments, GB at 10µM was required to 
rescue serum deprived and staurosporine treated chick neurons whereas in the mixed 
neuronal culture 100 µM GB was found to be effective against staurosporine-induced 
apoptosis (Ahlemeyer et al., 1999). GB at 100 µM has also been found to protect 
primary culture of hippocampal neurons against glutamate-induced excitotoxicity (Xu 
 158 
et al., 2010). The neuroprotective effect of GB on glutamate and NMDA-induced 
excitotoxicity has been investigated by another group, Zhu et al (1997), who have 
observed enhancement in neuronal viability with reduction of Ca
2+
 level in primary 
culture of cerebral cortical neurons with 2mg/L GB (Zhu et al., 1997).   
 
In contradiction with the results of this study, both Ginkgolide A and B treatment 
enhanced cellular viability and were associated with enhancement of the 
mitochondrial membrane potential after SNP treatment in PC12 cells at a 
concentration of 0.01 mg/ml and in dissociated brain cells at concentrations of 0.05 
mg/ml (Abdel-Kader et al., 2007).  
 
In this study, no significant effect was observed with Ginkgolide A after 1% DMSO, 
UV40 and NaN3 treatment. However, GA at 0.5, 1 and 2.5µg/ml reduced the number 
of apoptotic RGCs after DMSO treatment as revealed by Hoechst staining. In line 
with these findings, no protection was observed with Ginkgolide A in either serum-
deprived or staurosporine-treated neuronal cells (Ahlemeyer et al., 1999). However, 
dose dependent protective effect was observed with GA at 0.25-1 µg/ml with the best 
protection at the lower dose in THP-1 macrophages (Cheung et al., 2001). 
 
This discrepancy in the potency between GA and GB has been described by Ivic et al 
(2003) when they were examining the effect of terpenoid fraction of Ginkgo biloba on 
the glycine and GABA, type A receptors. These authors noticed that GB was 
significantly more potent than GA, and they have explained this by the fact that GB 
have a 1-OH group whereas GA does not, and the higher potency of GB is due to the 
direct interaction of the 1-OH group with the receptor. Furthermore, the position of 
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the lactone group in GA and GB was found to be different which has an implication 
on receptor binding (Ivic et al., 2003). 
 
In this work, the protective effect of 1µg/ml GA and 0.5µg/ml GB on 50 µM Aß 25-35-
induced death in RGC-5 was confirmed, which is partially consistent with an earlier 
finding in SH-SY5Y cells were both GA and GB were able to block neurotoxicity of 
Aß 1-42 (Bate et al., 2004). However, it seems that the effective concentration of 
different Ginkgo biloba constituents is variable in different cell lines, and in different 
models of inducing cell death. GB has previously demonstrated its best protection 
against 100µg/ml  Aß 1-42-induced toxicity in SH-SY5Y cells at 10µg/ml whereas 5 
and 20µg/ml GB could not display any protection (Shi et al., 2009). Another 
experiment highlighted the lower potency of GA when they found that GB but not 
GA was able to suppress the K
+
-evoked Ach release in rat hippocampal slices treated 
with Aß 25-35 (Lee et al., 2004). 
 
In these experiments only 0.5 and 1 µg/ml Bil were able to protect RGC-5 from 
UV40-induced cell loss with higher neuroprotection at 1 µg/ml. No other used 
concentration of Bil was effective in enhancing cell survival with other apoptotic 
induces: 1% DMSO, NaN3 and 50mM Aβ25-35 treated RGC-5. This discrepancy in the 
neuroprotective potential of Bilobalide was observed by other researchers, where the 
prominent protective effect of Bil was observed at 10 µM against hypoxic damage of 
chick neurons, while poor effect was seen against excitotoxic damage of hippocampal 
neurons (Krieglstein et al., 1995). The same group also found that Bil demonstrated 
neuroprotective effects in the rat model of focal cerebral ischemia but no effect was 
seen in the rat model of global ischemia (ibid).   
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The effective concentration of Bilobalide in our experiments were 0.5 and 1 µg/ml, 
which is equal to 1.53, 3.06 µM. Similar protection by Bil was observed in 
macrophages derived from a human monocytic cell line at a concentration range of 
0.25-1 µg/ml, via selective inhibitory effect on iNOS mRNA expression (Cheung et 
al., 2001). In agreement with Cheung et al (2001), Bil (25-100µM) demonstrated a 
dose dependent reduction in apoptosis which was induced in PC12 cells with the ROS 
producer, xanthine, in addition to the anti-oxidant property of Bil, in the same 
experiment the authors found reduction in ROS-induced elevation of Bax and active 
caspase-3 (Zhou and Zhu, 2000). The anti-oxidant effect of Bil was also observed in 
chick embryonic neurons exposed to serum deprivation and staurosporine  
(Ahlemeyer et al., 1999),  Bil protection was observed at 1 µM in chick embryonic 
neurons exposed to serum deprivation and at 10 µM in those exposed to staurosporine 
(ibid). Furthermore, Bil at 100 µM was found to rescue mixed culture of hippocampal 
neurons and astrocytes from serum deprivation induced apoptosis (ibid). Conversely, 
no protective effect with Bilobalide was observed in work by other groups in the same 
cell line.  Rapin et al 1998  found that addition of 0.1-1 µg/ml  (0.3-3 µM) Bil failed 
to protect hippocampal neurons from peroyl radical-induced apoptosis (Rapin et al., 
1998) and Bastianetto et al (2000) have also documented that treatment with 1–5 
µg/ml Bil did not protect hippocampal cells from the SNP-induced toxicity. In this 
research the authors believed that the documented neuroprotective potential of EGb 
761 against NO-induced toxicity was attributed to its flavonoid fraction (Bastianetto 
et al., 2000b).  
 
The neuroprotective effects of Bilobalide have been attributed to its positive effects 
on mitochondrial membrane potential (Abdel-Kader et al., 2007), and to enhancement 
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of the mitochondrial respiratory chain (Tendi et al., 2002). The protective effects of 
Bil which were observed in, PC 12 cells, at 10 µg/ml, a higher concentration than our 
study, is believed to be mediated via up regulation of mitochondrial gene expression 
of NADH dehydrogenase (ibid).  
 
Glycine and GABA receptors antagonism are also  believed to mediate the 
neuroprotective effects of Bil (Ivic et al., 2003). This was recently investigated by 
another group where Bilobalide at concentration of 10 μM was able to decrease 
NMDA-induced choline release by more than 90% (Kiewert et al., 2008), and exert 
antagonistic effect on GABA receptors (Kiewert et al., 2007).  
 
In this work Bilobalide failed to confer any protection against 50 µM Aß25-35 induced 
toxicity. This result was partially consistent with another group where they found that 
both Bil and GB failed to confer any protection against  Aß toxicity in primary culture 
of hippocampal cells (Bastianetto and Quirion, 2002). Conversely in PC12 cells 25-
100 µM Bil, dose dependently blocked the toxicity of 100 µM Aß 25-35 (Zhou et al., 
2000). 
Beside cell line variations and the differences in apoptotic inducers used, another 
reason that might explain the discrepancies in the neuroprotective potential of GA, 
GB and Bil in this experiments and work conducted by other groups is the solvent 
used to dissolve Ginkgo biloba constituents, while most other groups have used 
DMSO and ethanol to dissolve GA, GB and Bil, in this work GA was dissolved in 
DMF, GB in DMSO and Bil in Acetone according to the manufacturer’s instruction.   
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5. Conclusion and summary 
 
 
Managing glaucoma patients can be clinically challenging to ophthalmologist due to 
the fact that most glaucoma patients are asymptomatic until a considerable amount of 
visual field loss occurs. However, during the last years, much progress has been made 
in understanding pathogenic mechanisms involved in glaucoma and mechanism of 
action of neuroprotective agents. Even though, there has historically been a problem 
in translating preclinical and experimental drugs to patients for many reasons in 
particular: the lack of good experimental models of disease; the narrow therapeutic 
index of the neuroprotective drugs due to undesirable side effects on the patients 
(Levin and Peeples, 2008), as well as the lack of good clinical end points. It is now 
believed that better clinical end points are necessary to access the new therapeutic 
agents. Unfortunately a failure of phase III clinical trial of memantine in glaucoma 
patients has reduced enthusiasm for those drugs as neuroprotective (Osborne, 2008), 
however, recent advance in imaging technology should provide clinician and 
researchers with more reliable tools to access the efficacy neuroprotective agents 
(Cordeiro et al., 2004;Cordeiro et al., 2010;Cordeiro et al., 2011).  The results of a 
recently published, well-designed glaucoma clinical trial, the Low Pressure Glaucoma 
Treatment Study (LoGTS), showing evidence of Brimonidine neuroprotection 
(Krupin et al., 2011) is highly encouraging for using the non IOP lowering agents in 
 glaucoma patients (Cordeiro and Levin, 2011). 
Ginkgo biloba has been shown to have neuroprotective effect in several 
neurodegenerative diseases via modulation of APP, Aß, inflammatory mediators and 
apoptosis related caspases, in the this study we investigated the immunoreactivity of 
cytochrome c, caspase-3,TNF RI, APP and  Aß, in the normal and OHT rat retina as 
potential pharmacological target for Ginkgo biloba. We can report that RGCs in the 
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OHT model established by the group,  express these molecular targets and that could 
be used to slow the progression of RGCs loss in glaucoma.  
 
We can conclude with certainty that individual component of Ginkgo biloba terpene 
fraction: Ginkgolide A, Ginkgolide B and Bilobalide have some neuroprotective 
effect on RGC-5 death whether it was produced by 1% DMSO, UV40, 1mM NaN3 or 
50 µM Aß25-35 toxicity with Ginkgolide B having the profound neuroprotection. 
However, the neuroprotective potential of GA, GB and Bil was different depending 
on the apoptotic stimuli used.  More studies are needed to understand the precise 
mechanism by which DMSO, UV40, Aß 25-35 induced RGC-5 death and to clarify the 
mechanism of neuroprotection by Ginkgo biloba constituents in blocking RGC-5 
apoptosis, which will help to provide the pharmacological basis of its use in 
preventing or retarding RGCs loss in glaucoma patients.  
 
5.1 Future perspective 
 
Work in this study support the role of neuroprotection in glaucoma management by 
using non-IOP treatment modalities that directly target RGCs. in the in vitro 
experiments Ginkgolide B showed the most profound nuroprotective effects on RGC-
5 against apoptotic inducers which simulate glaucomatous stress. Therefore, it could 
be the most active ingredient of the commonly used herb Ginkgo biloba in glaucoma 
and it would be very interesting to do a clinical trial to access the nuroprotective 
potential of Ginkgolide B in glaucoma patients.  
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